



(51) International Patent Classification:

A61K 31/505 (2006.01) C07D 403/02 (2006.01)
A61K 31/506 (2006.01)

(21) International Application Number:

PCT/US2019/066201

(22) International Filing Date:

13 December 2019 (13.12.2019)

(25) Filing Language:

English

(26) Publication Language:

English

(30) Priority Data:

62/780,066 14 December 2018 (14.12.2018) US

(71) Applicant: **DANA-FARBER CANCER INSTITUTE, INC.** [US/US]; 450 Brookline Avenue, Boston, MA 02215 (US).

(72) Inventors: **GRAY, Nathanael, S.**; 26 Greenview Avenue, Boston, MA 02130 (US). **ZHANG, Tinghu**; 91 Chestnut Street, #3, Brookline, MA 02445 (US). **LIU, Yao**; 252 As-

pinwall Avenue, Apt. 3, Brookline, MA 02445 (US). **GAO, Yang**; 381 Dorchester Street, Apt 2A, Boston, MA 02127 (US).

(74) Agent: **BAKER, C., Hunter et al.**; Wolf, Greenfield & Sacks, P.C., 600 Atlantic Avenue, Boston, MA 02210-2206 (US).

(81) Designated States (unless otherwise indicated, for every kind of national protection available): AE, AG, AL, AM, AO, AT, AU, AZ, BA, BB, BG, BH, BN, BR, BW, BY, BZ, CA, CH, CL, CN, CO, CR, CU, CZ, DE, DJ, DK, DM, DO, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, GT, HN, HR, HU, ID, IL, IN, IR, IS, JO, JP, KE, KG, KH, KN, KP, KR, KW, KZ, LA, LC, LK, LR, LS, LU, LY, MA, MD, ME, MG, MK, MN, MW, MX, MY, MZ, NA, NG, NI, NO, NZ, OM, PA, PE, PG, PH, PL, PT, QA, RO, RS, RU, RW, SA, SC, SD, SE, SG, SK, SL, SM, ST, SV, SY, TH, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, ZA, ZM, ZW.

(84) Designated States (unless otherwise indicated, for every kind of regional protection available): ARIPO (BW, GH,

(54) Title: PYRAZOLOPYRIDINE INHIBITORS OF C-JUN-N-TERMINAL KINASES AND USES THEREOF





Figure 1

(57) Abstract: Provided herein are compounds of Formula (I), and pharmaceutically acceptable salts, solvates, hydrates, polymorphs, co-crystals, tautomers, stereoisomers, isotopologues, prodrugs, and compositions thereof. Also provided are methods and kits involving the inventive compounds or compositions for treating and/or preventing diseases (e.g., proliferative diseases (e.g., cancers and benign neoplasms), inflammatory diseases (e.g., rheumatoid arthritis), and vascular diseases (e.g., atherosclerosis) in a subject. Provided are methods of inhibiting a JNK (e.g., JNK1, JNK2, or JNK3) in a subject.



GM, KE, LR, LS, MW, MZ, NA, RW, SD, SL, ST, SZ, TZ,
UG, ZM, ZW), Eurasian (AM, AZ, BY, KG, KZ, RU, TJ,
TM), European (AL, AT, BE, BG, CH, CY, CZ, DE, DK,
EE, ES, FI, FR, GB, GR, HR, HU, IE, IS, IT, LT, LU, LV,
MC, MK, MT, NL, NO, PL, PT, RO, RS, SE, SI, SK, SM,
TR), OAPI (BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW,
KM, ML, MR, NE, SN, TD, TG).

Published:

— *with international search report (Art. 21(3))*

PYRAZOLOPYRIDINE INHIBITORS OF C-JUN-N-TERMINAL KINASES AND USES THEREOF

RELATED APPLICATIONS

[001] The present application claims priority under 35 U.S.C. § 119(e) to U.S. provisional application, U.S.S.N. 62/780,066, filed December 14, 2018, which is incorporated herein by reference.

BACKGROUND OF THE INVENTION

[002] In mammalian cells, the MAPK (Mitogen-Activated Protein Kinase) In mammalian cells, the MAPK (Mitogen-Activated Protein Kinase) signaling system is comprised of, at least, four distinct signaling modules defined by a core of MAP4K, MAP3K, MAP2K, and MAPKs that are named after the “terminal” MAPK kinase in each pathway: ERK1, ERK2, JNK1, JNK2, JNK3, p38alpha/beta, and ERK5 (Chang *et al.*, 2001; Johnson *et al.*, 2002; Pearson *et al.*, 2001; and Raman *et al.*, 2007). JNKs (c-Jun N-terminal kinases) become highly activated after cells are exposed to stress conditions such as cytokines, osmotic stress, hypoxia, and UV light, and are poorly activated by exposure to growth factors or mitogens (Derijard *et al.*, 1994; and Pulverer *et al.*, 1991). There are three distinct genes JNK1, JNK2, and JNK3 that are alternatively spliced to yield approximately ten different proteins with the predominant isoforms: JNK1 and JNK2 expressed ubiquitously, and JNK3 expressed primarily in the nervous system (Derijard *et al.*, 1994; Kallunki *et al.*, 1994; Sluss *et al.*, 1994; and Mohit *et al.*, 1995). JNKs are activated by phosphorylation at the activation T-loop residues Thr183/Tyr185 by the MAP2Ks: MKK4 and MKK7, and are deactivated by MAP kinase phosphatases including MKP1 and MKP5. Signaling through the JNK-pathway is organized through binding to “scaffolding” proteins such as JIP which assemble signaling complexes containing MAP3K, MAP2K, and MAPKs in addition to transcription factors such as c-Jun, ATF2, and Elk1 which are phosphorylated by JNK. As JNKs comprise a central node in the inflammatory signaling network, it is not surprising that hyperactivation of JNK signaling is a very common finding in a number of disease states, including cell proliferative disease (*e.g.*, cancer), inflammatory diseases, autoimmune diseases, cardiovascular diseases, and neurodegenerative diseases. A significant body of genetic and pharmacological evidence has been generated that suggest that inhibitors of JNK signaling may provide a promising therapeutic strategy. JNK3 knockout mice exhibit amelioration of neurodegeneration in animal models of Parkinson’s and Alzheimer’s disease (Kyriakis *et al.*,


2001; Zhang *et al.*, 2005; and Hunot *et al.*, 2004). JNK1 phosphorylates IRS-1, a key molecule in the insulin-sensing pathway which down-regulates insulin signaling, and JNK1 knockout mice are resistant to diet-induced obesity (Aguirre *et al.*, 2000 and 2002; Hirosumi *et al.*, 2002; and Sabio *et al.*, 2010). JNK2, often in concert with JNK1, has been implicated in the pathology of autoimmune disorders, such as rheumatoid arthritis (Han *et al.*, 2002) and asthma (Wong, W.S., 2005; Pelaia *et al.*, 2005; Blease *et al.*, 2003; Chialda *et al.*, 2005); and a recent study suggests that JNK2 may play a role in cardiovascular disease and atherosclerosis as well (Osto *et al.*, 2008).

[003] The ability to gain selectivity among highly homologous kinases with similarly placed cysteine residues would set an important precedent for the large number of other kinases where a similar problem exists, and there is a need for new compounds that inhibit JNK signaling, particularly ones that selectively inhibit JNK2. Thus, the present invention is directed toward covalent inhibitors of JNK2 that target Cys116, a residue conserved in JNK1 and JNK3, based upon the compounds' ability to recognize conformations that are unique to JNK2.

SUMMARY OF THE INVENTION

[004] The present invention provides compounds of Formula (I), and pharmaceutically acceptable salts, solvates, hydrates, polymorphs, co-crystals, tautomers, stereoisomers, isotopologues, prodrugs, and compositions thereof. The present invention further provides methods of using the inventive compounds, and pharmaceutically acceptable salts, solvates, hydrates, polymorphs, co-crystals, tautomers, stereoisomers, isotopologues, prodrugs, and compositions thereof, to study the inhibition of JNK and JNK signaling, as well as therapeutics for the prevention and treatment of diseases associated with JNK activity. In certain embodiments, the inventive compounds are used for the prevention and treatment of proliferative diseases (*e.g.*, cancer and benign neoplasms), inflammatory diseases (*e.g.*, rheumatoid arthritis), autoimmune diseases, and cardiovascular diseases (*e.g.*, atherosclerosis)) in a subject, biological sample, tissue, or cell.

[005] In one aspect, the present disclosure provides compounds of Formula (I):



and pharmaceutically acceptable salts, solvates, hydrates, polymorphs, co-crystals, tautomers, stereoisomers, isotopologues, and prodrugs thereof, wherein:

R^1 is optionally substituted aryl or optionally substituted heteroaryl;

R^2 , R^3 , R^4 , and R^5 are each independently hydrogen, halogen, optionally substituted acyl, optionally substituted alkyl, optionally substituted alkenyl, optionally substituted alkynyl, optionally substituted carbocyclyl, optionally substituted heterocyclyl, optionally substituted aryl, optionally substituted heteroaryl, $-NO_2$, $-CN$, $-SCN$, $-OR^{D1}$, $-N(R^{D1a})_2$, or $-SR^{D1}$, wherein R^{D1} is independently hydrogen, optionally substituted acyl, optionally substituted alkyl, optionally substituted alkenyl, optionally substituted alkynyl, optionally substituted carbocyclyl, optionally substituted heterocyclyl, optionally substituted aryl, optionally substituted heteroaryl, an oxygen protecting group when attached to an oxygen atom, a nitrogen protecting group when attached to a nitrogen atom, or a sulfur protecting group when attached to a sulfur atom;

n is 1, 2, or 3;

m is 1, 2, 3, or 4;

L^1 is O, S, or $-N(R^a)-$, wherein R^a is hydrogen, optionally substituted acyl, optionally substituted C_{1-6} alkyl, or a nitrogen protecting group;

L^2 is O, S, $-NR^{L2a}-$, $-C=O-$, $-NR^{L2a}C(=O)-$, or $-C(=O)NR^{L2a}-$, wherein R^{L2a} is hydrogen, optionally substituted acyl, optionally substituted C_{1-6} alkyl, or a nitrogen protecting group;

V^1 is $C(R^{1a})H$;

V^2 is $C(R^{1b})H$;


V^3 is N or $C(R^{1c})$;

R^{1a} and R^{1b} are independently hydrogen, halogen, optionally substituted acyl, optionally substituted alkyl, optionally substituted alkenyl, optionally substituted alkynyl, optionally substituted carbocyclyl, optionally substituted heterocyclyl, optionally substituted aryl, optionally substituted heteroaryl, $-CN$, $-OR^{C1}$, $-N(R^{C1})_2$, or $-SR^{C1}$, wherein R^{C1} is independently hydrogen, optionally substituted acyl, optionally substituted alkyl, optionally substituted alkenyl, optionally substituted alkynyl, optionally substituted carbocyclyl, optionally substituted heterocyclyl, optionally substituted aryl, optionally substituted heteroaryl, a nitrogen protecting group when attached to a nitrogen atom, an oxygen protecting group when attached to an oxygen atom, a sulfur protecting group when attached to a sulfur atom, or R^{1a} and R^{1b} are joined together to form an optionally substituted bridged ring;


R^{1c} is hydrogen, or substituted or unsubstituted C₁₋₆ alkyl;

p is 1, 2, or 3;


D¹ is a warhead of any one of Formulae (i-1) to (i-42):




(i-1)




(i-2)




(i-3)




(i-4)




(i-5)




(i-6)




(i-7)




(i-8)




(i-9)




(i-10)




(i-11)




(i-12)




(i-13)




(i-14)




(i-15)




(i-16)




(i-17)




(i-18)




(i-19)




(i-20)




(i-21)





















(i-22)



(i-23)



(i-24)



wherein:

L^3 is a bond or an optionally substituted C_{1-4} hydrocarbon chain, optionally wherein one or more carbon units of the hydrocarbon chain are independently replaced with $-O-$, $-S-$, $-NR^{L3a}-$, $-NR^{L3a}C(=O)-$, $-C(=O)NR^{L3a}-$, $-SC(=O)-$, $-C(=O)S-$, $-OC(=O)-$, $-C(=O)O-$, $-NR^{L3a}C(=S)-$, $-C(=S)NR^{L3a}-$, *trans*- $CR^{L3b}=CR^{L3b}-$, *cis*- $CR^{L3b}=CR^{L3b}-$, $-C\equiv C-$, $-S(=O)-$, $-S(=O)O-$, $-OS(=O)-$, $-S(=O)NR^{L3a}-$, $-NR^{L3a}S(=O)-$, $-S(=O)_2-$, $-S(=O)_2O-$, $-OS(=O)_2-$, $-S(=O)_2NR^{L3a}-$, or $-NR^{L3a}S(=O)_2-$, wherein R^{L3a} is hydrogen, substituted or unsubstituted C_{1-6} alkyl, or a nitrogen protecting group, and wherein each occurrence of R^{L3b} is independently selected from the group consisting of hydrogen, halogen, optionally substituted alkyl, optionally substituted alkenyl, optionally substituted alkynyl, optionally substituted carbocyclyl, optionally substituted heterocyclyl, optionally substituted aryl, and optionally

substituted heteroaryl, or two R^{L3b} groups are joined to form an optionally substituted carbocyclic or optionally substituted heterocyclic ring;

L^4 is a bond or an optionally substituted C_{1-4} hydrocarbon chain;

R^{E1} is selected from the group consisting of hydrogen, halogen, optionally substituted alkyl, optionally substituted alkenyl, optionally substituted alkynyl, optionally substituted carbocyclyl, optionally substituted heterocyclyl, optionally substituted aryl, optionally substituted heteroaryl, $-CN$, $-CH_2OR^{E1a}$, $-CH_2N(R^{E1a})_2$, $-CH_2SR^{E1a}$, $-OR^{E1a}$, $-N(R^{E1a})_2$, $-Si(R^{E1a})_3$, and $-SR^{E1a}$, wherein each occurrence of R^{E1a} is independently selected from the group consisting of hydrogen, optionally substituted alkyl, optionally substituted alkenyl, optionally substituted alkynyl, optionally substituted carbocyclyl, optionally substituted heterocyclyl, optionally substituted aryl, and optionally substituted heteroaryl, or two R^{E1a} groups are joined to form an optionally substituted heterocyclic ring;

R^{E2} is selected from the group consisting of hydrogen, halogen, optionally substituted alkyl, optionally substituted alkenyl, optionally substituted alkynyl, optionally substituted carbocyclyl, optionally substituted heterocyclyl, optionally substituted aryl, optionally substituted heteroaryl, $-CN$, $-CH_2OR^{E2a}$, $-CH_2N(R^{E2a})_2$, $-CH_2SR^{E2a}$, $-OR^{E2a}$, $-N(R^{E2a})_2$, and $-SR^{E2a}$, wherein each occurrence of R^{E2a} is independently selected from the group consisting of hydrogen, optionally substituted alkyl, optionally substituted alkenyl, optionally substituted alkynyl, optionally substituted carbocyclyl, optionally substituted heterocyclyl, optionally substituted aryl, and optionally substituted heteroaryl, or two R^{E2a} groups are joined to form an optionally substituted heterocyclic ring;

R^{E3} is selected from the group consisting of hydrogen, halogen, optionally substituted alkyl, optionally substituted alkenyl, optionally substituted alkynyl, optionally substituted carbocyclyl, optionally substituted heterocyclyl, optionally substituted aryl, optionally substituted heteroaryl, $-CN$, $-CH_2OR^{E3a}$, $-CH_2N(R^{E3a})_2$, $-CH_2SR^{E3a}$, $-OR^{E3a}$, $-N(R^{E3a})_2$, and $-SR^{E3a}$, wherein each occurrence of R^{E3a} is independently selected from the group consisting of hydrogen, optionally substituted alkyl, optionally substituted alkoxy, optionally substituted alkenyl, optionally substituted alkynyl, optionally substituted carbocyclyl, optionally substituted heterocyclyl, optionally substituted aryl, and optionally substituted heteroaryl, or two R^{E3a} groups are joined to form an optionally substituted heterocyclic ring;

or R^{E1} and R^{E3} , or R^{E2} and R^{E3} , or R^{E1} and R^{E2} are joined to form an optionally substituted carbocyclic or optionally substituted heterocyclic ring;

R^{E4} is a leaving group;


R^{E5} is halogen;

Y is O, S, or NR^{E6}, wherein R^{E6} is hydrogen, substituted or unsubstituted C₁₋₆ alkyl, or a nitrogen protecting group;

a is 1 or 2; and

each instance of z is independently 0, 1, 2, 3, 4, 5, or 6.

[006] Exemplary compounds of Formula (I) include, but are not limited to:



and pharmaceutically acceptable salts, solvates, hydrates, polymorphs, co-crystals, tautomers, stereoisomers, isotopologues, and prodrugs thereof.

[007] In another aspect, the invention provides methods and compositions for the treatment of diseases in a subject, biological sample, tissue, or cell. The diseases being treated by the inventive methods include JNK-associated diseases. Exemplary diseases include, but are not limited to, proliferative diseases (*e.g.*, cancer and benign neoplasms), inflammatory diseases, autoimmune diseases (*e.g.*, rheumatoid arthritis), and cardiovascular diseases (*e.g.*, atherosclerosis). The methods of the invention include administering to a subject in need of treatment of a disease a therapeutically effective amount of a compound of Formula (I). The compound of Formula (I) may be, *e.g.*, I-1, I-2, I-3, I-4, I-5, I-6, I-7, I-8, I-9, I-10, I-11, I-12, I-13, I-14, I-15, I-16, I-17, I-18, I-19, I-20, I-21, I-22, I-23, I-24, I-25, I-26, I-27, I-28, I-29, or I-30, or a pharmaceutically acceptable salt, solvate, hydrate, polymorph, co-crystal, tautomer, stereoisomer, isotopologues, or prodrug thereof.

[008] In another aspect, the present disclosure provides pharmaceutical compositions including a compound described herein, and optionally a pharmaceutically acceptable excipient. In certain embodiments, the pharmaceutical compositions described herein include a therapeutically or prophylactically effective amount of a compound described herein. The pharmaceutical composition may be useful for treating and/or preventing a disease (*e.g.*, proliferative diseases (*e.g.*, cancer and benign neoplasms), inflammatory diseases (*e.g.*, rheumatoid arthritis), autoimmune diseases, and cardiovascular diseases (*e.g.*, atherosclerosis)) in a subject in need thereof. The pharmaceutical composition may be useful for inhibiting the activity of JNK (*e.g.*, JNK2) in a subject, biological sample, tissue, or cell.

[009] In another aspect, the present disclosure provides pharmaceutical compositions including a compound described herein, and optionally a pharmaceutically acceptable excipient. In certain embodiments, the pharmaceutical compositions described herein include a therapeutically or prophylactically effective amount of a compound described herein. The pharmaceutical composition may be useful for treating a disease (*e.g.*, proliferative diseases (*e.g.*, cancer and benign neoplasms), inflammatory diseases (*e.g.*, rheumatoid arthritis), autoimmune diseases, and cardiovascular diseases (*e.g.*, atherosclerosis)) in a subject in need thereof, or inhibiting the activity of a JNK (*e.g.*, JNK2) in a biological sample, tissue, or cell.

[0010] In another aspect, described herein are methods for treating and/or preventing a disease (*e.g.*, proliferative diseases (*e.g.*, cancer and benign neoplasms), inflammatory diseases (*e.g.*, rheumatoid arthritis), autoimmune diseases, and cardiovascular diseases (*e.g.*, atherosclerosis)) in a subject, biological sample, tissue, or cell. Exemplary proliferative diseases which may be treated include diseases associated with the overexpression or increased activity of a JNK (*e.g.*, cancer or benign neoplasms).

[0011] Another aspect relates to methods of inhibiting the activity of a kinase (*e.g.*, JNK (*e.g.*, JNK2)) using a compound described herein in a biological sample (*e.g.*, cell, or tissue). In another aspect, described herein are methods of inhibiting the activity of a kinase (*e.g.*, a JNK (*e.g.*, JNK2)) using a compound described herein in a subject. Another aspect relates to methods of selectively inhibiting the activity of a kinase (*e.g.*, JNK (*e.g.*, JNK2)) using a compound described herein in a biological sample (*e.g.*, cell, or tissue). In another aspect, described herein are methods of selectively inhibiting the activity of a kinase (*e.g.*, a JNK (*e.g.*, JNK2)) using a compound described herein in a subject.

[0012] In another aspect, the present disclosure provides compounds of Formula (I), and pharmaceutically acceptable salts, solvates, hydrates, polymorphs, co-crystals, tautomers, stereoisomers, isotopologues, prodrugs, and compositions thereof, for use in the treatment of a disease (*e.g.*, proliferative diseases (*e.g.*, cancer and benign neoplasms), inflammatory diseases (*e.g.*, rheumatoid arthritis), autoimmune diseases, and cardiovascular diseases (*e.g.*, atherosclerosis)) in a subject.

[0013] In another aspect, the present disclosure provides compounds of Formula (I), and pharmaceutically acceptable salts, solvates, hydrates, polymorphs, co-crystals, tautomers, stereoisomers, isotopologues, prodrugs, and compositions thereof, for use in selectively inhibiting the activity of a kinase (*e.g.*, a JNK (*e.g.*, JNK2)) in a subject, biological sample, tissue, or cell.

[0014] Another aspect of the present disclosure relates to kits comprising a container with a compound, or pharmaceutical composition thereof, as described herein. The kits described herein may include a single dose or multiple doses of the compound or pharmaceutical composition. The kits may be useful in a method of the disclosure. In certain embodiments, the kit further includes instructions for using the compound or pharmaceutical composition. A kit described herein may also include information (*e.g.*, prescribing information) as required by a regulatory agency, such as the U.S. Food and Drug Administration (FDA).


[0015] The details of one or more embodiments of the invention are set forth herein. Other features, objects, and advantages of the invention will be apparent from the Detailed Description, Examples, Figures, and Claims.

DEFINITIONS

[0016] Definitions of specific functional groups and chemical terms are described in more detail below. The chemical elements are identified in accordance with the Periodic Table of the Elements, CAS version, Handbook of Chemistry and Physics, 75th Ed., inside cover, and

specific functional groups are generally defined as described therein. Additionally, general principles of organic chemistry, as well as specific functional moieties and reactivity, are described in Thomas Sorrell, *Organic Chemistry*, University Science Books, Sausalito, 1999; Michael B. Smith, *March's Advanced Organic Chemistry*, 7th Edition, John Wiley & Sons, Inc., New York, 2013; Richard C. Larock, *Comprehensive Organic Transformations*, John Wiley & Sons, Inc., New York, 2018; and Carruthers, *Some Modern Methods of Organic Synthesis*, 3rd Edition, Cambridge University Press, Cambridge, 1987.

[0017] Compounds described herein can comprise one or more asymmetric centers, and thus can exist in various stereoisomeric forms, *e.g.*, enantiomers and/or diastereomers. For example, the compounds described herein can be in the form of an individual enantiomer, diastereomer or geometric isomer, or can be in the form of a mixture of stereoisomers, including racemic mixtures and mixtures enriched in one or more stereoisomer. Isomers can be isolated from mixtures by methods known to those skilled in the art, including chiral high pressure liquid chromatography (HPLC) and the formation and crystallization of chiral salts; or preferred isomers can be prepared by asymmetric syntheses. See, for example, Jacques *et al.*, *Enantiomers, Racemates and Resolutions* (Wiley Interscience, New York, 1981); Wilen *et al.*, *Tetrahedron* 33:2725 (1977); Eliel, E.L. *Stereochemistry of Carbon Compounds* (McGraw-Hill, NY, 1962); and Wilen, S.H., *Tables of Resolving Agents and Optical Resolutions* p. 268 (E.L. Eliel, Ed., Univ. of Notre Dame Press, Notre Dame, IN 1972). The invention additionally encompasses compounds as individual isomers substantially free of other isomers, and alternatively, as mixtures of various isomers.

[0018] In a formula, the bond  is a single bond, the dashed line --- is a single bond or absent, and the bond == or === is a single or double bond.

[0019] The term “isotopologue” refers to compounds that differ only in their isotopic composition. Unless otherwise stated, structures depicted herein are also meant to include compounds that differ only in the presence of one or more isotopically enriched atoms. For example, compounds having the present structures except for the replacement of hydrogen by deuterium or tritium, replacement of ¹⁹F with ¹⁸F, or the replacement of ¹²C with ¹³C or ¹⁴C are within the scope of the disclosure. Such compounds are useful, for example, as analytical tools or probes in biological assays.

[0020] When a range of values (“range”) is listed, it is intended to encompass each value and sub-range within the range. A range is inclusive of the values at the two ends of the range unless otherwise provided. For example “C₁₋₆ alkyl” is intended to encompass, C₁, C₂, C₃, C₄,

C₅, C₆, C₁₋₆, C₁₋₅, C₁₋₄, C₁₋₃, C₁₋₂, C₂₋₆, C₂₋₅, C₂₋₄, C₂₋₃, C₃₋₆, C₃₋₅, C₃₋₄, C₄₋₆, C₄₋₅, and C₅₋₆ alkyl.

[0021] The term “aliphatic” refers to alkyl, alkenyl, alkynyl, and carbocyclic groups.

Likewise, the term “heteroaliphatic” refers to heteroalkyl, heteroalkenyl, heteroalkynyl, and heterocyclic groups.

[0022] The term “alkyl” refers to a radical of a straight-chain or branched saturated hydrocarbon group having from 1 to 20 carbon atoms (“C₁₋₂₀ alkyl”). In some embodiments, an alkyl group has 1 to 12 carbon atoms (“C₁₋₁₂ alkyl”). In some embodiments, an alkyl group has 1 to 10 carbon atoms (“C₁₋₁₀ alkyl”). In some embodiments, an alkyl group has 1 to 9 carbon atoms (“C₁₋₉ alkyl”). In some embodiments, an alkyl group has 1 to 8 carbon atoms (“C₁₋₈ alkyl”). In some embodiments, an alkyl group has 1 to 7 carbon atoms (“C₁₋₇ alkyl”). In some embodiments, an alkyl group has 1 to 6 carbon atoms (“C₁₋₆ alkyl”). In some embodiments, an alkyl group has 1 to 5 carbon atoms (“C₁₋₅ alkyl”). In some embodiments, an alkyl group has 1 to 4 carbon atoms (“C₁₋₄ alkyl”). In some embodiments, an alkyl group has 1 to 3 carbon atoms (“C₁₋₃ alkyl”). In some embodiments, an alkyl group has 1 to 2 carbon atoms (“C₁₋₂ alkyl”). In some embodiments, an alkyl group has 1 carbon atom (“C₁ alkyl”). In some embodiments, an alkyl group has 2 to 6 carbon atoms (“C₂₋₆ alkyl”). Examples of C₁₋₆ alkyl groups include methyl (C₁), ethyl (C₂), propyl (C₃) (*e.g.*, *n*-propyl, isopropyl), butyl (C₄) (*e.g.*, *n*-butyl, *tert*-butyl, *sec*-butyl, isobutyl), pentyl (C₅) (*e.g.*, *n*-pentyl, 3-pentanyl, amyl, neopentyl, 3-methyl-2-butanyl, *tert*-amyl), and hexyl (C₆) (*e.g.*, *n*-hexyl). Additional examples of alkyl groups include *n*-heptyl (C₇), *n*-octyl (C₈), *n*-dodecyl (C₁₂), and the like. Unless otherwise specified, each instance of an alkyl group is independently unsubstituted (an “unsubstituted alkyl”) or substituted (a “substituted alkyl”) with one or more substituents (*e.g.*, halogen, such as F). In certain embodiments, the alkyl group is an unsubstituted C₁₋₁₂ alkyl (such as unsubstituted C₁₋₆ alkyl, *e.g.*, -CH₃ (Me), unsubstituted ethyl (Et), unsubstituted propyl (Pr, *e.g.*, unsubstituted *n*-propyl (*n*-Pr), unsubstituted isopropyl (*i*-Pr)), unsubstituted butyl (Bu, *e.g.*, unsubstituted *n*-butyl (*n*-Bu), unsubstituted *tert*-butyl (*tert*-Bu or *t*-Bu), unsubstituted *sec*-butyl (*sec*-Bu or *s*-Bu), unsubstituted isobutyl (*i*-Bu)). In certain embodiments, the alkyl group is a substituted C₁₋₁₂ alkyl (such as substituted C₁₋₆ alkyl, *e.g.*, -CH₂F, -CHF₂, -CF₃, -CH₂CH₂F, -CH₂CHF₂, -CH₂CF₃, or benzyl (Bn)).


[0023] The term “heteroalkyl” refers to an alkyl group, which further includes at least one heteroatom (*e.g.*, 1, 2, 3, or 4 heteroatoms) selected from oxygen, nitrogen, or sulfur within (*e.g.*, inserted between adjacent carbon atoms of) and/or placed at one or more terminal

position(s) of the parent chain. In certain embodiments, a heteroalkyl group refers to a saturated group having from 1 to 20 carbon atoms and 1 or more heteroatoms within the parent chain (“heteroC₁₋₂₀ alkyl”). In certain embodiments, a heteroalkyl group refers to a saturated group having from 1 to 12 carbon atoms and 1 or more heteroatoms within the parent chain (“heteroC₁₋₁₂ alkyl”). In some embodiments, a heteroalkyl group is a saturated group having 1 to 11 carbon atoms and 1 or more heteroatoms within the parent chain (“heteroC₁₋₁₁ alkyl”). In some embodiments, a heteroalkyl group is a saturated group having 1 to 10 carbon atoms and 1 or more heteroatoms within the parent chain (“heteroC₁₋₁₀ alkyl”). In some embodiments, a heteroalkyl group is a saturated group having 1 to 9 carbon atoms and 1 or more heteroatoms within the parent chain (“heteroC₁₋₉ alkyl”). In some embodiments, a heteroalkyl group is a saturated group having 1 to 8 carbon atoms and 1 or more heteroatoms within the parent chain (“heteroC₁₋₈ alkyl”). In some embodiments, a heteroalkyl group is a saturated group having 1 to 7 carbon atoms and 1 or more heteroatoms within the parent chain (“heteroC₁₋₇ alkyl”). In some embodiments, a heteroalkyl group is a saturated group having 1 to 6 carbon atoms and 1 or more heteroatoms within the parent chain (“heteroC₁₋₆ alkyl”). In some embodiments, a heteroalkyl group is a saturated group having 1 to 5 carbon atoms and 1 or 2 heteroatoms within the parent chain (“heteroC₁₋₅ alkyl”). In some embodiments, a heteroalkyl group is a saturated group having 1 to 4 carbon atoms and 1 or 2 heteroatoms within the parent chain (“heteroC₁₋₄ alkyl”). In some embodiments, a heteroalkyl group is a saturated group having 1 to 3 carbon atoms and 1 heteroatom within the parent chain (“heteroC₁₋₃ alkyl”). In some embodiments, a heteroalkyl group is a saturated group having 1 to 2 carbon atoms and 1 heteroatom within the parent chain (“heteroC₁₋₂ alkyl”). In some embodiments, a heteroalkyl group is a saturated group having 1 carbon atom and 1 heteroatom (“heteroC₁ alkyl”). In some embodiments, a heteroalkyl group is a saturated group having 2 to 6 carbon atoms and 1 or 2 heteroatoms within the parent chain (“heteroC₂₋₆ alkyl”). Unless otherwise specified, each instance of a heteroalkyl group is independently unsubstituted (an “unsubstituted heteroalkyl”) or substituted (a “substituted heteroalkyl”) with one or more substituents. In certain embodiments, the heteroalkyl group is an unsubstituted heteroC₁₋₁₂ alkyl. In certain embodiments, the heteroalkyl group is a substituted heteroC₁₋₁₂ alkyl.


[0024] The term “heteroalkyl” refers to an alkyl group, which further includes at least one heteroatom (*e.g.*, 1, 2, 3, or 4 heteroatoms) selected from oxygen, nitrogen, or sulfur within (*i.e.*, inserted between adjacent carbon atoms of) and/or placed at one or more terminal position(s) of the parent chain. In certain embodiments, a heteroalkyl group refers to a

saturated group having from 1 to 10 carbon atoms and 1 or more heteroatoms within the parent chain (“heteroC₁₋₁₀ alkyl”). In some embodiments, a heteroalkyl group is a saturated group having 1 to 9 carbon atoms and 1 or more heteroatoms within the parent chain (“heteroC₁₋₉ alkyl”). In some embodiments, a heteroalkyl group is a saturated group having 1 to 8 carbon atoms and 1 or more heteroatoms within the parent chain (“heteroC₁₋₈ alkyl”). In some embodiments, a heteroalkyl group is a saturated group having 1 to 7 carbon atoms and 1 or more heteroatoms within the parent chain (“heteroC₁₋₇ alkyl”). In some embodiments, a heteroalkyl group is a saturated group having 1 to 6 carbon atoms and 1 or more heteroatoms within the parent chain (“heteroC₁₋₆ alkyl”). In some embodiments, a heteroalkyl group is a saturated group having 1 to 5 carbon atoms and 1 or 2 heteroatoms within the parent chain (“heteroC₁₋₅ alkyl”). In some embodiments, a heteroalkyl group is a saturated group having 1 to 4 carbon atoms and 1 or 2 heteroatoms within the parent chain (“heteroC₁₋₄ alkyl”). In some embodiments, a heteroalkyl group is a saturated group having 1 to 3 carbon atoms and 1 heteroatom within the parent chain (“heteroC₁₋₃ alkyl”). In some embodiments, a heteroalkyl group is a saturated group having 1 to 2 carbon atoms and 1 heteroatom within the parent chain (“heteroC₁₋₂ alkyl”). In some embodiments, a heteroalkyl group is a saturated group having 1 carbon atom and 1 heteroatom (“heteroC₁ alkyl”). In some embodiments, a heteroalkyl group is a saturated group having 2 to 6 carbon atoms and 1 or 2 heteroatoms within the parent chain (“heteroC₂₋₆ alkyl”). Unless otherwise specified, each instance of a heteroalkyl group is independently unsubstituted (an “unsubstituted heteroalkyl”) or substituted (a “substituted heteroalkyl”) with one or more substituents. In certain embodiments, the heteroalkyl group is an unsubstituted heteroC₁₋₁₀ alkyl. In certain embodiments, the heteroalkyl group is a substituted heteroC₁₋₁₀ alkyl.

[0025] The term “alkenyl” refers to a radical of a straight-chain or branched hydrocarbon group having from 2 to 10 carbon atoms and one or more carbon-carbon double bonds (*e.g.*, 1, 2, 3, or 4 double bonds). In some embodiments, an alkenyl group has 2 to 9 carbon atoms (“C₂₋₉ alkenyl”). In some embodiments, an alkenyl group has 2 to 8 carbon atoms (“C₂₋₈ alkenyl”). In some embodiments, an alkenyl group has 2 to 7 carbon atoms (“C₂₋₇ alkenyl”). In some embodiments, an alkenyl group has 2 to 6 carbon atoms (“C₂₋₆ alkenyl”). In some embodiments, an alkenyl group has 2 to 5 carbon atoms (“C₂₋₅ alkenyl”). In some embodiments, an alkenyl group has 2 to 4 carbon atoms (“C₂₋₄ alkenyl”). In some embodiments, an alkenyl group has 2 to 3 carbon atoms (“C₂₋₃ alkenyl”). In some embodiments, an alkenyl group has 2 carbon atoms (“C₂ alkenyl”). The one or more carbon-carbon double bonds can be internal (such as in 2-butenyl) or terminal (such as in 1-butenyl).

Examples of C₂₋₄ alkenyl groups include ethenyl (C₂), 1-propenyl (C₃), 2-propenyl (C₃), 1-butenyl (C₄), 2-butenyl (C₄), butadienyl (C₄), and the like. Examples of C₂₋₆ alkenyl groups include the aforementioned C₂₋₄ alkenyl groups as well as pentenyl (C₅), pentadienyl (C₅), hexenyl (C₆), and the like. Additional examples of alkenyl include heptenyl (C₇), octenyl (C₈), octatrienyl (C₈), and the like. Unless otherwise specified, each instance of an alkenyl group is independently unsubstituted (an “unsubstituted alkenyl”) or substituted (a “substituted alkenyl”) with one or more substituents. In certain embodiments, the alkenyl group is an unsubstituted C₂₋₁₀ alkenyl. In certain embodiments, the alkenyl group is a substituted C₂₋₁₀ alkenyl. In an alkenyl group, a C=C double bond for which the stereochemistry is not specified (*e.g.*, -CH=CHCH₃ or ) may be an (E)- or (Z)-double bond.

[0026] The term “alkenyl” refers to a radical of a straight-chain or branched hydrocarbon group having from 1 to 20 carbon atoms and one or more carbon-carbon double bonds (*e.g.*, 1, 2, 3, or 4 double bonds). In some embodiments, an alkenyl group has 1 to 20 carbon atoms (“C₁₋₂₀ alkenyl”). In some embodiments, an alkenyl group has 1 to 12 carbon atoms (“C₁₋₁₂ alkenyl”). In some embodiments, an alkenyl group has 1 to 11 carbon atoms (“C₁₋₁₁ alkenyl”). In some embodiments, an alkenyl group has 1 to 10 carbon atoms (“C₁₋₁₀ alkenyl”). In some embodiments, an alkenyl group has 1 to 9 carbon atoms (“C₁₋₉ alkenyl”). In some embodiments, an alkenyl group has 1 to 8 carbon atoms (“C₁₋₈ alkenyl”). In some embodiments, an alkenyl group has 1 to 7 carbon atoms (“C₁₋₇ alkenyl”). In some embodiments, an alkenyl group has 1 to 6 carbon atoms (“C₁₋₆ alkenyl”). In some embodiments, an alkenyl group has 1 to 5 carbon atoms (“C₁₋₅ alkenyl”). In some embodiments, an alkenyl group has 1 to 4 carbon atoms (“C₁₋₄ alkenyl”). In some embodiments, an alkenyl group has 1 to 3 carbon atoms (“C₁₋₃ alkenyl”). In some embodiments, an alkenyl group has 1 to 2 carbon atoms (“C₁₋₂ alkenyl”). In some embodiments, an alkenyl group has 1 carbon atom (“C₁ alkenyl”). The one or more carbon-carbon double bonds can be internal (such as in 2-butenyl) or terminal (such as in 1-butenyl). Examples of C₁₋₄ alkenyl groups include methyldenyl (C₁), ethenyl (C₂), 1-propenyl (C₃), 2-propenyl (C₃), 1-butenyl (C₄), 2-butenyl (C₄), butadienyl (C₄), and the like. Examples of C₁₋₆ alkenyl groups include the aforementioned C₂₋₄ alkenyl groups as well as pentenyl (C₅), pentadienyl (C₅), hexenyl (C₆), and the like. Additional examples of alkenyl include heptenyl (C₇), octenyl (C₈), octatrienyl (C₈), and the like. Unless otherwise specified, each instance of an alkenyl group is independently unsubstituted (an “unsubstituted alkenyl”) or substituted (a

“substituted alkenyl”) with one or more substituents. In certain embodiments, the alkenyl group is an unsubstituted C₁₋₂₀ alkenyl. In certain embodiments, the alkenyl group is a substituted C₁₋₂₀ alkenyl. In an alkenyl group, a C=C double bond for which the stereochemistry is not specified (*e.g.*, $-\text{CH}=\text{CHCH}_3$ or ) may be in the (*E*)- or (*Z*)-configuration.

[0027] The term “alkynyl” refers to a radical of a straight-chain or branched hydrocarbon group having from 1 to 20 carbon atoms and one or more carbon-carbon triple bonds (*e.g.*, 1, 2, 3, or 4 triple bonds) (“C₁₋₂₀ alkynyl”). In some embodiments, an alkynyl group has 1 to 10 carbon atoms (“C₁₋₁₀ alkynyl”). In some embodiments, an alkynyl group has 1 to 9 carbon atoms (“C₁₋₉ alkynyl”). In some embodiments, an alkynyl group has 1 to 8 carbon atoms (“C₁₋₈ alkynyl”). In some embodiments, an alkynyl group has 1 to 7 carbon atoms (“C₁₋₇ alkynyl”). In some embodiments, an alkynyl group has 1 to 6 carbon atoms (“C₁₋₆ alkynyl”). In some embodiments, an alkynyl group has 1 to 5 carbon atoms (“C₁₋₅ alkynyl”). In some embodiments, an alkynyl group has 1 to 4 carbon atoms (“C₁₋₄ alkynyl”). In some embodiments, an alkynyl group has 1 to 3 carbon atoms (“C₁₋₃ alkynyl”). In some embodiments, an alkynyl group has 1 to 2 carbon atoms (“C₁₋₂ alkynyl”). In some embodiments, an alkynyl group has 1 carbon atom (“C₁ alkynyl”). The one or more carbon-carbon triple bonds can be internal (such as in 2-butyne) or terminal (such as in 1-butyne). Examples of C₁₋₄ alkynyl groups include, without limitation, methylidyne (C₁), ethynyl (C₂), 1-propynyl (C₃), 2-propynyl (C₃), 1-butyne (C₄), 2-butyne (C₄), and the like. Examples of C₁₋₆ alkenyl groups include the aforementioned C₂₋₄ alkynyl groups as well as pentynyl (C₅), hexynyl (C₆), and the like. Additional examples of alkynyl include heptyne (C₇), octynyl (C₈), and the like. Unless otherwise specified, each instance of an alkynyl group is independently unsubstituted (an “unsubstituted alkynyl”) or substituted (a “substituted alkynyl”) with one or more substituents. In certain embodiments, the alkynyl group is an unsubstituted C₁₋₂₀ alkynyl. In certain embodiments, the alkynyl group is a substituted C₁₋₂₀ alkynyl.

[0028] The term “heteroalkynyl” refers to an alkynyl group, which further includes at least one heteroatom (*e.g.*, 1, 2, 3, or 4 heteroatoms) selected from oxygen, nitrogen, or sulfur within (*e.g.*, inserted between adjacent carbon atoms of) and/or placed at one or more terminal position(s) of the parent chain. In certain embodiments, a heteroalkynyl group refers to a group having from 1 to 20 carbon atoms, at least one triple bond, and 1 or more heteroatoms within the parent chain (“heteroC₁₋₂₀ alkynyl”). In certain embodiments, a

heteroalkynyl group refers to a group having from 1 to 10 carbon atoms, at least one triple bond, and 1 or more heteroatoms within the parent chain (“heteroC₁₋₁₀ alkynyl”). In some embodiments, a heteroalkynyl group has 1 to 9 carbon atoms, at least one triple bond, and 1 or more heteroatoms within the parent chain (“heteroC₁₋₉ alkynyl”). In some embodiments, a heteroalkynyl group has 1 to 8 carbon atoms, at least one triple bond, and 1 or more heteroatoms within the parent chain (“heteroC₁₋₈ alkynyl”). In some embodiments, a heteroalkynyl group has 1 to 7 carbon atoms, at least one triple bond, and 1 or more heteroatoms within the parent chain (“heteroC₁₋₇ alkynyl”). In some embodiments, a heteroalkynyl group has 1 to 6 carbon atoms, at least one triple bond, and 1 or more heteroatoms within the parent chain (“heteroC₁₋₆ alkynyl”). In some embodiments, a heteroalkynyl group has 1 to 5 carbon atoms, at least one triple bond, and 1 or 2 heteroatoms within the parent chain (“heteroC₁₋₅ alkynyl”). In some embodiments, a heteroalkynyl group has 1 to 4 carbon atoms, at least one triple bond, and 1 or 2 heteroatoms within the parent chain (“heteroC₁₋₄ alkynyl”). In some embodiments, a heteroalkynyl group has 1 to 3 carbon atoms, at least one triple bond, and 1 heteroatom within the parent chain (“heteroC₁₋₃ alkynyl”). In some embodiments, a heteroalkynyl group has 1 to 2 carbon atoms, at least one triple bond, and 1 heteroatom within the parent chain (“heteroC₁₋₂ alkynyl”). In some embodiments, a heteroalkynyl group has 1 to 6 carbon atoms, at least one triple bond, and 1 or 2 heteroatoms within the parent chain (“heteroC₁₋₆ alkynyl”). Unless otherwise specified, each instance of a heteroalkynyl group is independently unsubstituted (an “unsubstituted heteroalkynyl”) or substituted (a “substituted heteroalkynyl”) with one or more substituents. In certain embodiments, the heteroalkynyl group is an unsubstituted heteroC₁₋₂₀ alkynyl. In certain embodiments, the heteroalkynyl group is a substituted heteroC₁₋₂₀ alkynyl.

[0029] The term “carbocyclyl” or “carbocyclic” refers to a radical of a non-aromatic cyclic hydrocarbon group having from 3 to 14 ring carbon atoms (“C₃₋₁₄ carbocyclyl”) and zero heteroatoms in the non-aromatic ring system. In some embodiments, a carbocyclyl group has 3 to 14 ring carbon atoms (“C₃₋₁₄ carbocyclyl”). In some embodiments, a carbocyclyl group has 3 to 13 ring carbon atoms (“C₃₋₁₃ carbocyclyl”). In some embodiments, a carbocyclyl group has 3 to 12 ring carbon atoms (“C₃₋₁₂ carbocyclyl”). In some embodiments, a carbocyclyl group has 3 to 11 ring carbon atoms (“C₃₋₁₁ carbocyclyl”). In some embodiments, a carbocyclyl group has 3 to 10 ring carbon atoms (“C₃₋₁₀ carbocyclyl”). In some embodiments, a carbocyclyl group has 3 to 8 ring carbon atoms (“C₃₋₈ carbocyclyl”). In some embodiments, a carbocyclyl group has 3 to 7 ring carbon atoms (“C₃₋₇ carbocyclyl”). In some embodiments, a carbocyclyl group has 3 to 6 ring carbon atoms (“C₃₋₆ carbocyclyl”). In some

embodiments, a carbocyclyl group has 4 to 6 ring carbon atoms (“C₄₋₆ carbocyclyl”). In some embodiments, a carbocyclyl group has 5 to 6 ring carbon atoms (“C₅₋₆ carbocyclyl”). In some embodiments, a carbocyclyl group has 5 to 10 ring carbon atoms (“C₅₋₁₀ carbocyclyl”). Exemplary C₃₋₆ carbocyclyl groups include cyclopropyl (C₃), cyclopropenyl (C₃), cyclobutyl (C₄), cyclobutenyl (C₄), cyclopentyl (C₅), cyclopentenyl (C₅), cyclohexyl (C₆), cyclohexenyl (C₆), cyclohexadienyl (C₆), and the like. Exemplary C₃₋₈ carbocyclyl groups include the aforementioned C₃₋₆ carbocyclyl groups as well as cycloheptyl (C₇), cycloheptenyl (C₇), cycloheptadienyl (C₇), cycloheptatrienyl (C₇), cyclooctyl (C₈), cyclooctenyl (C₈), bicyclo[2.2.1]heptanyl (C₇), bicyclo[2.2.2]octanyl (C₈), and the like. Exemplary C₃₋₁₀ carbocyclyl groups include the aforementioned C₃₋₈ carbocyclyl groups as well as cyclononyl (C₉), cyclononenyl (C₉), cyclodecyl (C₁₀), cyclodecenyl (C₁₀), octahydro-1*H*-indenyl (C₉), decahydronaphthalenyl (C₁₀), spiro[4.5]decanyl (C₁₀), and the like. Exemplary C₃₋₈ carbocyclyl groups include the aforementioned C₃₋₁₀ carbocyclyl groups as well as cycloundecyl (C₁₁), spiro[5.5]undecanyl (C₁₁), cyclododecyl (C₁₂), cyclododecenyl (C₁₂), cyclotridecane (C₁₃), cyclotetradecane (C₁₄), and the like. As the foregoing examples illustrate, in certain embodiments, the carbocyclyl group is either monocyclic (“monocyclic carbocyclyl”) or polycyclic (*e.g.*, containing a fused, bridged or spiro ring system such as a bicyclic system (“bicyclic carbocyclyl”) or tricyclic system (“tricyclic carbocyclyl”)) and can be saturated or can contain one or more carbon-carbon double or triple bonds. “Carbocyclyl” also includes ring systems wherein the carbocyclyl ring, as defined above, is fused with one or more aryl or heteroaryl groups wherein the point of attachment is on the carbocyclyl ring, and in such instances, the number of carbons continue to designate the number of carbons in the carbocyclic ring system. Unless otherwise specified, each instance of a carbocyclyl group is independently unsubstituted (an “unsubstituted carbocyclyl”) or substituted (a “substituted carbocyclyl”) with one or more substituents. In certain embodiments, the carbocyclyl group is an unsubstituted C₃₋₁₄ carbocyclyl. In certain embodiments, the carbocyclyl group is a substituted C₃₋₁₄ carbocyclyl.

[0030] In some embodiments, “carbocyclyl” is a monocyclic, saturated carbocyclyl group having from 3 to 14 ring carbon atoms (“C₃₋₁₄ cycloalkyl”). In some embodiments, a cycloalkyl group has 3 to 10 ring carbon atoms (“C₃₋₁₀ cycloalkyl”). In some embodiments, a cycloalkyl group has 3 to 8 ring carbon atoms (“C₃₋₈ cycloalkyl”). In some embodiments, a cycloalkyl group has 3 to 6 ring carbon atoms (“C₃₋₆ cycloalkyl”). In some embodiments, a cycloalkyl group has 4 to 6 ring carbon atoms (“C₄₋₆ cycloalkyl”). In some embodiments, a cycloalkyl group has 5 to 6 ring carbon atoms (“C₅₋₆ cycloalkyl”). In some embodiments, a

cycloalkyl group has 5 to 10 ring carbon atoms (“C₅₋₁₀ cycloalkyl”). Examples of C₅₋₆ cycloalkyl groups include cyclopentyl (C₅) and cyclohexyl (C₆). Examples of C₃₋₆ cycloalkyl groups include the aforementioned C₅₋₆ cycloalkyl groups as well as cyclopropyl (C₃) and cyclobutyl (C₄). Examples of C₃₋₈ cycloalkyl groups include the aforementioned C₃₋₆ cycloalkyl groups as well as cycloheptyl (C₇) and cyclooctyl (C₈). Unless otherwise specified, each instance of a cycloalkyl group is independently unsubstituted (an “unsubstituted cycloalkyl”) or substituted (a “substituted cycloalkyl”) with one or more substituents. In certain embodiments, the cycloalkyl group is an unsubstituted C₃₋₁₄ cycloalkyl. In certain embodiments, the cycloalkyl group is a substituted C₃₋₁₄ cycloalkyl. In certain embodiments, the carbocyclyl includes 0, 1, or 2 C=C double bonds in the carbocyclic ring system, as valency permits.

[0031] The term “heterocyclyl” or “heterocyclic” refers to a radical of a 3- to 14-membered non-aromatic ring system having ring carbon atoms and 1 to 4 ring heteroatoms, wherein each heteroatom is independently selected from nitrogen, oxygen, and sulfur (“3–14 membered heterocyclyl”). In heterocyclyl groups that contain one or more nitrogen atoms, the point of attachment can be a carbon or nitrogen atom, as valency permits. A heterocyclyl group can either be monocyclic (“monocyclic heterocyclyl”) or polycyclic (*e.g.*, a fused, bridged or spiro ring system such as a bicyclic system (“bicyclic heterocyclyl”) or tricyclic system (“tricyclic heterocyclyl”)), and can be saturated or can contain one or more carbon-carbon double or triple bonds. Heterocyclyl polycyclic ring systems can include one or more heteroatoms in one or both rings. “Heterocyclyl” also includes ring systems wherein the heterocyclyl ring, as defined above, is fused with one or more carbocyclyl groups wherein the point of attachment is either on the carbocyclyl or heterocyclyl ring, or ring systems wherein the heterocyclyl ring, as defined above, is fused with one or more aryl or heteroaryl groups, wherein the point of attachment is on the heterocyclyl ring, and in such instances, the number of ring members continue to designate the number of ring members in the heterocyclyl ring system. Unless otherwise specified, each instance of heterocyclyl is independently unsubstituted (an “unsubstituted heterocyclyl”) or substituted (a “substituted heterocyclyl”) with one or more substituents. In certain embodiments, the heterocyclyl group is an unsubstituted 3–14 membered heterocyclyl. In certain embodiments, the heterocyclyl group is a substituted 3–14 membered heterocyclyl. In certain embodiments, the heterocyclyl is substituted or unsubstituted, 3- to 7-membered, monocyclic heterocyclyl, wherein 1, 2, or 3 atoms in the heterocyclic ring system are independently oxygen, nitrogen, or sulfur, as valency permits.

[0032] In some embodiments, a heterocyclyl group is a 5–10 membered non-aromatic ring system having ring carbon atoms and 1–4 ring heteroatoms, wherein each heteroatom is independently selected from nitrogen, oxygen, and sulfur (“5–10 membered heterocyclyl”). In some embodiments, a heterocyclyl group is a 5–8 membered non-aromatic ring system having ring carbon atoms and 1–4 ring heteroatoms, wherein each heteroatom is independently selected from nitrogen, oxygen, and sulfur (“5–8 membered heterocyclyl”). In some embodiments, a heterocyclyl group is a 5–6 membered non-aromatic ring system having ring carbon atoms and 1–4 ring heteroatoms, wherein each heteroatom is independently selected from nitrogen, oxygen, and sulfur (“5–6 membered heterocyclyl”). In some embodiments, the 5–6 membered heterocyclyl has 1–3 ring heteroatoms selected from nitrogen, oxygen, and sulfur. In some embodiments, the 5–6 membered heterocyclyl has 1–2 ring heteroatoms selected from nitrogen, oxygen, and sulfur. In some embodiments, the 5–6 membered heterocyclyl has 1 ring heteroatom selected from nitrogen, oxygen, and sulfur.

[0033] Exemplary 3-membered heterocyclyl groups containing 1 heteroatom include azirdinyl, oxiranyl, and thiiranyl. Exemplary 4-membered heterocyclyl groups containing 1 heteroatom include azetidiny, oxetanyl, and thietanyl. Exemplary 5-membered heterocyclyl groups containing 1 heteroatom include tetrahydrofuranly, dihydrofuranly, tetrahydrothiophenyl, dihydrothiophenyl, pyrrolidinyl, dihydropyrrolyl, and pyrrolyl-2,5-dione. Exemplary 5-membered heterocyclyl groups containing 2 heteroatoms include dioxolanyl, oxathiolanyl and dithiolanyl. Exemplary 5-membered heterocyclyl groups containing 3 heteroatoms include triazoliny, oxadiazoliny, and thiadiazoliny. Exemplary 6-membered heterocyclyl groups containing 1 heteroatom include piperidinyl, tetrahydropyranyl, dihydropyridiny, and thianyl. Exemplary 6-membered heterocyclyl groups containing 2 heteroatoms include piperazinyl, morpholinyl, dithianyl, and dioxanyl. Exemplary 6-membered heterocyclyl groups containing 3 heteroatoms include triazinyl. Exemplary 7-membered heterocyclyl groups containing 1 heteroatom include azepanyl, oxepanyl and thiepanyl. Exemplary 8-membered heterocyclyl groups containing 1 heteroatom include azocanyl, oxecanyl and thiocanyl. Exemplary bicyclic heterocyclyl groups include indolinyl, isoindolinyl, dihydrobenzofuranly, dihydrobenzothiényl, tetrahydrobenzothiényl, tetrahydrobenzofuranly, tetrahydroindolyl, tetrahydroquinolinyl, tetrahydroisoquinolinyl, decahydroquinolinyl, decahydroisoquinolinyl, octahydrochromenyl, octahydroisochromenyl, decahydronaphthyridiny, decahydro-1,8-naphthyridiny, octahydropyrrolo[3,2-b]pyrrole, indolinyl, phthalimidyl, naphthalimidyl, chromanyl, chromenyl, 1H-benzo[e][1,4]diazepiny, 1,4,5,7-tetrahydropyrano[3,4-b]pyrrolyl, 5,6-

dihydro-4H-furo[3,2-b]pyrrolyl, 6,7-dihydro-5H-furo[3,2-b]pyranyl, 5,7-dihydro-4H-thieno[2,3-c]pyranyl, 2,3-dihydro-1H-pyrrolo[2,3-b]pyridinyl, 2,3-dihydrofuro[2,3-b]pyridinyl, 4,5,6,7-tetrahydro-1H-pyrrolo[2,3-b]pyridinyl, 4,5,6,7-tetrahydrofuro[3,2-c]pyridinyl, 4,5,6,7-tetrahydrothieno[3,2-b]pyridinyl, 1,2,3,4-tetrahydro-1,6-naphthyridinyl, and the like.

[0034] The term “aryl” refers to a radical of a monocyclic or polycyclic (*e.g.*, bicyclic or tricyclic) $4n+2$ aromatic ring system (*e.g.*, having 6, 10, or 14 π electrons shared in a cyclic array) having 6–14 ring carbon atoms and zero heteroatoms provided in the aromatic ring system (“C₆₋₁₄ aryl”). In some embodiments, an aryl group has 6 ring carbon atoms (“C₆ aryl”; *e.g.*, phenyl). In some embodiments, an aryl group has 10 ring carbon atoms (“C₁₀ aryl”; *e.g.*, naphthyl such as 1-naphthyl and 2-naphthyl). In some embodiments, an aryl group has 14 ring carbon atoms (“C₁₄ aryl”; *e.g.*, anthracyl). “Aryl” also includes ring systems wherein the aryl ring, as defined above, is fused with one or more carbocyclyl or heterocyclyl groups wherein the radical or point of attachment is on the aryl ring, and in such instances, the number of carbon atoms continue to designate the number of carbon atoms in the aryl ring system. Unless otherwise specified, each instance of an aryl group is independently unsubstituted (an “unsubstituted aryl”) or substituted (a “substituted aryl”) with one or more substituents. In certain embodiments, the aryl group is an unsubstituted C₆₋₁₄ aryl. In certain embodiments, the aryl group is a substituted C₆₋₁₄ aryl.

[0035] “Aralkyl” is a subset of “alkyl” and refers to an alkyl group substituted by an aryl group, wherein the point of attachment is on the alkyl moiety.

[0036] The term “heteroaryl” refers to a radical of a 5-14 membered monocyclic or polycyclic (*e.g.*, bicyclic, tricyclic) $4n+2$ aromatic ring system (*e.g.*, having 6, 10, or 14 π electrons shared in a cyclic array) having ring carbon atoms and 1–4 ring heteroatoms provided in the aromatic ring system, wherein each heteroatom is independently selected from nitrogen, oxygen, and sulfur (“5-14 membered heteroaryl”). In heteroaryl groups that contain one or more nitrogen atoms, the point of attachment can be a carbon or nitrogen atom, as valency permits. Heteroaryl polycyclic ring systems can include one or more heteroatoms in one or both rings. “Heteroaryl” includes ring systems wherein the heteroaryl ring, as defined above, is fused with one or more carbocyclyl or heterocyclyl groups wherein the point of attachment is on the heteroaryl ring, and in such instances, the number of ring members continue to designate the number of ring members in the heteroaryl ring system. “Heteroaryl” also includes ring systems wherein the heteroaryl ring, as defined above, is

fused with one or more aryl groups wherein the point of attachment is either on the aryl or heteroaryl ring, and in such instances, the number of ring members designates the number of ring members in the fused polycyclic (aryl/heteroaryl) ring system. Polycyclic heteroaryl groups wherein one ring does not contain a heteroatom (*e.g.*, indolyl, quinoliny, carbazolyl, and the like) the point of attachment can be on either ring, *e.g.*, either the ring bearing a heteroatom (*e.g.*, 2-indolyl) or the ring that does not contain a heteroatom (*e.g.*, 5-indolyl). In certain embodiments, the heteroaryl is substituted or unsubstituted, 5- or 6-membered, monocyclic heteroaryl, wherein 1, 2, 3, or 4 atoms in the heteroaryl ring system are independently oxygen, nitrogen, or sulfur. In certain embodiments, the heteroaryl is substituted or unsubstituted, 9- or 10-membered, bicyclic heteroaryl, wherein 1, 2, 3, or 4 atoms in the heteroaryl ring system are independently oxygen, nitrogen, or sulfur.

[0037] In some embodiments, a heteroaryl group is a 5-10 membered aromatic ring system having ring carbon atoms and 1–4 ring heteroatoms provided in the aromatic ring system, wherein each heteroatom is independently selected from nitrogen, oxygen, and sulfur (“5-10 membered heteroaryl”). In some embodiments, a heteroaryl group is a 5-8 membered aromatic ring system having ring carbon atoms and 1–4 ring heteroatoms provided in the aromatic ring system, wherein each heteroatom is independently selected from nitrogen, oxygen, and sulfur (“5-8 membered heteroaryl”). In some embodiments, a heteroaryl group is a 5-6 membered aromatic ring system having ring carbon atoms and 1–4 ring heteroatoms provided in the aromatic ring system, wherein each heteroatom is independently selected from nitrogen, oxygen, and sulfur (“5-6 membered heteroaryl”). In some embodiments, the 5-6 membered heteroaryl has 1–3 ring heteroatoms selected from nitrogen, oxygen, and sulfur. In some embodiments, the 5-6 membered heteroaryl has 1–2 ring heteroatoms selected from nitrogen, oxygen, and sulfur. In some embodiments, the 5-6 membered heteroaryl has 1 ring heteroatom selected from nitrogen, oxygen, and sulfur. Unless otherwise specified, each instance of a heteroaryl group is independently unsubstituted (an “unsubstituted heteroaryl”) or substituted (a “substituted heteroaryl”) with one or more substituents. In certain embodiments, the heteroaryl group is an unsubstituted 5-14 membered heteroaryl. In certain embodiments, the heteroaryl group is a substituted 5-14 membered heteroaryl.

[0038] Exemplary 5-membered heteroaryl groups containing 1 heteroatom include pyrrolyl, furanyl, and thiophenyl. Exemplary 5-membered heteroaryl groups containing 2 heteroatoms include imidazolyl, pyrazolyl, oxazolyl, isoxazolyl, thiazolyl, and isothiazolyl. Exemplary 5-membered heteroaryl groups containing 3 heteroatoms include triazolyl, oxadiazolyl, and thiadiazolyl. Exemplary 5-membered heteroaryl groups containing 4 heteroatoms include

tetrazolyl. Exemplary 6-membered heteroaryl groups containing 1 heteroatom include pyridinyl. Exemplary 6-membered heteroaryl groups containing 2 heteroatoms include pyridazinyl, pyrimidinyl, and pyrazinyl. Exemplary 6-membered heteroaryl groups containing 3 or 4 heteroatoms include triazinyl and tetrazinyl, respectively. Exemplary 7-membered heteroaryl groups containing 1 heteroatom include azepinyl, oxepinyl, and thiopinyl. Exemplary 5,6-bicyclic heteroaryl groups include indolyl, isoindolyl, indazolyl, benzotriazolyl, benzothiophenyl, isobenzothiophenyl, benzofuranyl, benzoisofuranyl, benzimidazolyl, benzoxazolyl, benzisoxazolyl, benzoxadiazolyl, benzthiazolyl, benzisothiazolyl, benzthiadiazolyl, indoliziny, and purinyl. Exemplary 6,6-bicyclic heteroaryl groups include naphthyridinyl, pteridinyl, quinolinyl, isoquinolinyl, cinnolinyl, quinoxalinyl, phthalazinyl, and quinazolinyl. Exemplary tricyclic heteroaryl groups include phenanthridinyl, dibenzofuranyl, carbazolyl, acridinyl, phenothiazinyl, phenoxazinyl, and phenazinyl.

[0039] “Heteroaralkyl” is a subset of “alkyl” and refers to an alkyl group substituted by a heteroaryl group, wherein the point of attachment is on the alkyl moiety.

[0040] The term “unsaturated bond” refers to a double or triple bond.

[0041] The term “unsaturated” or “partially unsaturated” refers to a moiety that includes at least one double or triple bond.

[0042] The “saturated” or “fully saturated” refers to a moiety that does not contain a double or triple bond, *e.g.*, the moiety only contains single bonds.

[0043] Affixing the suffix “-ene” to a group indicates the group is a divalent moiety, *e.g.*, alkylene is the divalent moiety of alkyl, alkenylene is the divalent moiety of alkenyl, alkynylene is the divalent moiety of alkynyl, heteroalkylene is the divalent moiety of heteroalkyl, heteroalkenylene is the divalent moiety of heteroalkenyl, heteroalkynylene is the divalent moiety of heteroalkynyl, carbocyclylene is the divalent moiety of carbocyclyl, heterocyclylene is the divalent moiety of heterocyclyl, arylene is the divalent moiety of aryl, and heteroarylene is the divalent moiety of heteroaryl.

[0044] A group is optionally substituted unless expressly provided otherwise. The term “optionally substituted” refers to being substituted or unsubstituted. In certain embodiments, alkyl, alkenyl, alkynyl, heteroalkyl, heteroalkenyl, heteroalkynyl, carbocyclyl, heterocyclyl, aryl, and heteroaryl groups are optionally substituted. “Optionally substituted” refers to a group which may be substituted or unsubstituted (*e.g.*, “substituted” or “unsubstituted” alkyl, “substituted” or “unsubstituted” alkenyl, “substituted” or “unsubstituted” alkynyl, “substituted” or “unsubstituted” heteroalkyl, “substituted” or “unsubstituted” heteroalkenyl,

“substituted” or “unsubstituted” heteroalkynyl, “substituted” or “unsubstituted” carbocyclyl, “substituted” or “unsubstituted” heterocyclyl, “substituted” or “unsubstituted” aryl or “substituted” or “unsubstituted” heteroaryl group). In general, the term “substituted” means that at least one hydrogen present on a group is replaced with a permissible substituent, *e.g.*, a substituent which upon substitution results in a stable compound, *e.g.*, a compound which does not spontaneously undergo transformation such as by rearrangement, cyclization, elimination, or other reaction. Unless otherwise indicated, a “substituted” group has a substituent at one or more substitutable positions of the group, and when more than one position in any given structure is substituted, the substituent is either the same or different at each position. The term “substituted” is contemplated to include substitution with all permissible substituents of organic compounds, and includes any of the substituents described herein that results in the formation of a stable compound. The present invention contemplates any and all such combinations in order to arrive at a stable compound. For purposes of this invention, heteroatoms such as nitrogen may have hydrogen substituents and/or any suitable substituent as described herein which satisfy the valencies of the heteroatoms and results in the formation of a stable moiety. The invention is not intended to be limited in any manner by the exemplary substituents described herein.

[0045] Exemplary carbon atom substituents include halogen, $-\text{CN}$, $-\text{NO}_2$, $-\text{N}_3$, $-\text{SO}_2\text{H}$, $-\text{SO}_3\text{H}$, $-\text{OH}$, $-\text{OR}^{\text{aa}}$, $-\text{ON}(\text{R}^{\text{bb}})_2$, $-\text{N}(\text{R}^{\text{bb}})_2$, $-\text{N}(\text{R}^{\text{bb}})_3^+\text{X}^-$, $-\text{N}(\text{OR}^{\text{cc}})\text{R}^{\text{bb}}$, $-\text{SH}$, $-\text{SR}^{\text{aa}}$, $-\text{SSR}^{\text{cc}}$, $-\text{C}(=\text{O})\text{R}^{\text{aa}}$, $-\text{CO}_2\text{H}$, $-\text{CHO}$, $-\text{C}(\text{OR}^{\text{cc}})_2$, $-\text{CO}_2\text{R}^{\text{aa}}$, $-\text{OC}(=\text{O})\text{R}^{\text{aa}}$, $-\text{OCO}_2\text{R}^{\text{aa}}$, $-\text{C}(=\text{O})\text{N}(\text{R}^{\text{bb}})_2$, $-\text{OC}(=\text{O})\text{N}(\text{R}^{\text{bb}})_2$, $-\text{NR}^{\text{bb}}\text{C}(=\text{O})\text{R}^{\text{aa}}$, $-\text{NR}^{\text{bb}}\text{CO}_2\text{R}^{\text{aa}}$, $-\text{NR}^{\text{bb}}\text{C}(=\text{O})\text{N}(\text{R}^{\text{bb}})_2$, $-\text{C}(=\text{NR}^{\text{bb}})\text{R}^{\text{aa}}$, $-\text{C}(=\text{NR}^{\text{bb}})\text{OR}^{\text{aa}}$, $-\text{OC}(=\text{NR}^{\text{bb}})\text{R}^{\text{aa}}$, $-\text{OC}(=\text{NR}^{\text{bb}})\text{OR}^{\text{aa}}$, $-\text{C}(=\text{NR}^{\text{bb}})\text{N}(\text{R}^{\text{bb}})_2$, $-\text{OC}(=\text{NR}^{\text{bb}})\text{N}(\text{R}^{\text{bb}})_2$, $-\text{NR}^{\text{bb}}\text{C}(=\text{NR}^{\text{bb}})\text{N}(\text{R}^{\text{bb}})_2$, $-\text{C}(=\text{O})\text{NR}^{\text{bb}}\text{SO}_2\text{R}^{\text{aa}}$, $-\text{NR}^{\text{bb}}\text{SO}_2\text{R}^{\text{aa}}$, $-\text{SO}_2\text{N}(\text{R}^{\text{bb}})_2$, $-\text{SO}_2\text{R}^{\text{aa}}$, $-\text{SO}_2\text{OR}^{\text{aa}}$, $-\text{OSO}_2\text{R}^{\text{aa}}$, $-\text{S}(=\text{O})\text{R}^{\text{aa}}$, $-\text{OS}(=\text{O})\text{R}^{\text{aa}}$, $-\text{Si}(\text{R}^{\text{aa}})_3$, $-\text{OSi}(\text{R}^{\text{aa}})_3$, $-\text{C}(=\text{S})\text{N}(\text{R}^{\text{bb}})_2$, $-\text{C}(=\text{O})\text{SR}^{\text{aa}}$, $-\text{C}(=\text{S})\text{SR}^{\text{aa}}$, $-\text{SC}(=\text{S})\text{SR}^{\text{aa}}$, $-\text{SC}(=\text{O})\text{SR}^{\text{aa}}$, $-\text{OC}(=\text{O})\text{SR}^{\text{aa}}$, $-\text{SC}(=\text{O})\text{OR}^{\text{aa}}$, $-\text{SC}(=\text{O})\text{R}^{\text{aa}}$, $-\text{P}(=\text{O})(\text{R}^{\text{aa}})_2$, $-\text{P}(=\text{O})(\text{OR}^{\text{cc}})_2$, $-\text{OP}(=\text{O})(\text{R}^{\text{aa}})_2$, $-\text{OP}(=\text{O})(\text{OR}^{\text{cc}})_2$, $-\text{P}(=\text{O})(\text{N}(\text{R}^{\text{bb}})_2)_2$, $-\text{OP}(=\text{O})(\text{N}(\text{R}^{\text{bb}})_2)_2$, $-\text{NR}^{\text{bb}}\text{P}(=\text{O})(\text{R}^{\text{aa}})_2$, $-\text{NR}^{\text{bb}}\text{P}(=\text{O})(\text{OR}^{\text{cc}})_2$, $-\text{NR}^{\text{bb}}\text{P}(=\text{O})(\text{N}(\text{R}^{\text{bb}})_2)_2$, $-\text{P}(\text{R}^{\text{cc}})_2$, $-\text{P}(\text{OR}^{\text{cc}})_2$, $-\text{P}(\text{R}^{\text{cc}})_3^+\text{X}^-$, $-\text{P}(\text{OR}^{\text{cc}})_3^+\text{X}^-$, $-\text{P}(\text{R}^{\text{cc}})_4$, $-\text{P}(\text{OR}^{\text{cc}})_4$, $-\text{OP}(\text{R}^{\text{cc}})_2$, $-\text{OP}(\text{R}^{\text{cc}})_3^+\text{X}^-$, $-\text{OP}(\text{OR}^{\text{cc}})_2$, $-\text{OP}(\text{OR}^{\text{cc}})_3^+\text{X}^-$, $-\text{OP}(\text{R}^{\text{cc}})_4$, $-\text{OP}(\text{OR}^{\text{cc}})_4$, $-\text{B}(\text{R}^{\text{aa}})_2$, $-\text{B}(\text{OR}^{\text{cc}})_2$, $-\text{BR}^{\text{aa}}(\text{OR}^{\text{cc}})$, C_{1-20} alkyl, C_{1-20} perhaloalkyl, C_{1-20} alkenyl, C_{1-20} alkynyl, hetero C_{1-20} alkyl, hetero C_{1-20} alkenyl, hetero C_{1-20} alkynyl, C_{3-10} carbocyclyl, 3-14 membered heterocyclyl, C_{6-14} aryl, and 5-14 membered heteroaryl, wherein each alkyl, alkenyl, alkynyl, heteroalkyl, heteroalkenyl, heteroalkynyl, carbocyclyl,

heterocyclyl, aryl, and heteroaryl is independently substituted with 0, 1, 2, 3, 4, or 5 R^{dd} groups; wherein X⁻ is a counterion;

or two geminal hydrogens on a carbon atom are replaced with the group =O, =S, =NN(R^{bb})₂, =NNR^{bb}C(=O)R^{aa}, =NNR^{bb}C(=O)OR^{aa}, =NNR^{bb}S(=O)₂R^{aa}, =NR^{bb}, or =NOR^{cc};

each instance of R^{aa} is, independently, selected from C₁₋₂₀ alkyl, C₁₋₂₀ perhaloalkyl, C₁₋₂₀ alkenyl, C₁₋₂₀ alkynyl, heteroC₁₋₂₀ alkyl, heteroC₁₋₂₀ alkenyl, heteroC₁₋₂₀ alkynyl, C₃₋₁₀ carbocyclyl, 3-14 membered heterocyclyl, C₆₋₁₄ aryl, and 5-14 membered heteroaryl, or two R^{aa} groups are joined to form a 3-14 membered heterocyclyl or 5-14 membered heteroaryl ring, wherein each of the alkyl, alkenyl, alkynyl, heteroalkyl, heteroalkenyl, heteroalkynyl, carbocyclyl, heterocyclyl, aryl, and heteroaryl is independently substituted with 0, 1, 2, 3, 4, or 5 R^{dd} groups;

each instance of R^{bb} is, independently, selected from hydrogen, -OH, -OR^{aa}, -N(R^{cc})₂, -CN, -C(=O)R^{aa}, -C(=O)N(R^{cc})₂, -CO₂R^{aa}, -SO₂R^{aa}, -C(=NR^{cc})OR^{aa}, -C(=NR^{cc})N(R^{cc})₂, -SO₂N(R^{cc})₂, -SO₂R^{cc}, -SO₂OR^{cc}, -SOR^{aa}, -C(=S)N(R^{cc})₂, -C(=O)SR^{cc}, -C(=S)SR^{cc}, -P(=O)(R^{aa})₂, -P(=O)(OR^{cc})₂, -P(=O)(N(R^{cc})₂)₂, C₁₋₂₀ alkyl, C₁₋₂₀ perhaloalkyl, C₁₋₂₀ alkenyl, C₁₋₂₀ alkynyl, heteroC₁₋₂₀ alkyl, heteroC₁₋₂₀ alkenyl, heteroC₁₋₂₀ alkynyl, C₃₋₁₀ carbocyclyl, 3-14 membered heterocyclyl, C₆₋₁₄ aryl, and 5-14 membered heteroaryl, or two R^{bb} groups are joined to form a 3-14 membered heterocyclyl or 5-14 membered heteroaryl ring, wherein each alkyl, alkenyl, alkynyl, heteroalkyl, heteroalkenyl, heteroalkynyl, carbocyclyl, heterocyclyl, aryl, and heteroaryl is independently substituted with 0, 1, 2, 3, 4, or 5 R^{dd} groups;

each instance of R^{cc} is, independently, selected from hydrogen, C₁₋₂₀ alkyl, C₁₋₂₀ perhaloalkyl, C₁₋₂₀ alkenyl, C₁₋₂₀ alkynyl, heteroC₁₋₂₀ alkyl, heteroC₁₋₂₀ alkenyl, heteroC₁₋₂₀ alkynyl, C₃₋₁₀ carbocyclyl, 3-14 membered heterocyclyl, C₆₋₁₄ aryl, and 5-14 membered heteroaryl, or two R^{cc} groups are joined to form a 3-14 membered heterocyclyl or 5-14 membered heteroaryl ring, wherein each alkyl, alkenyl, alkynyl, heteroalkyl, heteroalkenyl, heteroalkynyl, carbocyclyl, heterocyclyl, aryl, and heteroaryl is independently substituted with 0, 1, 2, 3, 4, or 5 R^{dd} groups;

each instance of R^{dd} is, independently, selected from halogen, -CN, -NO₂, -N₃, -SO₂H, -SO₃H, -OH, -OR^{ee}, -ON(R^{ff})₂, -N(R^{ff})₂, -N(R^{ff})₃⁺X⁻, -N(OR^{ee})R^{ff}, -SH, -SR^{ee}, -SSR^{ee}, -C(=O)R^{ee}, -CO₂H, -CO₂R^{ee}, -OC(=O)R^{ee}, -OCO₂R^{ee}, -C(=O)N(R^{ff})₂, -OC(=O)N(R^{ff})₂, -NR^{ff}C(=O)R^{ee}, -NR^{ff}CO₂R^{ee}, -NR^{ff}C(=O)N(R^{ff})₂, -C(=NR^{ff})OR^{ee}, -OC(=NR^{ff})R^{ee}, -OC(=NR^{ff})OR^{ee}, -C(=NR^{ff})N(R^{ff})₂, -OC(=NR^{ff})N(R^{ff})₂, -NR^{ff}C(=NR^{ff})N(R^{ff})₂, -NR^{ff}SO₂R^{ee}, -SO₂N(R^{ff})₂, -SO₂R^{ee}, -SO₂OR^{ee}, -OSO₂R^{ee},

$-\text{S}(=\text{O})\text{R}^{\text{ee}}$, $-\text{Si}(\text{R}^{\text{ee}})_3$, $-\text{OSi}(\text{R}^{\text{ee}})_3$, $-\text{C}(=\text{S})\text{N}(\text{R}^{\text{ff}})_2$, $-\text{C}(=\text{O})\text{SR}^{\text{ee}}$, $-\text{C}(=\text{S})\text{SR}^{\text{ee}}$, $-\text{SC}(=\text{S})\text{SR}^{\text{ee}}$,
 $-\text{P}(=\text{O})(\text{OR}^{\text{ee}})_2$, $-\text{P}(=\text{O})(\text{R}^{\text{ee}})_2$, $-\text{OP}(=\text{O})(\text{R}^{\text{ee}})_2$, $-\text{OP}(=\text{O})(\text{OR}^{\text{ee}})_2$, C_{1-10} alkyl, C_{1-10}
perhaloalkyl, C_{1-10} alkenyl, C_{1-10} alkynyl, hetero C_{1-10} alkyl, hetero C_{1-10} alkenyl, hetero C_{1-10}
alkynyl, C_{3-10} carbocyclyl, 3-10 membered heterocyclyl, C_{6-10} aryl, 5-10 membered
heteroaryl, wherein each alkyl, alkenyl, alkynyl, heteroalkyl, heteroalkenyl, heteroalkynyl,
carbocyclyl, heterocyclyl, aryl, and heteroaryl is independently substituted with 0, 1, 2, 3, 4,
or 5 R^{gg} groups, or two geminal R^{dd} substituents can be joined to form $=\text{O}$ or $=\text{S}$; wherein X^-
is a counterion;

each instance of R^{ee} is, independently, selected from C_{1-10} alkyl, C_{1-10} perhaloalkyl,
 C_{1-10} alkenyl, C_{1-10} alkynyl, hetero C_{1-10} alkyl, hetero C_{1-10} alkenyl, hetero C_{1-10} alkynyl, C_{3-10}
carbocyclyl, C_{6-10} aryl, 3-10 membered heterocyclyl, and 3-10 membered heteroaryl,
wherein each alkyl, alkenyl, alkynyl, heteroalkyl, heteroalkenyl, heteroalkynyl, carbocyclyl,
heterocyclyl, aryl, and heteroaryl is independently substituted with 0, 1, 2, 3, 4, or 5 R^{gg}
groups;

each instance of R^{ff} is, independently, selected from hydrogen, C_{1-10} alkyl, C_{1-10}
perhaloalkyl, C_{1-10} alkenyl, C_{1-10} alkynyl, hetero C_{1-10} alkyl, hetero C_{1-10} alkenyl, hetero C_{1-10}
alkynyl, C_{3-10} carbocyclyl, 3-10 membered heterocyclyl, C_{6-10} aryl and 5-10 membered
heteroaryl, or two R^{ff} groups are joined to form a 3-10 membered heterocyclyl or 5-10
membered heteroaryl ring, wherein each alkyl, alkenyl, alkynyl, heteroalkyl, heteroalkenyl,
heteroalkynyl, carbocyclyl, heterocyclyl, aryl, and heteroaryl is independently substituted
with 0, 1, 2, 3, 4, or 5 R^{gg} groups;

each instance of R^{gg} is, independently, halogen, $-\text{CN}$, $-\text{NO}_2$, $-\text{N}_3$, $-\text{SO}_2\text{H}$, $-\text{SO}_3\text{H}$,
 $-\text{OH}$, $-\text{OC}_{1-6}$ alkyl, $-\text{ON}(\text{C}_{1-6}$ alkyl) $_2$, $-\text{N}(\text{C}_{1-6}$ alkyl) $_2$, $-\text{N}(\text{C}_{1-6}$ alkyl) $_3^+\text{X}^-$, $-\text{NH}(\text{C}_{1-6}$
alkyl) $_2^+\text{X}^-$, $-\text{NH}_2(\text{C}_{1-6}$ alkyl) $^+\text{X}^-$, $-\text{NH}_3^+\text{X}^-$, $-\text{N}(\text{OC}_{1-6}$ alkyl)(C_{1-6} alkyl), $-\text{N}(\text{OH})(\text{C}_{1-6}$
alkyl), $-\text{NH}(\text{OH})$, $-\text{SH}$, $-\text{SC}_{1-6}$ alkyl, $-\text{SS}(\text{C}_{1-6}$ alkyl), $-\text{C}(=\text{O})(\text{C}_{1-6}$ alkyl), $-\text{CO}_2\text{H}$,
 $-\text{CO}_2(\text{C}_{1-6}$ alkyl), $-\text{OC}(=\text{O})(\text{C}_{1-6}$ alkyl), $-\text{OCO}_2(\text{C}_{1-6}$ alkyl), $-\text{C}(=\text{O})\text{NH}_2$, $-\text{C}(=\text{O})\text{N}(\text{C}_{1-6}$
alkyl) $_2$, $-\text{OC}(=\text{O})\text{NH}(\text{C}_{1-6}$ alkyl), $-\text{NHC}(=\text{O})(\text{C}_{1-6}$ alkyl), $-\text{N}(\text{C}_{1-6}$ alkyl) $\text{C}(=\text{O})(\text{C}_{1-6}$ alkyl),
 $-\text{NHCO}_2(\text{C}_{1-6}$ alkyl), $-\text{NHC}(=\text{O})\text{N}(\text{C}_{1-6}$ alkyl) $_2$, $-\text{NHC}(=\text{O})\text{NH}(\text{C}_{1-6}$ alkyl), $-\text{NHC}(=\text{O})\text{NH}_2$,
 $-\text{C}(=\text{NH})\text{O}(\text{C}_{1-6}$ alkyl), $-\text{OC}(=\text{NH})(\text{C}_{1-6}$ alkyl), $-\text{OC}(=\text{NH})\text{OC}_{1-6}$ alkyl, $-\text{C}(=\text{NH})\text{N}(\text{C}_{1-6}$
alkyl) $_2$, $-\text{C}(=\text{NH})\text{NH}(\text{C}_{1-6}$ alkyl), $-\text{C}(=\text{NH})\text{NH}_2$, $-\text{OC}(=\text{NH})\text{N}(\text{C}_{1-6}$ alkyl) $_2$,
 $-\text{OC}(\text{NH})\text{NH}(\text{C}_{1-6}$ alkyl), $-\text{OC}(\text{NH})\text{NH}_2$, $-\text{NHC}(\text{NH})\text{N}(\text{C}_{1-6}$ alkyl) $_2$, $-\text{NHC}(=\text{NH})\text{NH}_2$,
 $-\text{NHSO}_2(\text{C}_{1-6}$ alkyl), $-\text{SO}_2\text{N}(\text{C}_{1-6}$ alkyl) $_2$, $-\text{SO}_2\text{NH}(\text{C}_{1-6}$ alkyl), $-\text{SO}_2\text{NH}_2$, $-\text{SO}_2\text{C}_{1-6}$ alkyl,
 $-\text{SO}_2\text{OC}_{1-6}$ alkyl, $-\text{OSO}_2\text{C}_{1-6}$ alkyl, $-\text{SOC}_{1-6}$ alkyl, $-\text{Si}(\text{C}_{1-6}$ alkyl) $_3$, $-\text{OSi}(\text{C}_{1-6}$ alkyl) $_3$
 $-\text{C}(=\text{S})\text{N}(\text{C}_{1-6}$ alkyl) $_2$, $\text{C}(=\text{S})\text{NH}(\text{C}_{1-6}$ alkyl), $\text{C}(=\text{S})\text{NH}_2$, $-\text{C}(=\text{O})\text{S}(\text{C}_{1-6}$ alkyl), $-\text{C}(=\text{S})\text{SC}_{1-6}$

alkyl, $-\text{SC}(=\text{S})\text{SC}_{1-6}$ alkyl, $-\text{P}(=\text{O})(\text{OC}_{1-6}$ alkyl) $_2$, $-\text{P}(=\text{O})(\text{C}_{1-6}$ alkyl) $_2$, $-\text{OP}(=\text{O})(\text{C}_{1-6}$ alkyl) $_2$, $-\text{OP}(=\text{O})(\text{OC}_{1-6}$ alkyl) $_2$, C_{1-10} alkyl, C_{1-10} perhaloalkyl, C_{1-10} alkenyl, C_{1-10} alkynyl, hetero C_{1-10} alkyl, hetero C_{1-10} alkenyl, hetero C_{1-10} alkynyl, C_{3-10} carbocyclyl, C_{6-10} aryl, 3-10 membered heterocyclyl, or 5-10 membered heteroaryl; or two geminal R^{gg} substituents can be joined to form $=\text{O}$ or $=\text{S}$; and

each X^- is a counterion.

[0046] The term “halo” or “halogen” refers to fluorine (fluoro, $-\text{F}$), chlorine (chloro, $-\text{Cl}$), bromine (bromo, $-\text{Br}$), or iodine (iodo, $-\text{I}$).

[0047] The term “hydroxyl” or “hydroxy” refers to the group $-\text{OH}$. The term “substituted hydroxyl” or “substituted hydroxyl,” by extension, refers to a hydroxyl group wherein the oxygen atom directly attached to the parent molecule is substituted with a group other than hydrogen, and includes groups selected from $-\text{OR}^{\text{aa}}$, $-\text{ON}(\text{R}^{\text{bb}})_2$, $-\text{OC}(=\text{O})\text{SR}^{\text{aa}}$, $-\text{OC}(=\text{O})\text{R}^{\text{aa}}$, $-\text{OCO}_2\text{R}^{\text{aa}}$, $-\text{OC}(=\text{O})\text{N}(\text{R}^{\text{bb}})_2$, $-\text{OC}(=\text{NR}^{\text{bb}})\text{R}^{\text{aa}}$, $-\text{OC}(=\text{NR}^{\text{bb}})\text{OR}^{\text{aa}}$, $-\text{OC}(=\text{NR}^{\text{bb}})\text{N}(\text{R}^{\text{bb}})_2$, $-\text{OS}(=\text{O})\text{R}^{\text{aa}}$, $-\text{OSO}_2\text{R}^{\text{aa}}$, $-\text{OSi}(\text{R}^{\text{aa}})_3$, $-\text{OP}(\text{R}^{\text{cc}})_2$, $-\text{OP}(\text{R}^{\text{cc}})_3^+\text{X}^-$, $-\text{OP}(\text{OR}^{\text{cc}})_2$, $-\text{OP}(\text{OR}^{\text{cc}})_3^+\text{X}^-$, $-\text{OP}(=\text{O})(\text{R}^{\text{aa}})_2$, $-\text{OP}(=\text{O})(\text{OR}^{\text{cc}})_2$, and $-\text{OP}(=\text{O})(\text{N}(\text{R}^{\text{bb}}))_2$, wherein X^- , R^{aa} , R^{bb} , and R^{cc} are as defined herein.

[0048] The term “thiol” or “thio” refers to the group $-\text{SH}$. The term “substituted thiol” or “substituted thio,” by extension, refers to a thiol group wherein the sulfur atom directly attached to the parent molecule is substituted with a group other than hydrogen, and includes groups selected from $-\text{SR}^{\text{aa}}$, $-\text{S}=\text{SR}^{\text{cc}}$, $-\text{SC}(=\text{S})\text{SR}^{\text{aa}}$, $-\text{SC}(=\text{S})\text{OR}^{\text{aa}}$, $-\text{SC}(=\text{S})\text{N}(\text{R}^{\text{bb}})_2$, $-\text{SC}(=\text{O})\text{SR}^{\text{aa}}$, $-\text{SC}(=\text{O})\text{OR}^{\text{aa}}$, $-\text{SC}(=\text{O})\text{N}(\text{R}^{\text{bb}})_2$, and $-\text{SC}(=\text{O})\text{R}^{\text{aa}}$, wherein R^{aa} and R^{cc} are as defined herein.

[0049] The term “amino” refers to the group $-\text{NH}_2$. The term “substituted amino,” by extension, refers to a monosubstituted amino, a disubstituted amino, or a trisubstituted amino. In certain embodiments, the “substituted amino” is a monosubstituted amino or a disubstituted amino group.

[0050] The term “monosubstituted amino” refers to an amino group wherein the nitrogen atom directly attached to the parent molecule is substituted with one hydrogen and one group other than hydrogen, and includes groups selected from $-\text{NH}(\text{R}^{\text{bb}})$, $-\text{NHC}(=\text{O})\text{R}^{\text{aa}}$, $-\text{NHCO}_2\text{R}^{\text{aa}}$, $-\text{NHC}(=\text{O})\text{N}(\text{R}^{\text{bb}})_2$, $-\text{NHC}(=\text{NR}^{\text{bb}})\text{N}(\text{R}^{\text{bb}})_2$, $-\text{NHSO}_2\text{R}^{\text{aa}}$, $-\text{NHP}(=\text{O})(\text{OR}^{\text{cc}})_2$, and $-\text{NHP}(=\text{O})(\text{N}(\text{R}^{\text{bb}}))_2$, wherein R^{aa} , R^{bb} and R^{cc} are as defined herein, and wherein R^{bb} of the group $-\text{NH}(\text{R}^{\text{bb}})$ is not hydrogen.

[0051] The term “disubstituted amino” refers to an amino group wherein the nitrogen atom directly attached to the parent molecule is substituted with two groups other than hydrogen,

and includes groups selected from $-N(R^{bb})_2$, $-NR^{bb}C(=O)R^{aa}$, $-NR^{bb}CO_2R^{aa}$, $-NR^{bb}C(=O)N(R^{bb})_2$, $-NR^{bb}C(=NR^{bb})N(R^{bb})_2$, $-NR^{bb}SO_2R^{aa}$, $-NR^{bb}P(=O)(OR^{cc})_2$, and $-NR^{bb}P(=O)(N(R^{bb})_2)_2$, wherein R^{aa} , R^{bb} , and R^{cc} are as defined herein, with the proviso that the nitrogen atom directly attached to the parent molecule is not substituted with hydrogen.

[0052] The term “trisubstituted amino” refers to an amino group wherein the nitrogen atom directly attached to the parent molecule is substituted with three groups, and includes groups selected from $-N(R^{bb})_3$ and $-N(R^{bb})_3^+X^-$, wherein R^{bb} and X^- are as defined herein.

[0053] The term “sulfonyl” refers to a group selected from $-SO_2N(R^{bb})_2$, $-SO_2R^{aa}$, and $-SO_2OR^{aa}$, wherein R^{aa} and R^{bb} are as defined herein.

[0054] The term “sulfinyl” refers to the group $-S(=O)R^{aa}$, wherein R^{aa} is as defined herein.

[0055] The term “acyl” refers to a group having the general formula $-C(=O)R^{X1}$, $-C(=O)OR^{X1}$, $-C(=O)-O-C(=O)R^{X1}$, $-C(=O)SR^{X1}$, $-C(=O)N(R^{X1})_2$, $-C(=S)R^{X1}$, $-C(=S)N(R^{X1})_2$, and $-C(=S)S(R^{X1})$, $-C(=NR^{X1})R^{X1}$, $-C(=NR^{X1})OR^{X1}$, $-C(=NR^{X1})SR^{X1}$, and $-C(=NR^{X1})N(R^{X1})_2$, wherein R^{X1} is hydrogen; halogen; substituted or unsubstituted hydroxyl; substituted or unsubstituted thiol; substituted or unsubstituted amino; substituted or unsubstituted acyl, cyclic or acyclic, substituted or unsubstituted, branched or unbranched aliphatic; cyclic or acyclic, substituted or unsubstituted, branched or unbranched heteroaliphatic; cyclic or acyclic, substituted or unsubstituted, branched or unbranched alkyl; cyclic or acyclic, substituted or unsubstituted, branched or unbranched alkenyl; substituted or unsubstituted alkynyl; substituted or unsubstituted aryl, substituted or unsubstituted heteroaryl, aliphaticoxy, heteroaliphaticoxy, alkyloxy, heteroalkyloxy, aryloxy, heteroaryloxy, aliphaticthioxy, heteroaliphaticthioxy, alkylthioxy, heteroalkylthioxy, arylthioxy, heteroarylthioxy, mono- or di- aliphaticamino, mono- or di- heteroaliphaticamino, mono- or di- alkylamino, mono- or di- heteroalkylamino, mono- or di-arylamino, or mono- or di-heteroarylamino; or two R^{X1} groups taken together form a 5- to 6-membered heterocyclic ring. Exemplary acyl groups include aldehydes ($-CHO$), carboxylic acids ($-CO_2H$), ketones, acyl halides, esters, amides, imines, carbonates, carbamates, and ureas. Acyl substituents include, but are not limited to, any of the substituents described herein, that result in the formation of a stable moiety (*e.g.*, aliphatic, alkyl, alkenyl, alkynyl, heteroaliphatic, heterocyclic, aryl, heteroaryl, acyl, oxo, imino, thiooxo, cyano, isocyano, amino, azido, nitro, hydroxyl, thiol, halo, aliphaticamino, heteroaliphaticamino, alkylamino, heteroalkylamino, arylamino, heteroarylamino, alkylaryl, arylalkyl, aliphaticoxy, heteroaliphaticoxy, alkyloxy, heteroalkyloxy, aryloxy, heteroaryloxy, aliphaticthioxy, heteroaliphaticthioxy, alkylthioxy,

heteroalkylthioxy, arylthioxy, heteroarylthioxy, acyloxy, and the like, each of which may or may not be further substituted).

[0056] The term “carbonyl” refers a group wherein the carbon directly attached to the parent molecule is sp^2 hybridized, and is substituted with an oxygen, nitrogen or sulfur atom, *e.g.*, a group selected from ketones ($-C(=O)R^{aa}$), carboxylic acids ($-CO_2H$), aldehydes ($-CHO$), esters ($-CO_2R^{aa}$, $-C(=O)SR^{aa}$, $-C(=S)SR^{aa}$), amides ($-C(=O)N(R^{bb})_2$, $-C(=O)NR^{bb}SO_2R^{aa}$, $-C(=S)N(R^{bb})_2$), and imines ($-C(=NR^{bb})R^{aa}$, $-C(=NR^{bb})OR^{aa}$, $-C(=NR^{bb})N(R^{bb})_2$), wherein R^{aa} and R^{bb} are as defined herein.

[0057] The term “oxo” refers to the group $=O$, and the term “thiooxo” refers to the group $=S$.

[0058] Nitrogen atoms can be substituted or unsubstituted as valency permits, and include primary, secondary, tertiary, and quaternary nitrogen atoms. Exemplary nitrogen atom substituents include, but are not limited to, hydrogen, $-OH$, $-OR^{aa}$, $-N(R^{cc})_2$, $-CN$, $-C(=O)R^{aa}$, $-C(=O)N(R^{cc})_2$, $-CO_2R^{aa}$, $-SO_2R^{aa}$, $-C(=NR^{bb})R^{aa}$, $-C(=NR^{cc})OR^{aa}$, $-C(=NR^{cc})N(R^{cc})_2$, $-SO_2N(R^{cc})_2$, $-SO_2R^{cc}$, $-SO_2OR^{cc}$, $-SOR^{aa}$, $-C(=S)N(R^{cc})_2$, $-C(=O)SR^{cc}$, $-C(=S)SR^{cc}$, $-P(=O)(OR^{cc})_2$, $-P(=O)(R^{aa})_2$, $-P(=O)(N(R^{cc})_2)_2$, C_{1-10} alkyl, C_{1-10} perhaloalkyl, C_{2-10} alkenyl, C_{2-10} alkynyl, hetero C_{1-10} alkyl, hetero C_{2-10} alkenyl, hetero C_{2-10} alkynyl, C_{3-10} carbocyclyl, 3-14 membered heterocyclyl, C_{6-14} aryl, and 5-14 membered heteroaryl, or two R^{cc} groups attached to an N atom are joined to form a 3-14 membered heterocyclyl or 5-14 membered heteroaryl ring, wherein each alkyl, alkenyl, alkynyl, heteroalkyl, heteroalkenyl, heteroalkynyl, carbocyclyl, heterocyclyl, aryl, and heteroaryl is independently substituted with 0, 1, 2, 3, 4, or 5 R^{dd} groups, and wherein R^{aa} , R^{bb} , R^{cc} and R^{dd} are as defined above.

[0059] In certain embodiments, the substituent present on the nitrogen atom is an nitrogen protecting group (also referred to herein as an “amino protecting group”). Nitrogen protecting groups include, but are not limited to, $-OH$, $-OR^{aa}$, $-N(R^{cc})_2$, $-C(=O)R^{aa}$, $-C(=O)N(R^{cc})_2$, $-CO_2R^{aa}$, $-SO_2R^{aa}$, $-C(=NR^{cc})R^{aa}$, $-C(=NR^{cc})OR^{aa}$, $-C(=NR^{cc})N(R^{cc})_2$, $-SO_2N(R^{cc})_2$, $-SO_2R^{cc}$, $-SO_2OR^{cc}$, $-SOR^{aa}$, $-C(=S)N(R^{cc})_2$, $-C(=O)SR^{cc}$, $-C(=S)SR^{cc}$, C_{1-10} alkyl (*e.g.*, aralkyl, heteroaralkyl), C_{2-10} alkenyl, C_{2-10} alkynyl, hetero C_{1-10} alkyl, hetero C_{2-10} alkenyl, hetero C_{2-10} alkynyl, C_{3-10} carbocyclyl, 3-14 membered heterocyclyl, C_{6-14} aryl, and 5-14 membered heteroaryl groups, wherein each alkyl, alkenyl, alkynyl, heteroalkyl, heteroalkenyl, heteroalkynyl, carbocyclyl, heterocyclyl, aralkyl, aryl, and heteroaryl is independently substituted with 0, 1, 2, 3, 4, or 5 R^{dd} groups, and wherein R^{aa} , R^{bb} , R^{cc} and R^{dd} are as defined herein. Nitrogen protecting groups are well known in the art and include those described in detail in *Protecting Groups in Organic Synthesis*, T. W. Greene and P. G. M. Wuts, 3rd edition, John Wiley & Sons, 1999, incorporated herein by reference.

[0060] For example, nitrogen protecting groups such as amide groups (*e.g.*, $-\text{C}(=\text{O})\text{R}^{\text{aa}}$) include, but are not limited to, formamide, acetamide, chloroacetamide, trichloroacetamide, trifluoroacetamide, phenylacetamide, 3-phenylpropanamide, picolinamide, 3-pyridylcarboxamide, N-benzoylphenylalanyl derivative, benzamide, p-phenylbenzamide, o-nitrophenylacetamide, o-nitrophenoxyacetamide, acetoacetamide, (N'-dithiobenzylxyacylamino)acetamide, 3-(p-hydroxyphenyl)propanamide, 3-(o-nitrophenyl)propanamide, 2-methyl-2-(o-nitrophenoxy)propanamide, 2-methyl-2-(o-phenylazophenoxy)propanamide, 4-chlorobutanamide, 3-methyl-3-nitrobutanamide, o-nitrocinnamide, N-acetylmethionine derivative, o-nitrobenzamide and o-(benzoyloxymethyl)benzamide.

[0061] Nitrogen protecting groups such as carbamate groups (*e.g.*, $-\text{C}(=\text{O})\text{OR}^{\text{aa}}$) include, but are not limited to, methyl carbamate, ethyl carbamate, 9-fluorenylmethyl carbamate (Fmoc), 9-(2-sulfo)fluorenylmethyl carbamate, 9-(2,7-dibromo)fluorenylmethyl carbamate, 2,7-di-t-butyl-[9-(10,10-dioxo-10,10,10,10-tetrahydrothioxanthyl)]methyl carbamate (DBD-Tmoc), 4-methoxyphenacyl carbamate (Phenoc), 2,2,2-trichloroethyl carbamate (Troc), 2-trimethylsilylethyl carbamate (Teoc), 2-phenylethyl carbamate (hZ), 1-(1-adamantyl)-1-methylethyl carbamate (Adpoc), 1,1-dimethyl-2-haloethyl carbamate, 1,1-dimethyl-2,2-dibromoethyl carbamate (DB-t-BOC), 1,1-dimethyl-2,2,2-trichloroethyl carbamate (TCBOC), 1-methyl-1-(4-biphenyl)ethyl carbamate (Bpoc), 1-(3,5-di-t-butylphenyl)-1-methylethyl carbamate (t-Bumeoc), 2-(2'- and 4'-pyridyl)ethyl carbamate (Pyoc), 2-(N,N-dicyclohexylcarboxamido)ethyl carbamate, t-butyl carbamate (BOC or Boc), 1-adamantyl carbamate (Adoc), vinyl carbamate (Voc), allyl carbamate (Alloc), 1-isopropylallyl carbamate (Ipaoc), cinnamyl carbamate (Coc), 4-nitrocinnamyl carbamate (Noc), 8-quinolyl carbamate, N-hydroxypiperidinyl carbamate, alkylthio carbamate, benzyl carbamate (Cbz), p-methoxybenzyl carbamate (Moz), p-nitobenzyl carbamate, p-bromobenzyl carbamate, p-chlorobenzyl carbamate, 2,4-dichlorobenzyl carbamate, 4-methylsulfinylbenzyl carbamate (MsZ), 9-anthrylmethyl carbamate, diphenylmethyl carbamate, 2-methylthioethyl carbamate, 2-methylsulfonylethyl carbamate, 2-(p-toluenesulfonyl)ethyl carbamate, [2-(1,3-dithianyl)]methyl carbamate (Dmoc), 4-methylthiophenyl carbamate (Mtpc), 2,4-dimethylthiophenyl carbamate (Bmpc), 2-phosphonioethyl carbamate (Peoc), 2-triphenylphosphonioisopropyl carbamate (Ppoc), 1,1-dimethyl-2-cyanoethyl carbamate, m-chloro-p-acyloxybenzyl carbamate, p-(dihydroxyboryl)benzyl carbamate, 5-benzisoxazolylmethyl carbamate, 2-(trifluoromethyl)-6-chromonylmethyl carbamate (Tcroc),

m-nitrophenyl carbamate, 3,5-dimethoxybenzyl carbamate, o-nitrobenzyl carbamate, 3,4-dimethoxy-6-nitrobenzyl carbamate, phenyl(o-nitrophenyl)methyl carbamate, t-amyl carbamate, S-benzyl thiocarbamate, p-cyanobenzyl carbamate, cyclobutyl carbamate, cyclohexyl carbamate, cyclopentyl carbamate, cyclopropylmethyl carbamate, p-decyloxybenzyl carbamate, 2,2-dimethoxyacrylvinyl carbamate, o-(N,N-dimethylcarboxamido)benzyl carbamate, 1,1-dimethyl-3-(N,N-dimethylcarboxamido)propyl carbamate, 1,1-dimethylpropynyl carbamate, di(2-pyridyl)methyl carbamate, 2-furanylmethyl carbamate, 2-iodoethyl carbamate, isoborynl carbamate, isobutyl carbamate, isonicotinyl carbamate, p-(p'-methoxyphenylazo)benzyl carbamate, 1-methylcyclobutyl carbamate, 1-methylcyclohexyl carbamate, 1-methyl-1-cyclopropylmethyl carbamate, 1-methyl-1-(3,5-dimethoxyphenyl)ethyl carbamate, 1-methyl-1-(p-phenylazophenyl)ethyl carbamate, 1-methyl-1-phenylethyl carbamate, 1-methyl-1-(4-pyridyl)ethyl carbamate, phenyl carbamate, p-(phenylazo)benzyl carbamate, 2,4,6-tri-t-butylphenyl carbamate, 4-(trimethylammonium)benzyl carbamate, and 2,4,6-trimethylbenzyl carbamate.

[0062] Nitrogen protecting groups such as sulfonamide groups (*e.g.*, $-S(=O)_2R^{aa}$) include, but are not limited to, p-toluenesulfonamide (Ts), benzenesulfonamide, 2,3,6-trimethyl-4-methoxybenzenesulfonamide (Mtr), 2,4,6-trimethoxybenzenesulfonamide (Mtb), 2,6-dimethyl-4-methoxybenzenesulfonamide (Pme), 2,3,5,6-tetramethyl-4-methoxybenzenesulfonamide (Mte), 4-methoxybenzenesulfonamide (Mbs), 2,4,6-trimethylbenzenesulfonamide (Mts), 2,6-dimethoxy-4-methylbenzenesulfonamide (iMds), 2,2,5,7,8-pentamethylchroman-6-sulfonamide (Pmc), methanesulfonamide (Ms), β -trimethylsilylethanesulfonamide (SES), 9-anthracenesulfonamide, 4-(4',8'-dimethoxynaphthylmethyl)benzenesulfonamide (DNMBS), benzylsulfonamide, trifluoromethylsulfonamide, and phenaclysulfonamide.

[0063] Other nitrogen protecting groups include, but are not limited to, phenothiazinyl-(10)-acyl derivative, N'-p-toluenesulfonylaminoacyl derivative, N'-phenylaminothioacyl derivative, N-benzoylphenylalanyl derivative, N-acetylmethionine derivative, 4,5-diphenyl-3-oxazolin-2-one, N-phthalimide, N-dithiasuccinimide (Dts), N-2,3-diphenylmaleimide, N-2,5-dimethylpyrrole, N-1,1,4,4-tetramethyldisilylazacyclopentane adduct (STABASE), 5-substituted 1,3-dimethyl-1,3,5-triazacyclohexan-2-one, 5-substituted 1,3-dibenzyl-1,3,5-triazacyclohexan-2-one, 1-substituted 3,5-dinitro-4-pyridone, N-methylamine, N-allylamine, N-[2-(trimethylsilyl)ethoxy]methylamine (SEM), N-3-acetoxypropylamine, N-(1-isopropyl-4-nitro-2-oxo-3-pyroolin-3-yl)amine, quaternary ammonium salts, N-benzylamine, N-di(4-

methoxyphenyl)methylamine, N-5-dibenzosuberylamine, N-triphenylmethylamine (Tr), N-[(4-methoxyphenyl)diphenylmethyl]amine (MMTr), N-9-phenylfluorenylamine (PhF), N-2,7-dichloro-9-fluorenylmethyleneamine, N-ferrocenylmethylamino (Fcm), N-2-picolylamino N'-oxide, N-1,1-dimethylthiomethyleneamine, N-benzylideneamine, N-p-methoxybenzylideneamine, N-diphenylmethyleneamine, N-[(2-pyridyl)mesityl]methyleneamine, N-(N',N'-dimethylaminomethylene)amine, N,N'-isopropylidenediamine, N-p-nitrobenzylideneamine, N-salicylideneamine, N-5-chlorosalicylideneamine, N-(5-chloro-2-hydroxyphenyl)phenylmethyleneamine, N-cyclohexylideneamine, N-(5,5-dimethyl-3-oxo-1-cyclohexenyl)amine, N-borane derivative, N-diphenylborinic acid derivative, N-[phenyl(pentaacylchromium- or tungsten)acyl]amine, N-copper chelate, N-zinc chelate, N-nitroamine, N-nitrosoamine, amine N-oxide, diphenylphosphinamide (Dpp), dimethylthiophosphinamide (Mpt), diphenylthiophosphinamide (Ppt), dialkyl phosphoramidates, dibenzyl phosphoramidate, diphenyl phosphoramidate, benzenesulfenamide, o-nitrobenzenesulfenamide (Nps), 2,4-dinitrobenzenesulfenamide, pentachlorobenzenesulfenamide, 2-nitro-4-methoxybenzenesulfenamide, triphenylmethylsulfenamide, and 3-nitropyridinesulfenamide (Npys).

[0064] In certain embodiments, the substituent present on an oxygen atom is an oxygen protecting group (also referred to herein as a "hydroxyl protecting group"). Oxygen protecting groups include, but are not limited to, $-R^{aa}$, $-N(R^{bb})_2$, $-C(=O)SR^{aa}$, $-C(=O)R^{aa}$, $-CO_2R^{aa}$, $-C(=O)N(R^{bb})_2$, $-C(=NR^{bb})R^{aa}$, $-C(=NR^{bb})OR^{aa}$, $-C(=NR^{bb})N(R^{bb})_2$, $-S(=O)R^{aa}$, $-SO_2R^{aa}$, $-Si(R^{aa})_3$, $-P(R^{cc})_2$, $-P(R^{cc})_3^+X^-$, $-P(OR^{cc})_2$, $-P(OR^{cc})_3^+X^-$, $-P(=O)(R^{aa})_2$, $-P(=O)(OR^{cc})_2$, and $-P(=O)(N(R^{bb})_2)_2$, wherein X^- , R^{aa} , R^{bb} , and R^{cc} are as defined herein. Oxygen protecting groups are well known in the art and include those described in detail in *Protecting Groups in Organic Synthesis*, T. W. Greene and P. G. M. Wuts, 3rd edition, John Wiley & Sons, 1999, incorporated herein by reference.

[0065] Exemplary oxygen protecting groups include, but are not limited to, methyl, methoxymethyl (MOM), methylthiomethyl (MTM), t-butylthiomethyl, (phenyldimethylsilyl)methoxymethyl (SMOM), benzyloxymethyl (BOM), p-methoxybenzyloxymethyl (PMBM), (4-methoxyphenoxy)methyl (p-AOM), guaiacolmethyl (GUM), t-butoxymethyl, 4-pentenylloxymethyl (POM), siloxymethyl, 2-methoxyethoxymethyl (MEM), 2,2,2-trichloroethoxymethyl, bis(2-chloroethoxy)methyl, 2-(trimethylsilyl)ethoxymethyl (SEMOR), tetrahydropyranyl (THP), 3-bromotetrahydropyranyl, tetrahydrothiopyranyl, 1-methoxycyclohexyl, 4-

methoxytetrahydropyranyl (MTHP), 4-methoxytetrahydrothiopyranyl, 4-methoxytetrahydrothiopyranyl S,S-dioxide, 1-[(2-chloro-4-methyl)phenyl]-4-methoxypiperidin-4-yl (CTMP), 1,4-dioxan-2-yl, tetrahydrofuran-yl, tetrahydrothiofuran-yl, 2,3,3a,4,5,6,7,7a-octahydro-7,8,8-trimethyl-4,7-methanobenzofuran-2-yl, 1-ethoxyethyl, 1-(2-chloroethoxy)ethyl, 1-methyl-1-methoxyethyl, 1-methyl-1-benzyloxyethyl, 1-methyl-1-benzyloxy-2-fluoroethyl, 2,2,2-trichloroethyl, 2-trimethylsilylethyl, 2-(phenylselenyl)ethyl, t-butyl, allyl, p-chlorophenyl, p-methoxyphenyl, 2,4-dinitrophenyl, benzyl (Bn), p-methoxybenzyl, 3,4-dimethoxybenzyl, o-nitrobenzyl, p-nitrobenzyl, p-halobenzyl, 2,6-dichlorobenzyl, p-cyanobenzyl, p-phenylbenzyl, 2-picoyl, 4-picoyl, 3-methyl-2-picoyl N-oxido, diphenylmethyl, p,p'-dinitrobenzhydryl, 5-dibenzosuberyl, triphenylmethyl, α -naphthylidiphenylmethyl, p-methoxyphenyldiphenylmethyl, di(p-methoxyphenyl)phenylmethyl, tri(p-methoxyphenyl)methyl, 4-(4'-bromophenacyloxyphenyl)diphenylmethyl, 4,4',4''-tris(4,5-dichlorophthalimidophenyl)methyl, 4,4',4''-tris(levulinoyloxyphenyl)methyl, 4,4',4''-tris(benzoyloxyphenyl)methyl, 3-(imidazol-1-yl)bis(4',4''-dimethoxyphenyl)methyl, 1,1-bis(4-methoxyphenyl)-1'-pyrenylmethyl, 9-anthryl, 9-(9-phenyl)xanthenyl, 9-(9-phenyl-10-oxo)anthryl, 1,3-benzodithiolan-2-yl, benzisothiazolyl S,S-dioxido, trimethylsilyl (TMS), triethylsilyl (TES), triisopropylsilyl (TIPS), dimethylisopropylsilyl (IPDMS), diethylisopropylsilyl (DEIPS), dimethylhexylsilyl, t-butyl dimethylsilyl (TBDMS), t-butyl diphenylsilyl (TBDPS), tribenzylsilyl, tri-p-xylylsilyl, triphenylsilyl, diphenylmethylsilyl (DPMS), t-butylmethoxyphenylsilyl (TBMPS), formate, benzoylformate, acetate, chloroacetate, dichloroacetate, trichloroacetate, trifluoroacetate, methoxyacetate, triphenylmethoxyacetate, phenoxyacetate, p-chlorophenoxyacetate, 3-phenylpropionate, 4-oxopentanoate (levulinate), 4,4-(ethylenedithio)pentanoate (levulinoyldithioacetal), pivaloate, adamantoate, crotonate, 4-methoxycrotonate, benzoate, p-phenylbenzoate, 2,4,6-trimethylbenzoate (mesitoate), methyl carbonate, 9-fluorenylmethyl carbonate (Fmoc), ethyl carbonate, 2,2,2-trichloroethyl carbonate (Troc), 2-(trimethylsilyl)ethyl carbonate (TMSEC), 2-(phenylsulfonyl) ethyl carbonate (Psec), 2-(triphenylphosphonio) ethyl carbonate (Peoc), isobutyl carbonate, vinyl carbonate, allyl carbonate, t-butyl carbonate (BOC or Boc), p-nitrophenyl carbonate, benzyl carbonate, p-methoxybenzyl carbonate, 3,4-dimethoxybenzyl carbonate, o-nitrobenzyl carbonate, p-nitrobenzyl carbonate, S-benzyl thiocarbonate, 4-ethoxy-1-naphthyl carbonate, methyl dithiocarbonate, 2-iodobenzoate, 4-azidobutyrate, 4-nitro-4-methylpentanoate, o-(dibromomethyl)benzoate, 2-formylbenzenesulfonate, 2-(methylthiomethoxy)ethyl, 4-(methylthiomethoxy)butyrate, 2-

(methylthiomethoxymethyl)benzoate, 2,6-dichloro-4-methylphenoxyacetate, 2,6-dichloro-4-(1,1,3,3-tetramethylbutyl)phenoxyacetate, 2,4-bis(1,1-dimethylpropyl)phenoxyacetate, chlorodiphenylacetate, isobutyrate, monosuccinoate, (E)-2-methyl-2-butenolate, o-(methoxyacyl)benzoate, α -naphthoate, nitrate, alkyl N,N,N',N'-tetramethylphosphorodiamidate, alkyl N-phenylcarbamate, borate, dimethylphosphinothioyl, alkyl 2,4-dinitrophenylsulfenate, sulfate, methanesulfonate (mesylate), benzylsulfonate, and tosylate (Ts).

[0066] In certain embodiments, the substituent present on a sulfur atom is a sulfur protecting group (also referred to as a “thiol protecting group”). Sulfur protecting groups include, but are not limited to, $-R^{aa}$, $-N(R^{bb})_2$, $-C(=O)SR^{aa}$, $-C(=O)R^{aa}$, $-CO_2R^{aa}$, $-C(=O)N(R^{bb})_2$, $-C(=NR^{bb})R^{aa}$, $-C(=NR^{bb})OR^{aa}$, $-C(=NR^{bb})N(R^{bb})_2$, $-S(=O)R^{aa}$, $-SO_2R^{aa}$, $-Si(R^{aa})_3$, $-P(R^{cc})_2$, $-P(R^{cc})_3^+X^-$, $-P(OR^{cc})_2$, $-P(OR^{cc})_3^+X^-$, $-P(=O)(R^{aa})_2$, $-P(=O)(OR^{cc})_2$, and $-P(=O)(N(R^{bb})_2)_2$, wherein R^{aa} , R^{bb} , and R^{cc} are as defined herein. Sulfur protecting groups are well known in the art and include those described in detail in *Protecting Groups in Organic Synthesis*, T. W. Greene and P. G. M. Wuts, 3rd edition, John Wiley & Sons, 1999, incorporated herein by reference.

[0067] A “counterion” or “anionic counterion” is a negatively charged group associated with a positively charged group in order to maintain electronic neutrality. An anionic counterion may be monovalent (*e.g.*, including one formal negative charge). An anionic counterion may also be multivalent (*e.g.*, including more than one formal negative charge), such as divalent or trivalent. Exemplary counterions include halide ions (*e.g.*, F^- , Cl^- , Br^- , I^-), NO_3^- , ClO_4^- , OH^- , $H_2PO_4^-$, HCO_3^- , HSO_4^- , sulfonate ions (*e.g.*, methanesulfonate, trifluoromethanesulfonate, *p*-toluenesulfonate, benzenesulfonate, 10-camphor sulfonate, naphthalene-2-sulfonate, naphthalene-1-sulfonic acid-5-sulfonate, ethan-1-sulfonic acid-2-sulfonate, and the like), carboxylate ions (*e.g.*, acetate, propanoate, benzoate, glycerate, lactate, tartrate, glycolate, gluconate, and the like), BF_4^- , PF_4^- , PF_6^- , AsF_6^- , SbF_6^- , $B[3,5-(CF_3)_2C_6H_3]_4^-$, $B(C_6F_5)_4^-$, BPh_4^- , $Al(OC(CF_3)_3)_4^-$, and carborane anions (*e.g.*, $CB_{11}H_{12}^-$ or $(HCB_{11}Me_5Br_6)^-$). Exemplary counterions which may be multivalent include CO_3^{2-} , HPO_4^{2-} , PO_4^{3-} , $B_4O_7^{2-}$, SO_4^{2-} , $S_2O_3^{2-}$, carboxylate anions (*e.g.*, tartrate, citrate, fumarate, maleate, malate, malonate, gluconate, succinate, glutarate, adipate, pimelate, suberate, azelate, sebacate, salicylate, phthalates, aspartate, glutamate, and the like), and carboranes.

[0068] As used herein, a “leaving group” (LG) is an art-understood term referring to a molecular fragment that departs with a pair of electrons in heterolytic bond cleavage, wherein the molecular fragment is an anion or neutral molecule. As used herein, a leaving group can

be an atom or a group capable of being displaced by a nucleophile. See, for example, Smith, March Advanced Organic Chemistry 6th ed. (501–502). Exemplary leaving groups include, but are not limited to, halo (*e.g.*, chloro, bromo, iodo) and activated substituted hydroxyl groups (*e.g.*, $-\text{OC}(=\text{O})\text{SR}^{\text{aa}}$, $-\text{OC}(=\text{O})\text{R}^{\text{aa}}$, $-\text{OCO}_2\text{R}^{\text{aa}}$, $-\text{OC}(=\text{O})\text{N}(\text{R}^{\text{bb}})_2$, $-\text{OC}(=\text{NR}^{\text{bb}})\text{R}^{\text{aa}}$, $-\text{OC}(=\text{NR}^{\text{bb}})\text{OR}^{\text{aa}}$, $-\text{OC}(=\text{NR}^{\text{bb}})\text{N}(\text{R}^{\text{bb}})_2$, $-\text{OS}(=\text{O})\text{R}^{\text{aa}}$, $-\text{OSO}_2\text{R}^{\text{aa}}$, $-\text{OP}(\text{R}^{\text{cc}})_2$, $-\text{OP}(\text{R}^{\text{cc}})_3$, $-\text{OP}(=\text{O})_2\text{R}^{\text{aa}}$, $-\text{OP}(=\text{O})(\text{R}^{\text{aa}})_2$, $-\text{OP}(=\text{O})(\text{OR}^{\text{cc}})_2$, $-\text{OP}(=\text{O})_2\text{N}(\text{R}^{\text{bb}})_2$, and $-\text{OP}(=\text{O})(\text{NR}^{\text{bb}})_2$, wherein R^{aa} , R^{bb} , and R^{cc} are as defined herein).

[0069] Use of the phrase “at least one instance” refers to 1, 2, 3, 4, or more instances, but also encompasses a range, *e.g.*, for example, from 1 to 4, from 1 to 3, from 1 to 2, from 2 to 4, from 2 to 3, or from 3 to 4 instances, inclusive.

[0070] The term “carbohydrate” or “saccharide” refers to an aldehydic or ketonic derivative of polyhydric alcohols. Carbohydrates include compounds with relatively small molecules (*e.g.*, sugars) as well as macromolecular or polymeric substances (*e.g.*, starch, glycogen, and cellulose polysaccharides). The term “sugar” refers to monosaccharides, disaccharides, or polysaccharides. Monosaccharides are the simplest carbohydrates in that they cannot be hydrolyzed to smaller carbohydrates. Most monosaccharides can be represented by the general formula $\text{C}_y\text{H}_{2y}\text{O}_y$ (*e.g.*, $\text{C}_6\text{H}_{12}\text{O}_6$ (a hexose such as glucose)), wherein y is an integer equal to or greater than 3. Certain polyhydric alcohols not represented by the general formula described above may also be considered monosaccharides. For example, deoxyribose is of the formula $\text{C}_5\text{H}_{10}\text{O}_4$ and is a monosaccharide. Monosaccharides usually consist of five or six carbon atoms and are referred to as pentoses and hexoses, respectively. If the monosaccharide contains an aldehyde it is referred to as an aldose; and if it contains a ketone, it is referred to as a ketose. Monosaccharides may also consist of three, four, or seven carbon atoms in an aldose or ketose form and are referred to as trioses, tetroses, and heptoses, respectively. Glyceraldehyde and dihydroxyacetone are considered to be aldotriose and ketotriose sugars, respectively. Examples of aldotetrose sugars include erythrose and threose; and ketotetrose sugars include erythrulose. Aldopentose sugars include ribose, arabinose, xylose, and lyxose; and ketopentose sugars include ribulose, arabulose, xylulose, and lyxulose. Examples of aldohexose sugars include glucose (for example, dextrose), mannose, galactose, allose, altrose, talose, gulose, and idose; and ketohexose sugars include fructose, psicose, sorbose, and tagatose. Ketoheptose sugars include sedoheptulose. Each carbon atom of a monosaccharide bearing a hydroxyl group ($-\text{OH}$), with the exception of the first and last carbons, is asymmetric, making the carbon atom a stereocenter with two possible configurations (R or S). Because of this asymmetry, a number of isomers may exist for any

given monosaccharide formula. The aldohexose D-glucose, for example, has the formula $C_6H_{12}O_6$, of which all but two of its six carbon atoms are stereogenic, making D-glucose one of the 16 (i.e., 2^4) possible stereoisomers. The assignment of D or L is made according to the orientation of the asymmetric carbon furthest from the carbonyl group: in a standard Fischer projection if the hydroxyl group is on the right the molecule is a D sugar, otherwise it is an L sugar. The aldehyde or ketone group of a straight-chain monosaccharide will react reversibly with a hydroxyl group on a different carbon atom to form a hemiacetal or hemiketal, forming a heterocyclic ring with an oxygen bridge between two carbon atoms. Rings with five and six atoms are called furanose and pyranose forms, respectively, and exist in equilibrium with the straight-chain form. During the conversion from the straight-chain form to the cyclic form, the carbon atom containing the carbonyl oxygen, called the anomeric carbon, becomes a stereogenic center with two possible configurations: the oxygen atom may take a position either above or below the plane of the ring. The resulting possible pair of stereoisomers is called anomers. In an α anomer, the $-OH$ substituent on the anomeric carbon rests on the opposite side (trans) of the ring from the $-CH_2OH$ side branch. The alternative form, in which the $-CH_2OH$ substituent and the anomeric hydroxyl are on the same side (cis) of the plane of the ring, is called a β anomer. A carbohydrate including two or more joined monosaccharide units is called a disaccharide or polysaccharide (e.g., a trisaccharide), respectively. The two or more monosaccharide units bound together by a covalent bond known as a glycosidic linkage formed via a dehydration reaction, resulting in the loss of a hydrogen atom from one monosaccharide and a hydroxyl group from another. Exemplary disaccharides include sucrose, lactulose, lactose, maltose, isomaltose, trehalose, cellobiose, xylobiose, laminaribiose, gentiobiose, mannobiose, melibiose, nigerose, or rutinose. Exemplary trisaccharides include, but are not limited to, isomaltotriose, nigerotriose, maltotriose, melezitose, maltotriulose, raffinose, and kestose. The term carbohydrate also includes other natural or synthetic stereoisomers of the carbohydrates described herein.

[0071] The term “heteroatom” refers to an atom that is not hydrogen or carbon. In certain embodiments, the heteroatom is nitrogen. In certain embodiments, the heteroatom is oxygen. In certain embodiments, the heteroatom is sulfur.


[0072] The term “small molecule” refers to molecules, whether naturally-occurring or artificially created (e.g., via chemical synthesis) that have a relatively low molecular weight. Typically, a small molecule is an organic compound (i.e., it contains carbon). The small molecule may contain multiple carbon-carbon bonds, stereocenters, and other functional groups (e.g., amines, hydroxyl, carbonyls, and heterocyclic rings, etc.). In certain

embodiments, the molecular weight of a small molecule is not more than about 1,000 g/mol, not more than about 900 g/mol, not more than about 800 g/mol, not more than about 700 g/mol, not more than about 600 g/mol, not more than about 500 g/mol, not more than about 400 g/mol, not more than about 300 g/mol, not more than about 200 g/mol, or not more than about 100 g/mol. In certain embodiments, the molecular weight of a small molecule is at least about 100 g/mol, at least about 200 g/mol, at least about 300 g/mol, at least about 400 g/mol, at least about 500 g/mol, at least about 600 g/mol, at least about 700 g/mol, at least about 800 g/mol, or at least about 900 g/mol, or at least about 1,000 g/mol. Combinations of the above ranges (*e.g.*, at least about 200 g/mol and not more than about 500 g/mol) are also possible. In certain embodiments, the small molecule is a therapeutically active agent such as a drug (*e.g.*, a molecule approved by the U.S. Food and Drug Administration as provided in the Code of Federal Regulations (C.F.R.)). The small molecule may also be complexed with one or more metal atoms and/or metal ions. In this instance, the small molecule is also referred to as a “small organometallic molecule.” Preferred small molecules are biologically active in that they produce a biological effect in animals, preferably mammals, more preferably humans. Small molecules include, but are not limited to, radionuclides and imaging agents. In certain embodiments, the small molecule is a drug. Preferably, though not necessarily, the drug is one that has already been deemed safe and effective for use in humans or animals by the appropriate governmental agency or regulatory body. For example, drugs approved for human use are listed by the FDA under 21 C.F.R. §§ 330.5, 331 through 361, and 440 through 460, incorporated herein by reference; drugs for veterinary use are listed by the FDA under 21 C.F.R. §§ 500 through 589, incorporated herein by reference. All listed drugs are considered acceptable for use in accordance with the present invention.







[0073] The “molecular weight” of a monovalent moiety $-R$ is calculated by subtracting 1 from the molecular weight of the compound $R-H$. The “molecular weight” of a divalent moiety $-L-$ is calculated by subtracting 2 from the molecular weight of the compound $H-L-H$.



[0074] A “hydrocarbon chain” refers to a substituted or unsubstituted divalent alkyl, alkenyl, or alkynyl group. A hydrocarbon chain includes (1) one or more chains of carbon atoms immediately between the two radicals of the hydrocarbon chain; (2) optionally one or more hydrogen atoms on the chain(s) of carbon atoms; and (3) optionally one or more substituents (“non-chain substituents,” which are not hydrogen) on the chain(s) of carbon atoms. A chain of carbon atoms consists of consecutively connected carbon atoms (“chain atoms”) and does


not include hydrogen atoms or heteroatoms. However, a non-chain substituent of a hydrocarbon chain may include any atoms, including hydrogen atoms, carbon atoms, and heteroatoms. For example, hydrocarbon chain $-C^A H(C^B H_2 C^C H_3)-$ includes one chain atom C^A , one hydrogen atom on C^A , and non-chain substituent $-(C^B H_2 C^C H_3)$. The term “ C_x hydrocarbon chain,” wherein x is a positive integer, refers to a hydrocarbon chain that includes x number of chain atom(s) between the two radicals of the hydrocarbon chain. If there is more than one possible value of x , the smallest possible value of x is used for the definition of the hydrocarbon chain. For example, $-\text{CH}(\text{C}_2\text{H}_5)-$ is a C_1 hydrocarbon chain,



and is a C_3 hydrocarbon chain. When a range of values is used, the meaning of the range is as described herein. For example, a C_{3-10} hydrocarbon chain refers to a hydrocarbon chain where the number of chain atoms of the shortest chain of carbon atoms immediately between the two radicals of the hydrocarbon chain is 3, 4, 5, 6, 7, 8, 9, or 10. A hydrocarbon chain may be saturated (*e.g.*, $-(\text{CH}_2)_4-$). A hydrocarbon chain may also be unsaturated and include one or more $\text{C}=\text{C}$ and/or $\text{C}\equiv\text{C}$ bonds anywhere in the hydrocarbon chain. For instance, $-\text{CH}=\text{CH}-(\text{CH}_2)_2-$, $-\text{CH}_2-\text{C}\equiv\text{C}-\text{CH}_2-$, and $-\text{C}\equiv\text{C}-\text{CH}=\text{CH}-$ are all examples of a unsubstituted and unsaturated hydrocarbon chain. In certain embodiments, the hydrocarbon chain is unsubstituted (*e.g.*, $-\text{C}\equiv\text{C}-$ or $-(\text{CH}_2)_4-$). In certain embodiments, the hydrocarbon chain is substituted (*e.g.*, $-\text{CH}(\text{C}_2\text{H}_5)-$ and $-\text{CF}_2-$). Any two substituents on the hydrocarbon chain may be joined to form an optionally substituted carbocyclyl, optionally substituted heterocyclyl, optionally substituted aryl, or optionally substituted heteroaryl ring.

For instance, , , , , , and  are all examples of a hydrocarbon chain. In contrast, in certain embodiments,

 and  are not within the scope of the hydrocarbon chains described herein. When a chain atom of a C_x hydrocarbon chain is replaced with a heteroatom, the resulting group is referred to as a C_x hydrocarbon chain wherein a chain atom is replaced with

a heteroatom, as opposed to a C_{x-1} hydrocarbon chain. For example,  is a C_3 hydrocarbon chain wherein one chain atom is replaced with an oxygen atom.

[0075] The term “crystalline” or “crystalline form” refers to a solid form substantially exhibiting three-dimensional order. In certain embodiments, a crystalline form of a solid is a solid form that is substantially not amorphous. In certain embodiments, the X-ray powder diffraction (XRPD) pattern of a crystalline form includes one or more sharply defined peaks.

[0076] As used herein, the term “salt” refers to any and all salts, and encompasses pharmaceutically acceptable salts.

[0077] The term “pharmaceutically acceptable salt” refers to those salts which are, within the scope of sound medical judgment, suitable for use in contact with the tissues of humans and lower animals without undue toxicity, irritation, allergic response, and the like, and are commensurate with a reasonable benefit/risk ratio. Pharmaceutically acceptable salts are well known in the art. For example, Berge *et al.* describe pharmaceutically acceptable salts in detail in *J. Pharmaceutical Sciences*, 1977, 66, 1-19, incorporated herein by reference.

Pharmaceutically acceptable salts of the compounds of this invention include those derived from suitable inorganic and organic acids and bases. Examples of pharmaceutically acceptable, nontoxic acid addition salts are salts of an amino group formed with inorganic acids, such as hydrochloric acid, hydrobromic acid, phosphoric acid, sulfuric acid, and perchloric acid or with organic acids, such as acetic acid, oxalic acid, maleic acid, tartaric acid, citric acid, succinic acid, or malonic acid or by using other methods known in the art such as ion exchange. Other pharmaceutically acceptable salts include adipate, alginate, ascorbate, aspartate, benzenesulfonate, benzoate, bisulfate, borate, butyrate, camphorate, camphorsulfonate, citrate, cyclopentanepropionate, digluconate, dodecylsulfate, ethanesulfonate, formate, fumarate, glucoheptonate, glycerophosphate, gluconate, hemisulfate, heptanoate, hexanoate, hydroiodide, 2-hydroxy-ethanesulfonate, lactobionate, lactate, laurate, lauryl sulfate, malate, maleate, malonate, methanesulfonate, 2-naphthalenesulfonate, nicotinate, nitrate, oleate, oxalate, palmitate, pamoate, pectinate, persulfate, 3-phenylpropionate, phosphate, picrate, pivalate, propionate, stearate, succinate, sulfate, tartrate, thiocyanate, p-toluenesulfonate, undecanoate, valerate salts, and the like. Salts derived from appropriate bases include alkali metal, alkaline earth metal, ammonium, and $N^+(C_{1-4} \text{ alkyl})_4^-$ salts. Representative alkali or alkaline earth metal salts include sodium, lithium, potassium, calcium, magnesium, and the like. Further pharmaceutically acceptable salts include, when appropriate, nontoxic ammonium, quaternary ammonium, and amine

cations formed using counterions such as halide, hydroxide, carboxylate, sulfate, phosphate, nitrate, lower alkyl sulfonate, and aryl sulfonate.

[0078] The term “solvate” refers to forms of the compound, or a salt thereof, that are associated with a solvent, usually by a solvolysis reaction. This physical association may include hydrogen bonding. Conventional solvents include water, methanol, ethanol, acetic acid, DMSO, THF, diethyl ether, and the like. The compounds described herein may be prepared, *e.g.*, in crystalline form, and may be solvated. Suitable solvates include pharmaceutically acceptable solvates and further include both stoichiometric solvates and non-stoichiometric solvates. In certain instances, the solvate will be capable of isolation, for example, when one or more solvent molecules are incorporated in the crystal lattice of a crystalline solid. “Solvate” encompasses both solution-phase and isolatable solvates. Representative solvates include hydrates, ethanulates, and methanulates.

[0079] The term “hydrate” refers to a compound that is associated with water. Typically, the number of the water molecules contained in a hydrate of a compound is in a definite ratio to the number of the compound molecules in the hydrate. Therefore, a hydrate of a compound may be represented, for example, by the general formula $R \cdot x H_2O$, wherein R is the compound, and x is a number greater than 0. A given compound may form more than one type of hydrate, including, *e.g.*, monohydrates (x is 1), lower hydrates (x is a number greater than 0 and smaller than 1, *e.g.*, hemihydrates ($R \cdot 0.5 H_2O$)), and polyhydrates (x is a number greater than 1, *e.g.*, dihydrates ($R \cdot 2 H_2O$) and hexahydrates ($R \cdot 6 H_2O$)).

[0080] The term “tautomers” or “tautomeric” refers to two or more interconvertible compounds resulting from at least one formal migration of a hydrogen atom and at least one change in valency (*e.g.*, a single bond to a double bond, a triple bond to a single bond, or vice versa). The exact ratio of the tautomers depends on several factors, including temperature, solvent, and pH. Tautomerizations (*i.e.*, the reaction providing a tautomeric pair) may be catalyzed by acid or base. Exemplary tautomerizations include keto-to-enol, amide-to-imide, lactam-to-lactim, enamine-to-imine, and enamine-to-(a different enamine) tautomerizations.

[0081] It is also to be understood that compounds that have the same molecular formula but differ in the nature or sequence of bonding of their atoms or the arrangement of their atoms in space are termed “isomers”. Isomers that differ in the arrangement of their atoms in space are termed “stereoisomers”. Stereoisomers that are not mirror images of one another are termed “diastereomers” and those that are non-superimposable mirror images of each other are termed “enantiomers”. When a compound has an asymmetric center, for example, it is

bonded to four different groups, a pair of enantiomers is possible. An enantiomer can be characterized by the absolute configuration of its asymmetric center and is described by the R- and S-sequencing rules of Cahn and Prelog, or by the manner in which the molecule rotates the plane of polarized light and designated as dextrorotatory or levorotatory (i.e., as (+) or (-)-isomers respectively). A chiral compound can exist as either individual enantiomer or as a mixture thereof. A mixture containing equal proportions of the enantiomers is called a “racemic mixture”.

[0082] The term “polymorph” refers to a crystalline form of a compound (or a salt, hydrate, or solvate thereof). All polymorphs have the same elemental composition. Different crystalline forms usually have different X-ray diffraction patterns, infrared spectra, melting points, density, hardness, crystal shape, optical and electrical properties, stability, and solubility. Recrystallization solvent, rate of crystallization, storage temperature, and other factors may cause one crystal form to dominate. Various polymorphs of a compound can be prepared by crystallization under different conditions.

[0083] The term “prodrugs” refers to compounds that have cleavable groups and become by solvolysis or under physiological conditions the compounds described herein, which are pharmaceutically active *in vivo*. Such examples include, but are not limited to, choline ester derivatives and the like, N-alkylmorpholine esters and the like. Other derivatives of the compounds described herein have activity in both their acid and acid derivative forms, but in the acid sensitive form often offer advantages of solubility, tissue compatibility, or delayed release in the mammalian organism (see, Bundgard, H., *Design of Prodrugs*, pp. 7-9, 21-24, Elsevier, Amsterdam 1985). Prodrugs include acid derivatives well known to practitioners of the art, such as, for example, esters prepared by reaction of the parent acid with a suitable alcohol, or amides prepared by reaction of the parent acid compound with a substituted or unsubstituted amine, or acid anhydrides, or mixed anhydrides. Simple aliphatic or aromatic esters, amides, and anhydrides derived from acidic groups pendant on the compounds described herein are particular prodrugs. In some cases it is desirable to prepare double ester type prodrugs such as (acyloxy)alkyl esters or ((alkoxycarbonyl)oxy)alkylesters. C₁-C₈ alkyl, C₂-C₈ alkenyl, C₂-C₈ alkynyl, aryl, C₇-C₁₂ substituted aryl, and C₇-C₁₂ arylalkyl esters of the compounds described herein may be preferred.

[0084] The terms “composition” and “formulation” are used interchangeably.

[0085] A “subject” to which administration is contemplated refers to a human (i.e., male or female of any age group, *e.g.*, pediatric subject (*e.g.*, infant, child, or adolescent) or adult subject (*e.g.*, young adult, middle-aged adult, or senior adult)) or non-human animal. In

certain embodiments, the non-human animal is a mammal (*e.g.*, primate (*e.g.*, cynomolgus monkey or rhesus monkey), commercially relevant mammal (*e.g.*, cattle, pig, horse, sheep, goat, cat, or dog), or bird (*e.g.*, commercially relevant bird, such as chicken, duck, goose, or turkey)). In certain embodiments, the non-human animal is a fish, reptile, or amphibian. The non-human animal may be a male or female at any stage of development. The non-human animal may be a transgenic animal or genetically engineered animal. The term “patient” refers to a human subject in need of treatment of a disease.

[0086] The term “biological sample” refers to any sample including tissue samples (such as tissue sections and needle biopsies of a tissue); cell samples (*e.g.*, cytological smears (such as Pap or blood smears) or samples of cells obtained by microdissection); samples of whole organisms (such as samples of yeasts or bacteria); or cell fractions, fragments or organelles (such as obtained by lysing cells and separating the components thereof by centrifugation or otherwise). Other examples of biological samples include blood, serum, urine, semen, fecal matter, cerebrospinal fluid, interstitial fluid, mucous, tears, sweat, pus, biopsied tissue (*e.g.*, obtained by a surgical biopsy or needle biopsy), nipple aspirates, milk, vaginal fluid, saliva, swabs (such as buccal swabs), or any material containing biomolecules that is derived from a first biological sample.

[0087] The term “administer,” “administering,” or “administration” refers to implanting, absorbing, ingesting, injecting, inhaling, or otherwise introducing a compound described herein, or a composition thereof, in or on a subject.

[0088] The terms “treatment,” “treat,” and “treating” refer to reversing, alleviating, delaying the onset of, or inhibiting the progress of a disease described herein. In some embodiments, treatment may be administered after one or more signs or symptoms of the disease have developed or have been observed. In other embodiments, treatment may be administered in the absence of signs or symptoms of the disease. For example, treatment may be administered to a susceptible subject prior to the onset of symptoms (*e.g.*, in light of a history of symptoms and/or in light of exposure to a pathogen). Treatment may also be continued after symptoms have resolved, for example, to delay or prevent recurrence.

[0089] The terms “condition,” “disease,” and “disorder” are used interchangeably.

[0090] An “effective amount” of a compound described herein refers to an amount sufficient to elicit the desired biological response. An effective amount of a compound described herein may vary depending on such factors as the desired biological endpoint, the pharmacokinetics of the compound, the condition being treated, the mode of administration, and the age and health of the subject. In certain embodiments, an effective amount is a therapeutically

effective amount. In certain embodiments, an effective amount is a prophylactic treatment. In certain embodiments, an effective amount is the amount of a compound described herein in a single dose. In certain embodiments, an effective amount is the combined amounts of a compound described herein in multiple doses.

[0091] A “therapeutically effective amount” of a compound described herein is an amount sufficient to provide a therapeutic benefit in the treatment of a condition or to delay or minimize one or more symptoms associated with the condition. A therapeutically effective amount of a compound means an amount of therapeutic agent, alone or in combination with other therapies, which provides a therapeutic benefit in the treatment of the condition. The term “therapeutically effective amount” can encompass an amount that improves overall therapy, reduces or avoids symptoms, signs, or causes of the condition, and/or enhances the therapeutic efficacy of another therapeutic agent. In certain embodiments, a therapeutically effective amount is an amount sufficient for inhibition of JNK (*e.g.*, JNK2).

[0092] A “prophylactically effective amount” of a compound described herein is an amount sufficient to prevent a condition, or one or more symptoms associated with the condition or prevent its recurrence. A prophylactically effective amount of a compound means an amount of a therapeutic agent, alone or in combination with other agents, which provides a prophylactic benefit in the prevention of the condition. The term “prophylactically effective amount” can encompass an amount that improves overall prophylaxis or enhances the prophylactic efficacy of another prophylactic agent. In certain embodiments, a prophylactically effective amount is an amount sufficient for inhibition of JNK (*e.g.*, JNK2).

[0093] As used herein the term “inhibit” or “inhibition” in the context of proteins, for example, in the context of JNK, refers to a reduction in the activity of the kinase. In some embodiments, the term refers to a reduction of the level of activity, *e.g.*, JNK2 activity, to a level that is statistically significantly lower than an initial level, which may, for example, be a baseline level of activity. In some embodiments, the term refers to a reduction of the level of enzyme activity, *e.g.*, JNK2 activity, to a level that is less than 75%, less than 50%, less than 40%, less than 30%, less than 25%, less than 20%, less than 10%, less than 9%, less than 8%, less than 7%, less than 6%, less than 5%, less than 4%, less than 3%, less than 2%, less than 1%, less than 0.5%, less than 0.1%, less than 0.01%, less than 0.001%, or less than 0.0001% of an initial level, which may, for example, be a baseline level of enzyme activity.

[0094] Pharmaceutical compositions described herein can be prepared by any method known in the art of pharmacology. In general, such preparatory methods include bringing the compound described herein (*i.e.*, the “active ingredient”) into association with a carrier or

excipient, and/or one or more other accessory ingredients, and then, if necessary and/or desirable, shaping, and/or packaging the product into a desired single- or multi-dose unit.

[0095] A “proliferative disease” refers to a disease that occurs due to abnormal growth or extension by the multiplication of cells (Walker, *Cambridge Dictionary of Biology*; Cambridge University Press: Cambridge, UK, 1990). A proliferative disease may be associated with: 1) the pathological proliferation of normally quiescent cells; 2) the pathological migration of cells from their normal location (*e.g.*, metastasis of neoplastic cells); 3) the pathological expression of proteolytic enzymes such as the matrix metalloproteinases (*e.g.*, collagenases, gelatinases, and elastases); or 4) the pathological angiogenesis as in proliferative retinopathy and tumor metastasis. Exemplary proliferative diseases include cancers (*i.e.*, “malignant neoplasms”), benign neoplasms, angiogenesis, inflammatory diseases, and autoimmune diseases.

[0096] The term “angiogenesis” refers to the physiological process through which new blood vessels form from pre-existing vessels. Angiogenesis is distinct from vasculogenesis, which is the *de novo* formation of endothelial cells from mesoderm cell precursors. The first vessels in a developing embryo form through vasculogenesis, after which angiogenesis is responsible for most blood vessel growth during normal or abnormal development. Angiogenesis is a vital process in growth and development, as well as in wound healing and in the formation of granulation tissue. However, angiogenesis is also a fundamental step in the transition of tumors from a benign state to a malignant one, leading to the use of angiogenesis inhibitors in the treatment of cancer. Angiogenesis may be chemically stimulated by angiogenic proteins, such as growth factors (*e.g.*, VEGF). “Pathological angiogenesis” refers to abnormal (*e.g.*, excessive or insufficient) angiogenesis that amounts to and/or is associated with a disease.

[0097] The terms “neoplasm” and “tumor” are used herein interchangeably and refer to an abnormal mass of tissue wherein the growth of the mass surpasses and is not coordinated with the growth of a normal tissue. A neoplasm or tumor may be “benign” or “malignant,” depending on the following characteristics: degree of cellular differentiation (including morphology and functionality), rate of growth, local invasion, and metastasis. A “benign neoplasm” is generally well differentiated, has characteristically slower growth than a malignant neoplasm, and remains localized to the site of origin. In addition, a benign neoplasm does not have the capacity to infiltrate, invade, or metastasize to distant sites. Exemplary benign neoplasms include, but are not limited to, lipoma, chondroma, adenomas, acrochordon, senile angiomas, seborrheic keratoses, lentigos, and sebaceous hyperplasias. In some cases, certain “benign” tumors may later give rise to malignant neoplasms, which may

result from additional genetic changes in a subpopulation of the tumor's neoplastic cells, and these tumors are referred to as "pre-malignant neoplasms." An exemplary pre-malignant neoplasm is a teratoma. In contrast, a "malignant neoplasm" is generally poorly differentiated (anaplasia) and has characteristically rapid growth accompanied by progressive infiltration, invasion, and destruction of the surrounding tissue. Furthermore, a malignant neoplasm generally has the capacity to metastasize to distant sites. The term "metastasis," "metastatic," or "metastasize" refers to the spread or migration of cancerous cells from a primary or original tumor to another organ or tissue and is typically identifiable by the presence of a "secondary tumor" or "secondary cell mass" of the tissue type of the primary or original tumor and not of that of the organ or tissue in which the secondary (metastatic) tumor is located. For example, a prostate cancer that has migrated to bone is said to be metastasized prostate cancer and includes cancerous prostate cancer cells growing in bone tissue.

[0098] The term "cancer" refers to a class of diseases characterized by the development of abnormal cells that proliferate uncontrollably and have the ability to infiltrate and destroy normal body tissues. See, *e.g.*, *Stedman's Medical Dictionary*, 25th ed.; Hensyl ed.; Williams & Wilkins: Philadelphia, 1990. Exemplary cancers include, but are not limited to, acoustic neuroma; adenocarcinoma; adrenal gland cancer; anal cancer; angiosarcoma (*e.g.*, lymphangiosarcoma, lymphangioendotheliosarcoma, hemangiosarcoma); appendix cancer; benign monoclonal gammopathy; biliary cancer (*e.g.*, cholangiocarcinoma); bladder cancer; breast cancer (*e.g.*, adenocarcinoma of the breast, papillary carcinoma of the breast, mammary cancer, medullary carcinoma of the breast); brain cancer (*e.g.*, meningioma, glioblastomas, glioma (*e.g.*, astrocytoma, oligodendroglioma), medulloblastoma); bronchus cancer; carcinoid tumor; cervical cancer (*e.g.*, cervical adenocarcinoma); choriocarcinoma; chordoma; craniopharyngioma; colorectal cancer (*e.g.*, colon cancer, rectal cancer, colorectal adenocarcinoma); connective tissue cancer; epithelial carcinoma; ependymoma; endotheliosarcoma (*e.g.*, Kaposi's sarcoma, multiple idiopathic hemorrhagic sarcoma); endometrial cancer (*e.g.*, uterine cancer, uterine sarcoma); esophageal cancer (*e.g.*, adenocarcinoma of the esophagus, Barrett's adenocarcinoma); Ewing's sarcoma; ocular cancer (*e.g.*, intraocular melanoma, retinoblastoma); familiar hypereosinophilia; gall bladder cancer; gastric cancer (*e.g.*, stomach adenocarcinoma); gastrointestinal stromal tumor (GIST); germ cell cancer; head and neck cancer (*e.g.*, head and neck squamous cell carcinoma, oral cancer (*e.g.*, oral squamous cell carcinoma), throat cancer (*e.g.*, laryngeal cancer, pharyngeal cancer, nasopharyngeal cancer, oropharyngeal cancer)); hematopoietic cancers (*e.g.*, leukemia such as acute lymphocytic leukemia (ALL) (*e.g.*, B-cell ALL, T-cell ALL), acute

myelocytic leukemia (AML) (*e.g.*, B-cell AML, T-cell AML), chronic myelocytic leukemia (CML) (*e.g.*, B-cell CML, T-cell CML), and chronic lymphocytic leukemia (CLL) (*e.g.*, B-cell CLL, T-cell CLL)); lymphoma such as Hodgkin lymphoma (HL) (*e.g.*, B-cell HL, T-cell HL) and non-Hodgkin lymphoma (NHL) (*e.g.*, B-cell NHL such as diffuse large cell lymphoma (DLCL) (*e.g.*, diffuse large B-cell lymphoma), follicular lymphoma, chronic lymphocytic leukemia/small lymphocytic lymphoma (CLL/SLL), mantle cell lymphoma (MCL), marginal zone B-cell lymphomas (*e.g.*, mucosa-associated lymphoid tissue (MALT) lymphomas, nodal marginal zone B-cell lymphoma, splenic marginal zone B-cell lymphoma), primary mediastinal B-cell lymphoma, Burkitt lymphoma, lymphoplasmacytic lymphoma (*i.e.*, Waldenström's macroglobulinemia), hairy cell leukemia (HCL), immunoblastic large cell lymphoma, precursor B-lymphoblastic lymphoma and primary central nervous system (CNS) lymphoma; and T-cell NHL such as precursor T-lymphoblastic lymphoma/leukemia, peripheral T-cell lymphoma (PTCL) (*e.g.*, cutaneous T-cell lymphoma (CTCL) (*e.g.*, mycosis fungoides, Sezary syndrome), angioimmunoblastic T-cell lymphoma, extranodal natural killer T-cell lymphoma, enteropathy type T-cell lymphoma, subcutaneous panniculitis-like T-cell lymphoma, and anaplastic large cell lymphoma); a mixture of one or more leukemia/lymphoma as described above; and multiple myeloma (MM)), heavy chain disease (*e.g.*, alpha chain disease, gamma chain disease, mu chain disease); hemangioblastoma; hypopharynx cancer; inflammatory myofibroblastic tumors; immunocytic amyloidosis; kidney cancer (*e.g.*, nephroblastoma *a.k.a.* Wilms' tumor, renal cell carcinoma); liver cancer (*e.g.*, hepatocellular cancer (HCC), malignant hepatoma); lung cancer (*e.g.*, bronchogenic carcinoma, small cell lung cancer (SCLC), non-small cell lung cancer (NSCLC), adenocarcinoma of the lung); leiomyosarcoma (LMS); mastocytosis (*e.g.*, systemic mastocytosis); muscle cancer; myelodysplastic syndrome (MDS); mesothelioma; myeloproliferative disorder (MPD) (*e.g.*, polycythemia vera (PV), essential thrombocytosis (ET), agnogenic myeloid metaplasia (AMM) *a.k.a.* myelofibrosis (MF), chronic idiopathic myelofibrosis, chronic myelocytic leukemia (CML), chronic neutrophilic leukemia (CNL), hypereosinophilic syndrome (HES)); neuroblastoma; neurofibroma (*e.g.*, neurofibromatosis (NF) type 1 or type 2, schwannomatosis); neuroendocrine cancer (*e.g.*, gastroenteropancreatic neuroendocrine tumor (GEP-NET), carcinoid tumor); osteosarcoma (*e.g.*, bone cancer); ovarian cancer (*e.g.*, cystadenocarcinoma, ovarian embryonal carcinoma, ovarian adenocarcinoma); papillary adenocarcinoma; pancreatic cancer (*e.g.*, pancreatic adenocarcinoma, intraductal papillary mucinous neoplasm (IPMN), Islet cell tumors); penile cancer (*e.g.*, Paget's disease of the penis and scrotum); pinealoma; primitive neuroectodermal

tumor (PNT); plasma cell neoplasia; paraneoplastic syndromes; intraepithelial neoplasms; prostate cancer (*e.g.*, prostate adenocarcinoma); rectal cancer; rhabdomyosarcoma; salivary gland cancer; skin cancer (*e.g.*, squamous cell carcinoma (SCC), keratoacanthoma (KA), melanoma, basal cell carcinoma (BCC)); small bowel cancer (*e.g.*, appendix cancer); soft tissue sarcoma (*e.g.*, malignant fibrous histiocytoma (MFH), liposarcoma, malignant peripheral nerve sheath tumor (MPNST), chondrosarcoma, fibrosarcoma, myxosarcoma); sebaceous gland carcinoma; small intestine cancer; sweat gland carcinoma; synovioma; testicular cancer (*e.g.*, seminoma, testicular embryonal carcinoma); thyroid cancer (*e.g.*, papillary carcinoma of the thyroid, papillary thyroid carcinoma (PTC), medullary thyroid cancer); urethral cancer; vaginal cancer; and vulvar cancer (*e.g.*, Paget's disease of the vulva).

[0099] The term “inflammatory disease” refers to a disease caused by, resulting from, or resulting in inflammation. The term “inflammatory disease” may also refer to a dysregulated inflammatory reaction that causes an exaggerated response by macrophages, granulocytes, and/or T-lymphocytes leading to abnormal tissue damage and/or cell death. An inflammatory disease can be either an acute or chronic inflammatory condition and can result from infections or non-infectious causes. Inflammatory diseases include, without limitation, atherosclerosis, arteriosclerosis, autoimmune disorders, multiple sclerosis, systemic lupus erythematosus, polymyalgia rheumatica (PMR), gouty arthritis, degenerative arthritis, tendonitis, bursitis, psoriasis, cystic fibrosis, arthroseitis, rheumatoid arthritis, inflammatory arthritis, Sjogren's syndrome, giant cell arteritis, progressive systemic sclerosis (scleroderma), ankylosing spondylitis, polymyositis, dermatomyositis, pemphigus, pemphigoid, diabetes (*e.g.*, Type I), myasthenia gravis, Hashimoto's thyroiditis, Graves' disease, Goodpasture's disease, mixed connective tissue disease, sclerosing cholangitis, inflammatory bowel disease, Crohn's disease, ulcerative colitis, pernicious anemia, inflammatory dermatoses, usual interstitial pneumonitis (UIP), asbestosis, silicosis, bronchiectasis, berylliosis, talcosis, pneumoconiosis, sarcoidosis, desquamative interstitial pneumonia, lymphoid interstitial pneumonia, giant cell interstitial pneumonia, cellular interstitial pneumonia, extrinsic allergic alveolitis, Wegener's granulomatosis and related forms of angiitis (temporal arteritis and polyarteritis nodosa), inflammatory dermatoses, hepatitis, delayed-type hypersensitivity reactions (*e.g.*, poison ivy dermatitis), pneumonia, respiratory tract inflammation, Adult Respiratory Distress Syndrome (ARDS), encephalitis, immediate hypersensitivity reactions, asthma, hayfever, allergies, acute anaphylaxis, rheumatic fever, glomerulonephritis, pyelonephritis, cellulitis, cystitis, chronic cholecystitis,

ischemia (ischemic injury), reperfusion injury, allograft rejection, host-versus-graft rejection, appendicitis, arteritis, blepharitis, bronchiolitis, bronchitis, cervicitis, cholangitis, chorioamnionitis, conjunctivitis, dacryoadenitis, dermatomyositis, endocarditis, endometritis, enteritis, enterocolitis, epicondylitis, epididymitis, fasciitis, fibrositis, gastritis, gastroenteritis, gingivitis, ileitis, iritis, laryngitis, myelitis, myocarditis, nephritis, omphalitis, oophoritis, orchitis, osteitis, otitis, pancreatitis, parotitis, pericarditis, pharyngitis, pleuritis, phlebitis, pneumonitis, proctitis, prostatitis, rhinitis, salpingitis, sinusitis, stomatitis, synovitis, testitis, tonsillitis, urethritis, urocystitis, uveitis, vaginitis, vasculitis, vulvitis, vulvovaginitis, angitis, chronic bronchitis, osteomyelitis, optic neuritis, temporal arteritis, transverse myelitis, necrotizing fasciitis, and necrotizing enterocolitis. An ocular inflammatory disease includes, but is not limited to, post-surgical inflammation.

[00100] An “autoimmune disease” refers to a disease arising from an inappropriate immune response of the body of a subject against substances and tissues normally present in the body. In other words, the immune system mistakes some part of the body as a pathogen and attacks its own cells. This may be restricted to certain organs (*e.g.*, in autoimmune thyroiditis) or involve a particular tissue in different places (*e.g.*, Goodpasture’s disease which may affect the basement membrane in both the lung and kidney). The treatment of autoimmune diseases is typically with immunosuppression, *e.g.*, medications which decrease the immune response. Exemplary autoimmune diseases include, but are not limited to, glomerulonephritis, Goodpasture’s syndrome, necrotizing vasculitis, lymphadenitis, peri-arteritis nodosa, systemic lupus erythematosus, rheumatoid arthritis, psoriatic arthritis, systemic lupus erythematosus, psoriasis, ulcerative colitis, systemic sclerosis, dermatomyositis/polymyositis, anti-phospholipid antibody syndrome, scleroderma, pemphigus vulgaris, ANCA-associated vasculitis (*e.g.*, Wegener’s granulomatosis, microscopic polyangiitis), uveitis, Sjogren’s syndrome, Crohn’s disease, Reiter’s syndrome, ankylosing spondylitis, Lyme disease, Guillain-Barré syndrome, Hashimoto’s thyroiditis, and cardiomyopathy.

[00101] A “kinase” is a type of enzyme that transfers phosphate groups from high energy donor molecules, such as ATP, to specific substrates, referred to as phosphorylation. Kinases are part of the larger family of phosphotransferases. One of the largest groups of kinases are protein kinases, which act on and modify the activity of specific proteins. Kinases are used extensively to transmit signals and control complex processes in cells. Various other kinases act on small molecules such as lipids, carbohydrates, amino acids, and nucleotides, either for signaling or to prime them for metabolic pathways. Kinases are often named after their substrates. More than 500 different protein kinases have been identified in humans. These

exemplary human protein kinases include, but are not limited to, AAK1, ABL, ACK, ACTR2, ACTR2B, AKT1, AKT2, AKT3, ALK, ALK1, ALK2, ALK4, ALK7, AMPKa1, AMPKa2, ANKRD3, ANPa, ANPb, ARAF, ARAFps, ARG, AurA, AurAps1, AurAps2, AurB, AurBps1, AurC, AXL, BARK1, BARK2, BIKE, BLK, BMPR1A, BMPR1Aps1, BMPR1Aps2, BMPR1B, BMPR2, BMX, BRAF, BRAFps, BRK, BRSK1, BRSK2, BTK, BUB1, BUBR1, CaMK1a, CaMK1b, CaMK1d, CaMK1g, CaMK2a, CaMK2b, CaMK2d, CaMK2g, CaMK4, CaMKK1, CaMKK2, caMLCK, CASK, CCK4, CCRK, CDC2, CDC7, CDK10, CDK11, CDK2, CDK3, CDK4, CDK4ps, CDK5, CDK5ps, CDK6, CDK7, CDK7ps, CDK8, CDK8ps, CDK9, CDKL1, CDKL2, CDKL3, CDKL4, CDKL5, CGDps, CHED, CHK1, CHK2, CHK2ps1, CHK2ps2, CK1a, CK1a2, CK1aps1, CK1aps2, CK1aps3, CK1d, CK1e, CK1g1, CK1g2, CK1g2ps, CK1g3, CK2a1, CK2a1-rs, CK2a2, CLIK1, CLIK1L, CLK1, CLK2, CLK2ps, CLK3, CLK3ps, CLK4, COT, CRIK, CRK7, CSK, CTK, CYGD, CYGF, DAPK1, DAPK2, DAPK3, DCAMKL1, DCAMKL2, DCAMKL3, DDR1, DDR2, DLK, DMPK1, DMPK2, DRAK1, DRAK2, DYRK1A, DYRK1B, DYRK2, DYRK3, DYRK4, EGFR, EphA1, EphA10, EphA2, EphA3, EphA4, EphA5, EphA6, EphA7, EphA8, EphB1, EphB2, EphB3, EphB4, EphB6, Erk1, Erk2, Erk3, Erk3ps1, Erk3ps2, Erk3ps3, Erk3ps4, Erk4, Erk5, Erk7, FAK, FER, FERps, FES, FGFR1, FGFR2, FGFR3, FGFR4, FGR, FLT1, FLT1ps, FLT3, FLT4, FMS, FRK, Fused, FYN, GAK, GCK, GCN2, GCN22, GPRK4, GPRK5, GPRK6, GPRK6ps, GPRK7, GSK3A, GSK3B, Haspin, HCK, HER2/ErbB2, HER3/ErbB3, HER4/ErbB4, HH498, HIPK1, HIPK2, HIPK3, HIPK4, HPK1, HRI, HRIps, HSER, HUNK, ICK, IGF1R, IKKa, IKKb, IKKe, ILK, INSR, IRAK1, IRAK2, IRAK3, IRAK4, IRE1, IRE2, IRR, ITK, JAK1, JAK2, JAK3, JNK1, JNK2, JNK3, KDR, KHS1, KHS2, KIS, KIT, KSGCps, KSR1, KSR2, LATS1, LATS2, LCK, LIMK1, LIMK2, LIMK2ps, LKB1, LMR1, LMR2, LMR3, LOK, LRRK1, LRRK2, LTK, LYN, LZK, MAK, MAP2K1, MAP2K1ps, MAP2K2, MAP2K2ps, MAP2K3, MAP2K4, MAP2K5, MAP2K6, MAP2K7, MAP3K1, MAP3K2, MAP3K3, MAP3K4, MAP3K5, MAP3K6, MAP3K7, MAP3K8, MAPKAPK2, MAPKAPK3, MAPKAPK5, MAPKAPKps1, MARK1, MARK2, MARK3, MARK4, MARKps01, MARKps02, MARKps03, MARKps04, MARKps05, MARKps07, MARKps08, MARKps09, MARKps10, MARKps11, MARKps12, MARKps13, MARKps15, MARKps16, MARKps17, MARKps18, MARKps19, MARKps20, MARKps21, MARKps22, MARKps23, MARKps24, MARKps25, MARKps26, MARKps27, MARKps28, MARKps29, MARKps30, MAST1, MAST2, MAST3, MAST4, MASTL, MELK, MER, MET, MISR2, MLK1, MLK2, MLK3, MLK4, MLKL, MNK1, MNK1ps, MNK2, MOK, MOS, MPSK1, MPSK1ps, MRCKa, MRCKb, MRCKps, MSK1, MSK12, MSK2, MSK22,

MSSK1, MST1, MST2, MST3, MST3ps, MST4, MUSK, MYO3A, MYO3B, MYT1, NDR1, NDR2, NEK1, NEK10, NEK11, NEK2, NEK2ps1, NEK2ps2, NEK2ps3, NEK3, NEK4, NEK4ps, NEK5, NEK6, NEK7, NEK8, NEK9, NIK, NIM1, NLK, NRBP1, NRBP2, NuaK1, NuaK2, Obscn, Obscn2, OSR1, p38a, p38b, p38d, p38g, p70S6K, p70S6Kb, p70S6Kps1, p70S6Kps2, PAK1, PAK2, PAK2ps, PAK3, PAK4, PAK5, PAK6, PASK, PBK, PCTAIRE1, PCTAIRE2, PCTAIRE3, PDGFRa, PDGFRb, PDK1, PEK, PFTAIRE1, PFTAIRE2, PHKg1, PHKg1ps1, PHKg1ps2, PHKg1ps3, PHKg2, PIK3R4, PIM1, PIM2, PIM3, PINK1, PITSLRE, PKACa, PKACb, PKACg, PKCa, PKCb, PKCd, PKCe, PKCg, PKCh, PKCi, PKCips, PKCt, PKCz, PKD1, PKD2, PKD3, PKG1, PKG2, PKN1, PKN2, PKN3, PKR, PLK1, PLK1ps1, PLK1ps2, PLK2, PLK3, PLK4, PRKX, PRKXps, PRKY, PRP4, PRP4ps, PRPK, PSKH1, PSKH1ps, PSKH2, PYK2, QIK, QSK, RAF1, RAF1ps, RET, RHOK, RIPK1, RIPK2, RIPK3, RNaseL, ROCK1, ROCK2, RON, ROR1, ROR2, ROS, RSK1, RSK12, RSK2, RSK22, RSK3, RSK32, RSK4, RSK42, RSKL1, RSKL2, RYK, RYKps, SAKps, SBK, SCYL1, SCYL2, SCYL2ps, SCYL3, SGK, SgK050ps, SgK069, SgK071, SgK085, SgK110, SgK196, SGK2, SgK223, SgK269, SgK288, SGK3, SgK307, SgK384ps, SgK396, SgK424, SgK493, SgK494, SgK495, SgK496, SIK (*e.g.*, SIK1, SIK2), skMLCK, SLK, Slob, smMLCK, SNRK, SPEG, SPEG2, SRC, SRM, SRPK1, SRPK2, SRPK2ps, SSTK, STK33, STK33ps, STLK3, STLK5, STLK6, STLK6ps1, STLK6-rs, SuRTK106, SYK, TAK1, TAO1, TAO2, TAO3, TBCK, TBK1, TEC, TESK1, TESK2, TGFbR1, TGFbR2, TIE1, TIE2, TLK1, TLK1ps, TLK2, TLK2ps1, TLK2ps2, TNK1, Trad, Trb1, Trb2, Trb3, Trio, TRKA, TRKB, TRKC, TSSK1, TSSK2, TSSK3, TSSK4, TSSKps1, TSSKps2, TTBK1, TTBK2, TTK, TTN, TXK, TYK2, TYK22, TYRO3, TYRO3ps, ULK1, ULK2, ULK3, ULK4, VACAMKL, VRK1, VRK2, VRK3, VRK3ps, Wee1, Wee1B, Wee1Bps, Wee1ps1, Wee1ps2, Wnk1, Wnk2, Wnk3, Wnk4, YANK1, YANK2, YANK3, YES, YESps, YSK1, ZAK, ZAP70, ZC1/HGK, ZC2/TNIK, ZC3/MINK, and ZC4/NRK.

[00102] The term “inhibition,” “inhibiting,” “inhibit,” or “inhibitor” refer to the ability of a compound to reduce, slow, halt or prevent activity of a particular biological process (*e.g.*, a kinase) in a cell relative to vehicle.

[00103] Anti-cancer agents encompass biotherapeutic anti-cancer agents as well as chemotherapeutic agents.

[00104] Exemplary biotherapeutic anti-cancer agents include, but are not limited to, interferons, cytokines (*e.g.*, tumor necrosis factor, interferon α , interferon γ), vaccines, hematopoietic growth factors, monoclonal serotherapy, immunostimulants and/or immunodulatory agents (*e.g.*, IL-1, 2, 4, 6, or 12), immune cell growth factors (*e.g.*, GM-

CSF) and antibodies (*e.g.*, HERCEPTIN (trastuzumab), T-DM1, AVASTIN (bevacizumab), ERBITUX (cetuximab), VECTIBIX (panitumumab), RITUXAN (rituximab), BEXXAR (tositumomab)).

[00105] Exemplary chemotherapeutic agents include, but are not limited to, anti-estrogens (*e.g.* tamoxifen, raloxifene, and megestrol), LHRH agonists (*e.g.* goserelin and leuprolide), anti-androgens (*e.g.* flutamide and bicalutamide), photodynamic therapies (*e.g.* vertoporphin (BPD-MA), phthalocyanine, photosensitizer Pc4, and demethoxy-hypocrellin A (2BA-2-DMHA)), nitrogen mustards (*e.g.* cyclophosphamide, ifosfamide, trofosfamide, chlorambucil, estramustine, and melphalan), nitrosoureas (*e.g.* carmustine (BCNU) and lomustine (CCNU)), alkylsulphonates (*e.g.* busulfan and treosulfan), triazenes (*e.g.* dacarbazine, temozolomide), platinum containing compounds (*e.g.* cisplatin, carboplatin, oxaliplatin), vinca alkaloids (*e.g.* vincristine, vinblastine, vindesine, and vinorelbine), taxoids (*e.g.* paclitaxel or a paclitaxel equivalent such as nanoparticle albumin-bound paclitaxel (ABRAXANE), docosahexaenoic acid bound-paclitaxel (DHA-paclitaxel, Taxoprexin), polyglutamate bound-paclitaxel (PG-paclitaxel, paclitaxel poliglumex, CT-2103, XYOTAX), the tumor-activated prodrug (TAP) ANG1005 (Angiopep-2 bound to three molecules of paclitaxel), paclitaxel-EC-1 (paclitaxel bound to the erbB2-recognizing peptide EC-1), and glucose-conjugated paclitaxel, *e.g.*, 2'-paclitaxel methyl 2-glucopyranosyl succinate; docetaxel, taxol), epipodophyllins (*e.g.* etoposide, etoposide phosphate, teniposide, topotecan, 9-aminocamptothecin, camptoirinotecan, irinotecan, crisnatol, mytomyacin C), anti-metabolites, DHFR inhibitors (*e.g.* methotrexate, dichloromethotrexate, trimetrexate, edatrexate), IMP dehydrogenase inhibitors (*e.g.* mycophenolic acid, tiazofurin, ribavirin, and EICAR), ribonucleotide reductase inhibitors (*e.g.* hydroxyurea and deferoxamine), uracil analogs (*e.g.* 5-fluorouracil (5-FU), floxuridine, doxifluridine, ratitrexed, tegafur-uracil, capecitabine), cytosine analogs (*e.g.* cytarabine (ara C), cytosine arabinoside, and fludarabine), purine analogs (*e.g.* mercaptopurine and Thioguanine), Vitamin D3 analogs (*e.g.* EB 1089, CB 1093, and KH 1060), isoprenylation inhibitors (*e.g.* lovastatin), dopaminergic neurotoxins (*e.g.* 1-methyl-4-phenylpyridinium ion), cell cycle inhibitors (*e.g.* staurosporine), actinomycin (*e.g.* actinomycin D, dactinomycin), bleomycin (*e.g.* bleomycin A2, bleomycin B2, peplomycin), anthracycline (*e.g.* daunorubicin, doxorubicin, pegylated liposomal doxorubicin, idarubicin, epirubicin, pirarubicin, zorubicin, mitoxantrone), MDR inhibitors (*e.g.* verapamil), Ca²⁺ ATPase inhibitors (*e.g.* thapsigargin), imatinib, thalidomide, lenalidomide, tyrosine kinase inhibitors (*e.g.*, axitinib (AG013736), bosutinib (SKI-606), cediranib (RECENTIN™, AZD2171), dasatinib (SPRYCEL®, BMS-354825), erlotinib

(TARCEVA®), gefitinib (IRESSA®), imatinib (Gleevec®, CGP57148B, STI-571), lapatinib (TYKERB®, TYVERB®), lestaurtinib (CEP-701), neratinib (HKI-272), nilotinib (TASIGNA®), semaxanib (semaxinib, SU5416), sunitinib (SUTENT®, SU11248), toceranib (PALLADIA®), vandetanib (ZACTIMA®, ZD6474), vatalanib (PTK787, PTK/ZK), trastuzumab (HERCEPTIN®), bevacizumab (AVASTIN®), rituximab (RITUXAN®), cetuximab (ERBITUX®), panitumumab (VECTIBIX®), ranibizumab (Lucentis®), nilotinib (TASIGNA®), sorafenib (NEXAVAR®), everolimus (AFINITOR®), alemtuzumab (CAMPATH®), gemtuzumab ozogamicin (MYLOTARG®), temsirolimus (TORISEL®), ENMD-2076, PCI-32765, AC220, dovitinib lactate (TKI258, CHIR-258), BIBW 2992 (TOVOK™), SGX523, PF-04217903, PF-02341066, PF-299804, BMS-777607, ABT-869, MP470, BIBF 1120 (VARGATEF®), AP24534, JNJ-26483327, MGCD265, DCC-2036, BMS-690154, CEP-11981, tivozanib (AV-951), OSI-930, MM-121, XL-184, XL-647, and/or XL228), proteasome inhibitors (*e.g.*, bortezomib (VELCADE)), mTOR inhibitors (*e.g.*, rapamycin, temsirolimus (CCI-779), everolimus (RAD-001), ridaforolimus, AP23573 (Ariad), AZD8055 (AstraZeneca), BEZ235 (Novartis), BGT226 (Novartis), XL765 (Sanofi Aventis), PF-4691502 (Pfizer), GDC0980 (Genetech), SF1126 (Semafoe) and OSI-027 (OSI)), oblimersen, gemcitabine, carminomycin, leucovorin, pemetrexed, cyclophosphamide, dacarbazine, procarbazine, prednisolone, dexamethasone, campathecin, plicamycin, asparaginase, aminopterin, methopterin, porfiromycin, melphalan, leurosidine, leurosine, chlorambucil, trabectedin, procarbazine, discodermolide, carminomycin., aminopterin, and hexamethyl melamine.

[00106] When a compound, pharmaceutical composition, method, use, or kit is referred to as “selectively,” “specifically,” or “competitively” inhibiting a JNK kinase, pharmaceutical composition, method, use, or kit inhibits the HMT to a greater extent (*e.g.*, not less than 2-fold, not less than 5-fold, not less than 10-fold, not less than 30-fold, not less than 100-fold, not less than 1,000-fold, or not less than 10,000-fold; and/or: not more than 2-fold, not more than 5-fold, not more than 10-fold, not more than 30-fold, not more than 100-fold, not more than 1,000-fold, or not more than 10,000-fold) than inhibiting a different HMT.

[00107] The term “prevent,” “preventing,” or “prevention” refers to a prophylactic treatment of a subject who is not and was not with a disease but is at risk of developing the disease or who was with a disease, is not with the disease, but is at risk of regression of the disease. In certain embodiments, the subject is at a higher risk of developing the disease or at a higher risk of regression of the disease than an average healthy member of a population.

BRIEF DESCRIPTION OF THE DRAWINGS

[00108] **Figure 1** shows competition pulldown experiments from multiple myeloma MM1.S cells with a biotin-JNK-IN-7 as probe.

[00109] **Figure 2** shows competition pulldown assays using the MDA-MB-231 cell line.


DETAILED DESCRIPTION OF CERTAIN EMBODIMENTS OF THE INVENTION

[00110] The present invention provides compounds that inhibit a kinase, and pharmaceutical compositions thereof, for the prevention and treatment of a subject with a disease. In certain embodiments, the compounds selectively inhibit a kinase. In certain embodiments, the compounds inhibit JNKs. In certain embodiments, the compounds selectively inhibit JNKs. In certain embodiments, the compounds irreversibly inhibit JNK. The present invention further provides methods of using the compounds described herein, *e.g.*, as biological probes to study the inhibition of JNK activity, and as therapeutics, *e.g.*, in the prevention and treatment of diseases associated with JNK activity. In certain embodiments, the diseases include, but are not limited to, proliferative diseases (*e.g.*, cancer and benign neoplasms), inflammatory diseases (*e.g.*, rheumatoid arthritis), autoimmune diseases, and cardiovascular diseases (*e.g.*, atherosclerosis) in a subject, biological sample, tissue, or cell.

Compounds

[00111] Certain aspects of the present disclosure relate to the compounds described herein. The compounds described herein may be useful in treating and/or preventing a disease (*e.g.*, proliferative diseases (*e.g.*, cancer and benign neoplasms), inflammatory diseases (*e.g.*, rheumatoid arthritis), autoimmune diseases, cardiovascular diseases (*e.g.*, atherosclerosis)), or diseases associated with the activity of a JNK (*e.g.*, JNK2) in a subject, or inhibiting the activity of a JNK (*e.g.*, JNK2) in a subject, biological sample, tissue, or cell. In certain embodiments, a compound described herein is a compound of Formula (I), or a pharmaceutically acceptable salt, solvate, hydrate, polymorph, co-crystal, tautomer, stereoisomer, isotopologue, or prodrug thereof. In certain embodiments, a compound described herein is a compound of Formula (I), or a pharmaceutically acceptable salt thereof.

[00112] In certain embodiments, a compound described herein is of Formula (I):



or a pharmaceutically acceptable salt, solvate, hydrate, tautomer, or stereoisomer thereof, wherein:

R^1 is optionally substituted aryl or optionally substituted heteroaryl;

R^2 , R^3 , R^4 , and R^5 are each independently hydrogen, halogen, optionally substituted acyl, optionally substituted alkyl, optionally substituted alkenyl, optionally substituted alkynyl, optionally substituted carbocyclyl, optionally substituted heterocyclyl, optionally substituted aryl, optionally substituted heteroaryl, $-\text{NO}_2$, $-\text{CN}$, $-\text{SCN}$, $-\text{OR}^{\text{D}1}$, $-\text{N}(\text{R}^{\text{D}1})_2$, or $-\text{SR}^{\text{D}1}$, wherein $\text{R}^{\text{D}1}$ is independently hydrogen, optionally substituted acyl, optionally substituted alkyl, optionally substituted alkenyl, optionally substituted alkynyl, optionally substituted carbocyclyl, optionally substituted heterocyclyl, optionally substituted aryl, optionally substituted heteroaryl, an oxygen protecting group when attached to an oxygen atom, a nitrogen protecting group when attached to a nitrogen atom, or a sulfur protecting group when attached to a sulfur atom;

n is 1, 2, or 3;

m is 1, 2, 3, or 4;

L^1 is O, S, or $-\text{N}(\text{R}^a)-$, wherein R^a is hydrogen, optionally substituted acyl, optionally substituted C_{1-6} alkyl, or a nitrogen protecting group;

L^2 is O, S, $-\text{N}(\text{R}^{\text{L}2a})-$, $-\text{C}=\text{O}-$, $-\text{NR}^{\text{L}2a}\text{C}(=\text{O})-$, or $-\text{C}(=\text{O})\text{NR}^{\text{L}2a}-$, wherein $\text{R}^{\text{L}2a}$ is hydrogen, optionally substituted acyl, optionally substituted C_{1-6} alkyl, or a nitrogen protecting group;

V^1 is $\text{C}(\text{R}^{\text{L}1a})\text{H}$;

V^2 is $\text{C}(\text{R}^{\text{L}1b})\text{H}$;

V^3 is N or $\text{C}(\text{R}^{\text{L}1c})$;


$\text{R}^{\text{L}1a}$ and $\text{R}^{\text{L}1b}$ are independently hydrogen, halogen, optionally substituted acyl, optionally substituted alkyl, optionally substituted alkenyl, optionally substituted alkynyl, optionally substituted carbocyclyl, optionally substituted heterocyclyl, optionally substituted aryl, optionally substituted heteroaryl, $-\text{CN}$, $-\text{OR}^{\text{C}1}$, $-\text{N}(\text{R}^{\text{C}1})_2$, or $-\text{SR}^{\text{C}1}$, wherein $\text{R}^{\text{C}1}$ is independently hydrogen, optionally substituted acyl, optionally substituted alkyl, optionally


substituted alkenyl, optionally substituted alkynyl, optionally substituted carbocyclyl, optionally substituted heterocyclyl, optionally substituted aryl, optionally substituted heteroaryl, a nitrogen protecting group when attached to a nitrogen atom, an oxygen protecting group when attached to an oxygen atom, or a sulfur protecting group when attached to a sulfur atom, or R^{1a} and R^{1b} are joined together to form an optionally substituted bridged ring;

R^{1c} is hydrogen, or substituted or unsubstituted C₁₋₆ alkyl;


p is 1, 2, or 3;

D¹ is a warhead of any one of Formulae (i-1) to (i-42):







(i-21)




(i-22)




(i-23)




(i-24)




(i-25)




(i-26)




(i-27)




(i-28)




(i-29)




(i-30)




(i-31)




(i-32)




(i-33)




(i-34)




(i-35)




(i-36)




(i-37)




(i-38)




(i-39)



(i-40)



(i-41)



(i-42)

wherein:

L^3 is a bond or an optionally substituted C_{1-4} hydrocarbon chain, optionally wherein one or more carbon units of the hydrocarbon chain are independently replaced with $-O-$, $-S-$, $-NR^{L3a}-$, $-NR^{L3a}C(=O)-$, $-C(=O)NR^{L3a}-$, $-SC(=O)-$, $-C(=O)S-$, $-OC(=O)-$, $-C(=O)O-$, $-NR^{L3a}C(=S)-$, $-C(=S)NR^{L3a}-$, $trans-CR^{L3b}=CR^{L3b}-$, $cis-CR^{L3b}=CR^{L3b}-$, $-C\equiv C-$, $-S(=O)-$, $-S(=O)O-$, $-OS(=O)-$, $-S(=O)NR^{L3a}-$, $-NR^{L3a}S(=O)-$, $-S(=O)_2-$, $-S(=O)_2O-$, $-OS(=O)_2-$, $-$

$S(=O)_2NR^{L3a}$ -, or $-NR^{L3a}S(=O)_2$ -, wherein R^{L3a} is hydrogen, substituted or unsubstituted C_{1-6} alkyl, or a nitrogen protecting group, and wherein each occurrence of R^{L3b} is independently hydrogen, halogen, optionally substituted alkyl, optionally substituted alkenyl, optionally substituted alkynyl, optionally substituted carbocyclyl, optionally substituted heterocyclyl, optionally substituted aryl, or optionally substituted heteroaryl, or two R^{L3b} groups are joined to form an optionally substituted carbocyclic or optionally substituted heterocyclic ring;

L^4 is a bond or an optionally substituted C_{1-4} hydrocarbon chain;

R^{E1} is hydrogen, halogen, optionally substituted alkyl, optionally substituted alkenyl, optionally substituted alkynyl, optionally substituted carbocyclyl, optionally substituted heterocyclyl, optionally substituted aryl, optionally substituted heteroaryl, $-CN$, $-CH_2OR^{E1a}$, $-CH_2N(R^{E1a})_2$, $-CH_2SR^{E1a}$, $-OR^{E1a}$, $-N(R^{E1a})_2$, $-Si(R^{E1a})_3$, or $-SR^{E1a}$, wherein each occurrence of R^{E1a} is independently selected from the group consisting of hydrogen, optionally substituted alkyl, optionally substituted alkenyl, optionally substituted alkynyl, optionally substituted carbocyclyl, optionally substituted heterocyclyl, optionally substituted aryl, and optionally substituted heteroaryl, or two R^{E1a} groups are joined to form an optionally substituted heterocyclic ring;

R^{E2} is hydrogen, halogen, optionally substituted alkyl, optionally substituted alkenyl, optionally substituted alkynyl, optionally substituted carbocyclyl, optionally substituted heterocyclyl, optionally substituted aryl, optionally substituted heteroaryl, $-CN$, $-CH_2OR^{E2a}$, $-CH_2N(R^{E2a})_2$, $-CH_2SR^{E2a}$, $-OR^{E2a}$, $-N(R^{E2a})_2$, or $-SR^{E2a}$, wherein each occurrence of R^{E2a} is independently selected from the group consisting of hydrogen, optionally substituted alkyl, optionally substituted alkenyl, optionally substituted alkynyl, optionally substituted carbocyclyl, optionally substituted heterocyclyl, optionally substituted aryl, and optionally substituted heteroaryl, or two R^{E2a} groups are joined to form an optionally substituted heterocyclic ring;

R^{E3} is hydrogen, halogen, optionally substituted alkyl, optionally substituted alkenyl, optionally substituted alkynyl, optionally substituted carbocyclyl, optionally substituted heterocyclyl, optionally substituted aryl, optionally substituted heteroaryl, $-CN$, $-CH_2OR^{E3a}$, $-CH_2N(R^{E3a})_2$, $-CH_2SR^{E3a}$, $-OR^{E3a}$, $-N(R^{E3a})_2$, or $-SR^{E3a}$, wherein each occurrence of R^{E3a} is independently selected from the group consisting of hydrogen, optionally substituted alkyl, optionally substituted alkoxy, optionally substituted alkenyl, optionally substituted alkynyl, optionally substituted carbocyclyl, optionally substituted heterocyclyl, optionally substituted aryl, and optionally substituted heteroaryl, or two R^{E3a} groups are joined to form an optionally substituted heterocyclic ring;

or R^{E1} and R^{E3}, or R^{E2} and R^{E3}, or R^{E1} and R^{E2} are joined to form an optionally substituted carbocyclic or optionally substituted heterocyclic ring;

R^{E4} is a leaving group;

R^{E5} is halogen;

Y is O, S, or NR^{E6}, wherein R^{E6} is hydrogen, substituted or unsubstituted C₁₋₆ alkyl, or a nitrogen protecting group;

a is 1 or 2; and

each instance of z is independently 0, 1, 2, 3, 4, 5, or 6.

[00113] Formula (I) contains the substituent R¹. In certain embodiments, R¹ is optionally substituted aryl. In certain embodiments, R¹ is substituted phenyl. In certain embodiments, R¹ is unsubstituted phenyl. In certain embodiments, R¹ is 4-methoxyphenyl. In certain embodiments, R¹ is 4-chlorophenyl. In certain embodiments, R¹ is not hydrogen. In certain embodiments, R¹ is optionally substituted heteroaryl. In certain embodiments, R¹ is substituted or unsubstituted pyridine. In certain embodiments, R¹ is unsubstituted pyridine. In certain embodiments, R¹ is substituted or unsubstituted pyrimidine.

[00114] Formula (I) includes the substituents R², R³, R⁴, and R⁵. In certain embodiments, Formula (I) includes one or more instances of substituent R², R³, R⁴, or R⁵. In certain embodiments, n is 1. In certain embodiments, n is 2. In certain embodiments, n is 3. In certain embodiments, m is 1. In certain embodiments, m is 2. In certain embodiments, m is 3. In certain embodiments, m is 4. In certain embodiments, at least one instance of R², R³, R⁴, or R⁵ is hydrogen. In certain embodiments, at least one instance of R², R³, R⁴, or R⁵ is halogen. In certain embodiments, at least one instance of R², R³, R⁴, or R⁵ is optionally substituted acyl. In certain embodiments, at least one instance of R², R³, R⁴, or R⁵ optionally substituted alkyl (*e.g.*, C₁₋₆ alkyl, *e.g.*, Me, Et, Pr, or Bu). In certain embodiments, at least one instance of R², R³, R⁴, or R⁵ optionally substituted alkenyl (*e.g.*, substituted or unsubstituted vinyl or substituted or unsubstituted allyl). In certain embodiments, at least one instance of R², R³, R⁴, or R⁵ is optionally substituted alkynyl (*e.g.*, C₂₋₆ alkynyl). In certain embodiments, at least one instance of R² is optionally substituted carbocyclyl. In certain embodiments, at least one instance of R², R³, R⁴, or R⁵ is optionally substituted heterocyclyl. In certain embodiments, at least one instance of R² is optionally substituted aryl. In certain embodiments, at least one instance of R², R³, R⁴, or R⁵ is optionally substituted heteroaryl. In certain embodiments, at least one instance of R², R³, R⁴, or R⁵ is -NO₂. In certain embodiments, at least one instance of R², R³, R⁴, or R⁵ is -CN. In certain embodiments, at least one instance of R² is -SCN. In certain embodiments, at least one instance of R², R³, R⁴, or R⁵ is OR^{D1}, wherein R^{D1} is

independently hydrogen, optionally substituted acyl, optionally substituted alkyl, optionally substituted alkenyl, optionally substituted alkynyl, optionally substituted carbocyclyl, optionally substituted heterocyclyl, optionally substituted aryl, optionally substituted heteroaryl, or an oxygen protecting group. In certain embodiments, at least one instance of R^2 , R^3 , R^4 , or R^5 is $N(R^{D1a})_2$, wherein R^{D1} is independently hydrogen, optionally substituted acyl, optionally substituted alkyl, optionally substituted alkenyl, optionally substituted alkynyl, optionally substituted carbocyclyl, optionally substituted heterocyclyl, optionally substituted aryl, optionally substituted heteroaryl, or a nitrogen protecting group. In certain embodiments, at least one instance of R^2 is SR^{D1} , wherein R^{D1} is independently selected from hydrogen, optionally substituted acyl, optionally substituted alkyl, optionally substituted alkenyl, optionally substituted alkynyl, optionally substituted carbocyclyl, optionally substituted heterocyclyl, optionally substituted aryl, optionally substituted heteroaryl, or a sulfur protecting group.

[00115] In certain embodiments, R^3 and R^4 are the same. In certain embodiments, R^3 and R^4 are different. In certain embodiments, R^3 is hydrogen, and R^4 is hydrogen. In certain embodiments, R^3 is hydrogen, R^4 is hydrogen, and R^1 is not hydrogen. In certain embodiments, R^3 is hydrogen, R^4 is hydrogen, and R^1 is optionally substituted aryl. In certain embodiments, R^3 is hydrogen, R^4 is hydrogen, and R^1 is phenyl. In certain embodiments, R^3 is hydrogen, R^4 is hydrogen, and R^1 is 4-methoxyphenyl. In certain embodiments, R^3 is hydrogen, R^4 is hydrogen, and R^1 is 4-chlorophenyl. In certain embodiments, R^3 is hydrogen, R^4 is hydrogen, and R^1 is heteroaryl. In certain embodiments, R^3 is hydrogen, R^4 is hydrogen, and R^1 is pyridyl.

[00116] In certain embodiments, R^2 is hydrogen, R^3 is hydrogen, and R^4 is hydrogen. In certain embodiments, R^2 is hydrogen, R^3 is hydrogen, R^4 is hydrogen, and R^1 is not hydrogen. In certain embodiments, R^2 is hydrogen, R^3 is hydrogen, R^4 is hydrogen, and R^1 is optionally substituted aryl. In certain embodiments, R^2 is hydrogen, R^3 is hydrogen, R^4 is hydrogen, and R^1 is phenyl. In certain embodiments, R^2 is hydrogen, R^3 is hydrogen, R^4 is hydrogen, and R^1 is 4-methoxyphenyl. In certain embodiments, R^2 is hydrogen, R^3 is hydrogen, R^4 is hydrogen, and R^1 is 4-chlorophenyl. In certain embodiments, R^2 is hydrogen, R^3 is hydrogen, R^4 is hydrogen, and R^1 is heteroaryl. In certain embodiments, R^2 is hydrogen, R^3 is hydrogen, R^4 is hydrogen, and R^1 is pyridyl.

[00117] In certain embodiments, R^2 is hydrogen, R^3 is hydrogen, R^4 is hydrogen, and R^5 is hydrogen. In certain embodiments, R^2 is hydrogen, R^3 is hydrogen, R^4 is hydrogen, R^5 is hydrogen, and R^1 is not hydrogen. In certain embodiments, R^2 is hydrogen, R^3 is hydrogen,

R^4 is hydrogen, R^5 is hydrogen, and R^1 is optionally substituted aryl. In certain embodiments, R^2 is hydrogen, R^3 is hydrogen, R^4 is hydrogen, R^5 is hydrogen, and R^1 is phenyl. In certain embodiments, R^2 is hydrogen, R^3 is hydrogen, R^4 is hydrogen, R^5 is hydrogen, and R^1 is 4-methoxyphenyl. In certain embodiments, R^2 is hydrogen, R^3 is hydrogen, R^4 is hydrogen, R^5 is hydrogen, and R^1 is 4-chlorophenyl. In certain embodiments, R^2 is hydrogen, R^3 is hydrogen, R^4 is hydrogen, R^5 is hydrogen, and R^1 is heteroaryl. In certain embodiments, R^2 is hydrogen, R^3 is hydrogen, R^4 is hydrogen, R^5 is hydrogen, and R^1 is pyridyl.

[00118] In certain embodiments, R^2 is methyl. In certain embodiments, R^2 is methyl, R^3 is hydrogen, and R^4 is hydrogen. In certain embodiments, R^2 is methyl, R^3 is hydrogen, R^4 is hydrogen, and R^1 is not hydrogen. In certain embodiments, R^2 is methyl, R^3 is hydrogen, R^4 is hydrogen, and R^1 is optionally substituted aryl. In certain embodiments, R^2 is methyl, R^3 is hydrogen, R^4 is hydrogen, and R^1 is phenyl. In certain embodiments, R^2 is methyl, R^3 is hydrogen, R^4 is hydrogen, and R^1 is 4-methoxyphenyl. In certain embodiments, R^2 is methyl, R^3 is hydrogen, R^4 is hydrogen, and R^1 is 4-chlorophenyl. In certain embodiments, R^2 is methyl, R^3 is hydrogen, R^4 is hydrogen, and R^1 is heteroaryl. In certain embodiments, R^2 is methyl, R^3 is hydrogen, R^4 is hydrogen, and R^1 is pyridyl.

[00119] In certain embodiments, R^2 is methoxy. In certain embodiments, R^2 is methoxy, R^3 is hydrogen, and R^4 is hydrogen. In certain embodiments, R^2 is methoxy, R^3 is hydrogen, R^4 is hydrogen, and R^1 is not hydrogen. In certain embodiments, R^2 is methoxy, R^3 is hydrogen, R^4 is hydrogen, and R^1 is optionally substituted aryl. In certain embodiments, R^2 is methoxy, R^3 is hydrogen, R^4 is hydrogen, and R^1 is phenyl. In certain embodiments, R^2 is methoxy, R^3 is hydrogen, R^4 is hydrogen, and R^1 is 4-methoxyphenyl. In certain embodiments, R^2 is methoxy, R^3 is hydrogen, R^4 is hydrogen, and R^1 is 4-chlorophenyl. In certain embodiments, R^2 is methoxy, R^3 is hydrogen, R^4 is hydrogen, and R^1 is heteroaryl. In certain embodiments, R^2 is methoxy, R^3 is hydrogen, R^4 is hydrogen, and R^1 is pyridyl.

[00120] Formula (I) includes substituent L^1 . In certain embodiments, L^1 is $-O-$. In certain embodiments, L^1 is $-S-$. In certain embodiments, L^1 is $-N(R^a)-$ as valency permits, wherein R^a is independently hydrogen, substituted or unsubstituted C_{1-6} alkyl, or a nitrogen protecting group. In certain embodiments, R^a is hydrogen. In certain embodiments, R^a is C_{1-6} alkyl. In certain embodiments, R^a is substituted or unsubstituted methyl. In certain embodiments, L^1 is $-NH-$.

[00121] Formula (I) includes substituent L^2 . In certain embodiments, L^2 is $-O-$. In certain embodiments, L^2 is $-S-$. In certain embodiments, L^2 is $N(R^{L2a})$ as valency permits, wherein R^{L2a} is independently hydrogen, substituted or unsubstituted C_{1-6} alkyl, or a nitrogen

protecting group. In certain embodiments, R^{L2a} is hydrogen. In certain embodiments, R^{L2a} is C_{1-6} alkyl. In certain embodiments, R^{L2a} is substituted or unsubstituted methyl. In certain embodiments, L^2 is $-C(=O)-$. In certain embodiments, L^2 is $-NR^{L2a}C(=O)-$, wherein R^{L2a} is hydrogen, optionally substituted acyl, optionally substituted C_{1-6} alkyl, or a nitrogen protecting group. In certain embodiments, L^2 is $-C(=O)NR^{L2a}-$, wherein R^{L2a} is hydrogen, optionally substituted acyl, optionally substituted C_{1-6} alkyl, or a nitrogen protecting group. In certain embodiments, L^2 is $-C(=O)NH-$.

[00122] Formula (I) includes the substituent V^1 . In certain embodiments, V^1 is of the formula: $C(R^{1a})H$. In certain embodiments, R^{1a} is hydrogen. In certain embodiments, R^{1a} is halogen. In certain embodiments, R^{1a} is optionally substituted acyl. In certain embodiments, R^{1a} is optionally substituted alkyl. In certain embodiments, R^{1a} is optionally substituted alkenyl. In certain embodiments, R^{1a} is optionally substituted alkynyl. In certain embodiments, the R^{1a} forms a bicyclic ring system with another atom in the ring. In certain embodiments, R^{1a} is optionally substituted carbocyclyl. In certain embodiments, R^{1a} is optionally substituted heterocyclyl. In certain embodiments, R^{1a} is optionally substituted aryl. In certain embodiments, R^{1a} is optionally substituted heteroaryl. In certain embodiments, R^{1a} is $-CN$. In certain embodiments, R^{1a} is $-OR^{C1}$, wherein each occurrence of R^{C1} is hydrogen, optionally substituted acyl, optionally substituted alkyl, optionally substituted alkenyl, optionally substituted alkynyl, optionally substituted carbocyclyl, optionally substituted heterocyclyl, optionally substituted aryl, optionally substituted heteroaryl, a nitrogen protecting group when attached to a nitrogen atom, an oxygen protecting group when attached to an oxygen atom, and a sulfur protecting group when attached to a sulfur atom. In certain embodiments, R^{1a} is $-N(R^{C1})_2$ wherein each occurrence of R^{C1} is independently selected from the group consisting of hydrogen, optionally substituted acyl, optionally substituted alkyl, optionally substituted alkenyl, optionally substituted alkynyl, optionally substituted carbocyclyl, optionally substituted heterocyclyl, optionally substituted aryl, optionally substituted heteroaryl, a nitrogen protecting group when attached to a nitrogen atom, an oxygen protecting group when attached to an oxygen atom, and a sulfur protecting group when attached to a sulfur atom. In certain embodiments, R^{1a} is $-SR^{C1}$ wherein each occurrence of R^{C1} is hydrogen, optionally substituted acyl, optionally substituted alkyl, optionally substituted alkenyl, optionally substituted alkynyl, optionally substituted carbocyclyl, optionally substituted heterocyclyl, optionally substituted aryl, optionally substituted heteroaryl, a nitrogen protecting group when attached to a nitrogen atom, an


oxygen protecting group when attached to an oxygen atom, and a sulfur protecting group when attached to a sulfur atom.

[00123] Certain instances of Formula (I) include the substituent V^2 . In certain embodiments, Formula (I) contains no instances of V^2 . In certain embodiments, p is 0. In certain embodiments, p is 1. In certain embodiments, p is 2. In certain embodiments, p is 3. In certain embodiments, V^2 is of the formula: $C(R^{1b})H$. In certain embodiments, R^{1b} is hydrogen. In certain embodiments, R^{1b} is halogen. In certain embodiments, R^{1b} is optionally substituted acyl. In certain embodiments, R^{1b} is optionally substituted alkyl. In certain embodiments, R^{1b} is optionally substituted alkenyl. In certain embodiments, R^{1b} is optionally substituted alkynyl. In certain embodiments, R^{1b} is optionally substituted carbocyclyl. In certain embodiments, R^{1b} is optionally substituted heterocyclyl. In certain embodiments, R^{1b} is optionally substituted aryl. In certain embodiments, R^{1b} is optionally substituted heteroaryl. In certain embodiments, R^{1b} is $-(=O)-$. In certain embodiments, R^{1b} is $-CN$. In certain embodiments, R^{1b} is $-OR^{C1}$ wherein each occurrence of R^{C1} is hydrogen, optionally substituted acyl, optionally substituted alkyl, optionally substituted alkenyl, optionally substituted alkynyl, optionally substituted carbocyclyl, optionally substituted heterocyclyl, optionally substituted aryl, optionally substituted heteroaryl, a nitrogen protecting group when attached to a nitrogen atom, an oxygen protecting group when attached to an oxygen atom, and a sulfur protecting group when attached to a sulfur atom. In certain embodiments, R^{1b} is $-N(R^{C1})_2$ wherein each occurrence of R^{C1} is independently selected from the group consisting of hydrogen, optionally substituted acyl, optionally substituted alkyl, optionally substituted alkenyl, optionally substituted alkynyl, optionally substituted carbocyclyl, optionally substituted heterocyclyl, optionally substituted aryl, optionally substituted heteroaryl, a nitrogen protecting group when attached to a nitrogen atom, an oxygen protecting group when attached to an oxygen atom, and a sulfur protecting group when attached to a sulfur atom. In certain embodiments, R^{1b} is $-SR^{C1}$, wherein each occurrence of R^{C1} is hydrogen, optionally substituted acyl, optionally substituted alkyl, optionally substituted alkenyl, optionally substituted alkynyl, optionally substituted carbocyclyl, optionally substituted heterocyclyl, optionally substituted aryl, optionally substituted heteroaryl, a nitrogen protecting group when attached to a nitrogen atom, an oxygen protecting group when attached to an oxygen atom, and a sulfur protecting group when attached to a sulfur atom. In certain embodiments, R^{1a} and R^{1b} are joined together to form an optionally substituted bridged ring.


[00124] In certain embodiments, V_1 is $-\text{CH}_2-$, and V_2 is $-\text{CH}_2-$. In certain embodiments, V_1 is $-\text{CH}_2-$, and V_2 is $-\text{C}(\text{H})\text{F}-$. In certain embodiments, V_1 is $-\text{CH}_2-$, and V_2 is $-\text{C}(\text{H})\text{Me}-$. In certain embodiments, V_1 is $-\text{CH}_2-$, V_2 is $-\text{CH}_2-$, and $p=1$. In certain embodiments, V_1 is $-\text{CH}_2-$, V_2 is $-\text{CH}_2-$, and $p=2$. In certain embodiments, V_1 is $-\text{CH}_2-$, V_2 is $-\text{CH}_2-$, and $p=3$. In certain embodiments, V_1 is $-\text{CH}_2-$, V_2 is $-\text{CH}_2-$, and V_3 is $-\text{CH}-$. In certain embodiments, V_1 is $-\text{CH}_2-$, V_2 is $-\text{CH}_2-$, and V_3 is $-\text{N}-$.

[00125] Formula (I) includes the substituent V^3 . In certain embodiments, V^3 is $-\text{N}-$. In certain embodiments, V^3 is of the formula: $-\text{C}(\text{R}^{1c})-$. In certain embodiments, R^{1c} is hydrogen. In certain embodiments, R^{1c} is halogen. In certain embodiments, R^{1c} is optionally substituted acyl. In certain embodiments, R^{1c} is optionally substituted alkyl. In certain embodiments, R^{1c} is optionally substituted alkenyl. In certain embodiments, R^{1c} is optionally substituted alkynyl. In certain embodiments, R^{1c} is optionally substituted carbocyclyl. In certain embodiments, R^{1c} is optionally substituted heterocyclyl. In certain embodiments, R^{1c} is optionally substituted aryl. In certain embodiments, R^{1c} is optionally substituted heteroaryl. In certain embodiments, R^{1c} is $-\text{CN}$. In certain embodiments, R^{1c} is $-\text{OR}^{\text{C}1}$ wherein each occurrence of $\text{R}^{\text{C}1}$ is hydrogen, optionally substituted acyl, optionally substituted alkyl, optionally substituted alkenyl, optionally substituted alkynyl, optionally substituted carbocyclyl, optionally substituted heterocyclyl, optionally substituted aryl, optionally substituted heteroaryl, a nitrogen protecting group when attached to a nitrogen atom, an oxygen protecting group when attached to an oxygen atom, and a sulfur protecting group when attached to a sulfur atom. In certain embodiments, R^{1c} is $-\text{N}(\text{R}^{\text{C}1})_2$, wherein each occurrence of $\text{R}^{\text{C}1}$ is independently selected from the group consisting of hydrogen, optionally substituted acyl, optionally substituted alkyl, optionally substituted alkenyl, optionally substituted alkynyl, optionally substituted carbocyclyl, optionally substituted heterocyclyl, optionally substituted aryl, optionally substituted heteroaryl, a nitrogen protecting group when attached to a nitrogen atom, an oxygen protecting group when attached to an oxygen atom, and a sulfur protecting group when attached to a sulfur atom. In certain embodiments, R^{1c} is $-\text{SR}^{\text{C}1}$ wherein each occurrence of $\text{R}^{\text{C}1}$ is hydrogen, optionally substituted acyl, optionally substituted alkyl, optionally substituted alkenyl, optionally substituted alkynyl, optionally substituted carbocyclyl, optionally substituted heterocyclyl, optionally substituted aryl, optionally substituted heteroaryl, a nitrogen protecting group when attached to a nitrogen atom, an oxygen protecting group when attached to an oxygen atom, and a sulfur protecting group when attached to a sulfur atom.

[00126] In certain embodiments, V^1 is $-\text{CH}_2-$, V_2 is $-\text{CH}_2-$, and V_3 is $-\text{N}-$. In certain embodiments, V^1 is $-\text{CH}_2-$, V_2 is $-\text{C}(\text{Me})\text{H}-$, and V_3 is $-\text{N}-$. In certain embodiments, V^1 is $-\text{CH}_2-$, V_2 is $-\text{C}(\text{F})\text{H}-$, and V_3 is $-\text{N}-$. In certain embodiments, Formula (I) is of the formula:



. In certain embodiments, Formula (I) is of the




formula:


[00127] In certain embodiments, V^1 is $-\text{CH}_2$, V_2 is $-\text{CH}_2-$, and V_3 is $-\text{CH}$. In certain embodiments, V^1 is $-\text{CH}_2$, V_2 is $-\text{CH}_2$, V_3 is $-\text{CH}$, and $p=2$.

[00128] In certain embodiments, L^1 is $-\text{NH}-$, V^1 is $-\text{CH}_2-$, V_3 is $-\text{N}$, and V_2 is $-\text{CH}_2$. In certain embodiments, L^1 is $-\text{NH}-$, V^1 is CH_2 , V_3 is N , V_2 is CH_2 , and $p=0$. In certain embodiments, L^1 is $-\text{NH}$, V^1 is CH_2 , V_3 is N , V_2 is CH_2 , and $p=1$. In certain embodiments, L^1 is $-\text{NH}-$, V^1 is CH_2 , V_3 is N , V_2 is CH_2 , and $p=2$. In certain embodiments, L^1 is $-\text{NH}-$, V^1 is $-\text{CH}_2-$, V_3 is $-\text{N}-$, V_2 is $-\text{CH}_2-$, and $p=3$. In certain embodiments, L^1 is $-\text{NH}-$, V^1 is $-\text{CH}_2-$, V_3 is $-\text{N}-$, V_2 is $-\text{CH}_2-$, and $p=3$.




[00129] In certain embodiments, Formula (I) is of the formula:







[00130] In certain embodiments, Formula (I) is of the formula:




. In certain embodiments, Formula (I) is of the




















[00131] In certain embodiments, L¹ is -NH-, V¹ is C(R^{1a})H, V₃ is N, and one instance of V₂ is C(R^{1b})H, wherein R^{1a} and R^{1b} are joined together to form an optionally substituted bridged ring. In certain embodiments, Formula (I) is of the formula:




[00132] As generally defined herein, Formula (I) includes substituent D¹, wherein D¹ is a warhead of Formulae (i-1) to (i-42):





and



wherein:

L³ is a bond or an optionally substituted C₁₋₄ hydrocarbon chain, optionally wherein one or more carbon units of the hydrocarbon chain are independently replaced with -O-, -S-, -NR^{L3a}-, -NR^{L3a}C(=O)-, -C(=O)NR^{L3a}-, -SC(=O)-, -C(=O)S-, -OC(=O)-, -C(=O)O-, -NR^{L3a}C(=S)-, -C(=S)NR^{L3a}-, *trans*-CR^{L3b}=CR^{L3b}-, *cis*-CR^{L3b}=CR^{L3b}-, -C≡C-, -S(=O)-, -S(=O)O-, -OS(=O)-, -S(=O)NR^{L3a}-, -NR^{L3a}S(=O)-, -S(=O)₂-, -S(=O)₂O-, -OS(=O)₂-, -S(=O)₂NR^{L3a}-, or -NR^{L3a}S(=O)₂-, wherein R^{L3a} is hydrogen, substituted or unsubstituted C₁₋₆ alkyl, or a nitrogen protecting group, and wherein each occurrence of R^{L3b} is independently selected from the group consisting of hydrogen, halogen, optionally substituted alkyl, optionally substituted alkenyl, optionally substituted alkynyl, optionally substituted carbocyclyl, optionally substituted heterocyclyl, optionally substituted aryl, and optionally

substituted heteroaryl, or two R^{L3b} groups are joined to form an optionally substituted carbocyclic or optionally substituted heterocyclic ring;

L^4 is a bond, or an optionally substituted C_{1-4} hydrocarbon chain;

R^{E1} is selected from the group consisting of hydrogen, halogen, optionally substituted alkyl, optionally substituted alkenyl, optionally substituted alkynyl, optionally substituted carbocyclyl, optionally substituted heterocyclyl, optionally substituted aryl, optionally substituted heteroaryl, $-CN$, $-CH_2OR^{E1a}$, $-CH_2N(R^{E1a})_2$, $-CH_2SR^{E1a}$, $-OR^{E1a}$, $-N(R^{E1a})_2$, $-Si(R^{E1a})_3$, and $-SR^{E1a}$, wherein each occurrence of R^{E1a} is independently selected from the group consisting of hydrogen, optionally substituted alkyl, optionally substituted alkenyl, optionally substituted alkynyl, optionally substituted carbocyclyl, optionally substituted heterocyclyl, optionally substituted aryl, and optionally substituted heteroaryl, or two R^{E1a} groups are joined to form an optionally substituted heterocyclic ring;

R^{E2} is selected from the group consisting of hydrogen, halogen, optionally substituted alkyl, optionally substituted alkenyl, optionally substituted alkynyl, optionally substituted carbocyclyl, optionally substituted heterocyclyl, optionally substituted aryl, optionally substituted heteroaryl, $-CN$, $-CH_2OR^{E2a}$, $-CH_2N(R^{E2a})_2$, $-CH_2SR^{E2a}$, $-OR^{E2a}$, $-N(R^{E2a})_2$, and $-SR^{E2a}$, wherein each occurrence of R^{E2a} is independently selected from the group consisting of hydrogen, optionally substituted alkyl, optionally substituted alkenyl, optionally substituted alkynyl, optionally substituted carbocyclyl, optionally substituted heterocyclyl, optionally substituted aryl, and optionally substituted heteroaryl, or two R^{E2a} groups are joined to form an optionally substituted heterocyclic ring;

R^{E3} is selected from the group consisting of hydrogen, halogen, optionally substituted alkyl, optionally substituted alkenyl, optionally substituted alkynyl, optionally substituted carbocyclyl, optionally substituted heterocyclyl, optionally substituted aryl, optionally substituted heteroaryl, $-CN$, $-CH_2OR^{E3a}$, $-CH_2N(R^{E3a})_2$, $-CH_2SR^{E3a}$, $-OR^{E3a}$, $-N(R^{E3a})_2$, and $-SR^{E3a}$, wherein each occurrence of R^{E3a} is independently selected from the group consisting of hydrogen, optionally substituted alkyl, optionally substituted alkoxy, optionally substituted alkenyl, optionally substituted alkynyl, optionally substituted carbocyclyl, optionally substituted heterocyclyl, optionally substituted aryl, and optionally substituted heteroaryl, or two R^{E3a} groups are joined to form an optionally substituted heterocyclic ring;

or R^{E1} and R^{E3} , or R^{E2} and R^{E3} , or R^{E1} and R^{E2} are joined to form an optionally substituted carbocyclic or optionally substituted heterocyclic ring;

R^{E4} is a leaving group;


R^{E5} is halogen;

Y is O, S, or NR^{E6}, wherein R^{E6} is hydrogen, substituted or unsubstituted C₁₋₆ alkyl, or a nitrogen protecting group;


a is 1 or 2; and

each instance of z is independently 0, 1, 2, 3, 4, 5, or 6.


[00133] In certain embodiments, D¹ is a warhead of Formula (i-1) through (i-42). In certain





embodiments, the warhead is of formula: (i-1). In certain embodiments, D¹ is a



warhead of formula: . In certain embodiments, D¹ is a warhead of formula:




. In certain embodiments, D¹ is a warhead of formula: . In certain




embodiments, D¹ is of formula: , or . In certain


embodiments, L³ is a bond. In certain embodiments, L³ is -NH-. In certain embodiments, R^{E1} and R^{E2} are hydrogen. In certain embodiments, R^{E1}, R^{E2}, and R^{E3} are hydrogen. In certain embodiments, R^{E3} is -CH₂NMe₂.




[00134] In certain embodiments, the warhead is of formula (i-2). In certain




embodiments, the warhead is of formula (i-3). In certain embodiments, the warhead




is of formula (i-4). In certain embodiments, the warhead is of formula




(i-5).




In certain embodiments, the warhead is of formula R^{E1} (i-6). In certain embodiments,




the warhead is of formula (i-7). In certain embodiments, the warhead is of




formula R^{E1} (i-8). In certain embodiments, the warhead is of formula: R^{E4} (i-





9). In certain embodiments, the warhead is of formula: R^{E4} (i-10). In certain




embodiments, the warhead is of formula: R^{E1} (i-11). In certain embodiments, the



warhead is of formula: R^{E1} (i-12). In certain embodiments, the warhead is of formula




(i-13). In certain embodiments, the warhead is of formula




(i-14). In

certain embodiments, the warhead is of formula




(i-15).

[00135] In certain embodiments, the warhead is of formula




(i-16). In certain

embodiments, the warhead is of formula




(i-17). In certain embodiments, the


warhead is of formula



(i-18). In certain embodiments, the warhead is of formula




(i-19). In certain embodiments, the warhead is of formula




(i-20). In certain

embodiments, the warhead is




(i-21). In certain embodiments, the warhead is of

formula




(i-22). In certain embodiments, the warhead is of formula




(i-

23). In certain embodiments, the warhead is of formula






(i-24). In certain


embodiments, the warhead is of formula





(i-25). In certain embodiments, the


warhead is of formula  (i-26). In certain embodiments, the warhead is of


formula  (i-27). In certain embodiments, the warhead is of formula 



(i-28). In certain embodiments, the warhead is of formula  (i-29).


In certain embodiments, the warhead is of formula  (i-30). In certain


embodiments, the warhead is of formula  (i-31). In certain embodiments, the

warhead is of formula  (i-32). In certain embodiments, the warhead is of


formula  (i-33). In certain embodiments, the warhead is of formula

 (i-34). In certain embodiments, the warhead is of formula  (i-35). In


certain embodiments, the warhead is of formula  (i-36). In certain embodiments,

the warhead is of formula  (i-37). In certain embodiments, the warhead is of


formula  (i-38). In certain embodiments, the warhead is of formula  (i-




39). In certain embodiments, the warhead is of formula (i-40). In certain




embodiments, the warhead is of formula (i-41). In certain embodiments, the warhead is



of formula (i-42). In certain embodiments, the warhead is of the formula,



. In certain embodiments, the warhead is of the formula,



[00136] In certain embodiments, L^3 is a bond (*e.g.*, a single bond, a double bond, or a triple bond). In certain embodiments, L^3 is a single bond. In certain embodiments, L^3 is a double bond. In certain embodiments, L^3 is a triple bond. In certain embodiments, L^3 is an optionally substituted C_{1-4} hydrocarbon chain, optionally wherein one or more carbon units of the hydrocarbon chain are independently replaced with $-C=O-$, $-O-$, $-S-$, $-NR^{L3a}-$, $-NR^{L3a}C(=O)-$, $-C(=O)NR^{L3a}-$, $-SC(=O)-$, $-C(=O)S-$, $-OC(=O)-$, $-C(=O)O-$, $-NR^{L3a}C(=S)-$, $-C(=S)NR^{L3a}-$, *trans*- $CR^{L3b}=CR^{L3b}-$, *cis*- $CR^{L3b}=CR^{L3b}-$, $-C\equiv C-$, $-S(=O)-$, $-S(=O)O-$, $-OS(=O)-$, $-S(=O)NR^{L3a}-$, $-NR^{L3a}S(=O)-$, $-S(=O)_2-$, $-S(=O)_2O-$, $-OS(=O)_2-$, $-S(=O)_2NR^{L3a}-$, or $-NR^{L3a}S(=O)_2-$, wherein R^{L3a} is hydrogen, substituted or unsubstituted C_{1-6} alkyl, or a nitrogen protecting group, and wherein each occurrence of R^{L3b} is independently hydrogen, halogen, optionally substituted alkyl, optionally substituted alkenyl, optionally substituted alkynyl, optionally substituted carbocyclyl, optionally substituted heterocyclyl, optionally substituted aryl, or optionally substituted heteroaryl, or two R^{L3b} groups are joined to form an optionally substituted carbocyclic or optionally substituted heterocyclic ring. In certain embodiments, L^4 is a bond (*e.g.*, a single bond, a double bond, or a triple bond). In

certain embodiments, L^4 is an optionally substituted branched C_{1-6} hydrocarbon chain (*e.g.*, *i*-Pr). In certain embodiments, L^4 is an optionally substituted unbranched C_{1-6} hydrocarbon chain (*e.g.*, *n*-Pr, or *n*-Bu). In certain embodiments, at least one instance of R^{E1} is H. In certain embodiments, at least one instance of R^{E1} is halogen (*e.g.*, F, Cl, Br, or I). In certain embodiments, at least one instance of R^{E1} is optionally substituted alkyl (*e.g.*, Me, or Et). In certain embodiments, at least one instance of R^{E1} is optionally substituted alkenyl (*e.g.*, optionally substituted vinyl). In certain embodiments, at least one instance of R^{E1} is optionally substituted alkynyl. In certain embodiments, at least one instance of R^{E1} is substituted or unsubstituted carbocyclyl (*e.g.*, substituted or unsubstituted, 3- to 7-membered, monocyclic carbocyclyl comprising zero, one, or two double bonds in the carbocyclic ring system). In certain embodiments, at least one instance of R^{E1} is substituted or unsubstituted heterocyclyl (*e.g.*, substituted or unsubstituted, 3- to 7-membered, monocyclic heterocyclyl comprising zero, one, or two double bonds in the heterocyclic ring system, wherein one, two, or three atoms in the heterocyclic ring system are independently nitrogen, oxygen, or sulfur). In certain embodiments, at least one instance of R^{E1} is substituted or unsubstituted aryl (*e.g.*, substituted or unsubstituted, 6- to 10-membered aryl). In certain embodiments, at least one instance of R^{E1} is substituted or unsubstituted phenyl. In certain embodiments, at least one instance of R^{E1} is substituted or unsubstituted heteroaryl (*e.g.*, substituted or unsubstituted, 5- to 6-membered, monocyclic heteroaryl, wherein one, two, three, or four atoms in the heteroaryl ring system are independently nitrogen, oxygen, or sulfur). In certain embodiments, at least one instance of R^{E1} is $-CN$. In certain embodiments, at least one instance of R^{E1} is $-CH_2OR^{EE}$, wherein each instance of R^{EE} is independently hydrogen, optionally substituted alkyl, optionally substituted alkoxy, optionally substituted alkenyl, optionally substituted alkynyl, optionally substituted carbocyclyl, optionally substituted heterocyclyl, optionally substituted aryl, or optionally substituted heteroaryl. In certain embodiments, at least one instance of R^{E1} is $-CH_2N(R^{EF})_2$ or $-N(R^{EF})_2$, wherein each instance of R^{EF} is independently hydrogen, optionally substituted alkyl, optionally substituted alkoxy, optionally substituted alkenyl, optionally substituted alkynyl, optionally substituted carbocyclyl, optionally substituted heterocyclyl, optionally substituted aryl, or optionally substituted heteroaryl, optionally wherein two R^{EF} groups are joined to form an optionally substituted heterocyclic ring. In certain embodiments, at least one instance of R^{E1} is $-CH_2SR^{EE}$ or $-SR^{EE}$ (*e.g.*, $-CH_2SMe$ or $-SMe$). In certain embodiments, at least one instance of R^{E1} is $-OR^{EE}$ (*e.g.*, $-OMe$). In certain embodiments, at least one instance of R^{E1} is $-Si(R^{EG})_3$, wherein each instance of R^{EG} is independently hydrogen, optionally substituted

alkyl, optionally substituted alkoxy, optionally substituted alkenyl, optionally substituted alkynyl, optionally substituted carbocyclyl, optionally substituted heterocyclyl, optionally substituted aryl, or optionally substituted heteroaryl (*e.g.*, $-\text{Si}(\text{Me})_3$).


[00137] In certain embodiments, at least one instance of R^{E2} is H. In certain embodiments, at least one instance of R^{E2} is halogen (*e.g.*, F, Cl, Br, or I). In certain embodiments, at least one instance of R^{E2} is optionally substituted alkyl (*e.g.*, Me, or Et). In certain embodiments, at least one instance of R^{E2} is optionally substituted alkenyl (*e.g.*, optionally substituted vinyl). In certain embodiments, at least one instance of R^{E2} is optionally substituted alkynyl. In certain embodiments, at least one instance of R^{E2} is substituted or unsubstituted carbocyclyl (*e.g.*, substituted or unsubstituted, 3- to 7-membered, monocyclic carbocyclyl comprising zero, one, or two double bonds in the carbocyclic ring system). In certain embodiments, at least one instance of R^{E2} is substituted or unsubstituted heterocyclyl (*e.g.*, substituted or unsubstituted, 3- to 7-membered, monocyclic heterocyclyl comprising zero, one, or two double bonds in the heterocyclic ring system, wherein one, two, or three atoms in the heterocyclic ring system are independently nitrogen, oxygen, or sulfur). In certain embodiments, at least one instance of R^{E2} is substituted or unsubstituted aryl (*e.g.*, substituted or unsubstituted, 6- to 10-membered aryl). In certain embodiments, at least one instance of R^{E2} is substituted or unsubstituted phenyl. In certain embodiments, at least one instance of R^{E2} is substituted or unsubstituted heteroaryl (*e.g.*, substituted or unsubstituted, 5- to 6-membered, monocyclic heteroaryl, wherein one, two, three, or four atoms in the heteroaryl ring system are independently nitrogen, oxygen, or sulfur). In certain embodiments, at least one instance of R^{E2} is $-\text{CN}$. In certain embodiments, at least one instance of R^{E2} is $-\text{CH}_2\text{OR}^{\text{EE}}$, wherein each instance of R^{EE} is independently hydrogen, optionally substituted alkyl, optionally substituted alkoxy, optionally substituted alkenyl, optionally substituted alkynyl, optionally substituted carbocyclyl, optionally substituted heterocyclyl, optionally substituted aryl, or optionally substituted heteroaryl. In certain embodiments, at least one instance of R^{E2} is $-\text{CH}_2\text{N}(\text{R}^{\text{EF}})_2$ or $-\text{N}(\text{R}^{\text{EF}})_2$, wherein each instance of R^{EF} is independently hydrogen, optionally substituted alkyl, optionally substituted alkoxy, optionally substituted alkenyl, optionally substituted alkynyl, optionally substituted carbocyclyl, optionally substituted heterocyclyl, optionally substituted aryl, or optionally substituted heteroaryl, optionally wherein two R^{EF} groups are joined to form an optionally substituted heterocyclic ring. In certain embodiments, at least one instance of R^{E2} is $-\text{CH}_2\text{SR}^{\text{EE}}$ or $-\text{SR}^{\text{EE}}$ (*e.g.*, $-\text{CH}_2\text{SMe}$ or $-\text{SMe}$). In certain embodiments, at least one instance of R^{E2} is $-\text{OR}^{\text{EE}}$ (*e.g.*, $-\text{OMe}$). In certain embodiments, at least one instance of R^{E2} is $-\text{Si}(\text{R}^{\text{EG}})_3$, wherein each


instance of R^{EG} is independently hydrogen, optionally substituted alkyl, optionally substituted alkoxy, optionally substituted alkenyl, optionally substituted alkynyl, optionally substituted carbocyclyl, optionally substituted heterocyclyl, optionally substituted aryl, or optionally substituted heteroaryl (*e.g.*, $-\text{Si}(\text{Me})_3$). In certain embodiments, at least one instance of R^{E3} is H. In certain embodiments, at least one instance of R^{E3} is halogen (*e.g.*, F, Cl, Br, or I). In certain embodiments, at least one instance of R^{E3} is optionally substituted alkyl (*e.g.*, Me, or Et). In certain embodiments, at least one instance of R^{E3} is optionally substituted alkenyl (*e.g.*, optionally substituted vinyl). In certain embodiments, at least one instance of R^{E3} is optionally substituted alkynyl. In certain embodiments, at least one instance of R^{E3} is substituted or unsubstituted carbocyclyl (*e.g.*, substituted or unsubstituted, 3- to 7-membered, monocyclic carbocyclyl comprising zero, one, or two double bonds in the carbocyclic ring system). In certain embodiments, at least one instance of R^{E3} is substituted or unsubstituted heterocyclyl (*e.g.*, substituted or unsubstituted, 3- to 7-membered, monocyclic heterocyclyl comprising zero, one, or two double bonds in the heterocyclic ring system, wherein one, two, or three atoms in the heterocyclic ring system are independently nitrogen, oxygen, or sulfur). In certain embodiments, at least one instance of R^{E3} is substituted or unsubstituted aryl (*e.g.*, substituted or unsubstituted, 6- to 10-membered aryl). In certain embodiments, at least one instance of R^{E3} is substituted or unsubstituted phenyl. In certain embodiments, at least one instance of R^{E3} is substituted or unsubstituted heteroaryl (*e.g.*, substituted or unsubstituted, 5- to 6-membered, monocyclic heteroaryl, wherein one, two, three, or four atoms in the heteroaryl ring system are independently nitrogen, oxygen, or sulfur). In certain embodiments, at least one instance of R^{E3} is $-\text{CN}$. In certain embodiments, at least one instance of R^{E3} is $-\text{CH}_2\text{OR}^{EE}$, wherein each instance of R^{EE} is independently hydrogen, optionally substituted alkyl, optionally substituted alkoxy, optionally substituted alkenyl, optionally substituted alkynyl, optionally substituted carbocyclyl, optionally substituted heterocyclyl, optionally substituted aryl, or optionally substituted heteroaryl. In certain embodiments, at least one instance of R^{E3} is $-\text{CH}_2\text{N}(\text{R}^{EF})_2$ or $-\text{N}(\text{R}^{EF})_2$, wherein each instance of R^{EF} is independently hydrogen, optionally substituted alkyl, optionally substituted alkoxy, optionally substituted alkenyl, optionally substituted alkynyl, optionally substituted carbocyclyl, optionally substituted heterocyclyl, optionally substituted aryl, or optionally substituted heteroaryl, optionally wherein two R^{EF} groups are joined to form an optionally substituted heterocyclic ring. In certain embodiments, at least one instance of R^{E3} is $-\text{CH}_2\text{SR}^{EE}$ or $-\text{SR}^{EE}$ (*e.g.*, $-\text{CH}_2\text{SMe}$ or $-\text{SMe}$). In certain embodiments, at least one instance of R^{E3} is $-\text{OR}^{EE}$ (*e.g.*, $-\text{OMe}$). In certain embodiments, at least one instance of R^{E3} is $-\text{OR}^{EE}$ (*e.g.*, $-\text{OMe}$).

$\text{Si}(\text{R}^{\text{EG}})_3$, wherein each instance of R^{EG} is independently hydrogen, optionally substituted alkyl, optionally substituted alkoxy, optionally substituted alkenyl, optionally substituted alkynyl, optionally substituted carbocyclyl, optionally substituted heterocyclyl, optionally substituted aryl, or optionally substituted heteroaryl (*e.g.*, $-\text{Si}(\text{Me})_3$). In certain embodiments, R^{E1} and R^{E3} are joined to form an optionally substituted carbocyclic ring (*e.g.*, substituted or unsubstituted, 3- to 7-membered, monocyclic carbocyclyl comprising zero, one, or two double bonds in the carbocyclic ring system). In certain embodiments, R^{E1} and R^{E3} are joined to form an optionally substituted heterocyclic ring (*e.g.*, substituted or unsubstituted, 3- to 7-membered, monocyclic heterocyclyl comprising zero, one, or two double bonds in the heterocyclic ring system, wherein one, two, or three atoms in the heterocyclic ring system are independently nitrogen, oxygen, or sulfur). In certain embodiments, R^{E2} and R^{E3} are joined to form an optionally substituted carbocyclic ring (*e.g.*, substituted or unsubstituted, 3- to 7-membered, monocyclic carbocyclyl comprising zero, one, or two double bonds in the carbocyclic ring system). In certain embodiments, R^{E2} and R^{E3} are joined to form an optionally substituted heterocyclic ring (*e.g.*, substituted or unsubstituted, 3- to 7-membered, monocyclic heterocyclyl comprising zero, one, or two double bonds in the heterocyclic ring system, wherein one, two, or three atoms in the heterocyclic ring system are independently nitrogen, oxygen, or sulfur). In certain embodiments, R^{E1} and R^{E2} are joined to form an optionally substituted carbocyclic ring (*e.g.*, substituted or unsubstituted, 3- to 7-membered, monocyclic carbocyclyl comprising zero, one, or two double bonds in the carbocyclic ring system). In certain embodiments, R^{E1} and R^{E2} are joined to form an optionally substituted heterocyclic ring (*e.g.*, substituted or unsubstituted, 3- to 7-membered, monocyclic heterocyclyl comprising zero, one, or two double bonds in the heterocyclic ring system, wherein one, two, or three atoms in the heterocyclic ring system are independently nitrogen, oxygen, or sulfur). In certain embodiments, R^{E4} is a leaving group (*e.g.*, halogen, or a sulfonic acid ester, *e.g.*, $-\text{O}(\text{tosylate})$ or $-\text{O}(\text{mesylate})$). In certain embodiments, R^{E5} is halogen (*e.g.*, F, Cl, Br, or I). In certain embodiments, R^{E6} is H. In certain embodiments, R^{E6} is substituted or unsubstituted C_{1-6} alkyl (*e.g.*, Me, is $-\text{CF}_3$, Bn, Et, perfluoroethyl, Pr, perfluoropropyl, Bu, or perfluorobutyl). In certain embodiments, R^{E6} is a nitrogen protecting group (*e.g.*, Bn, Boc, Cbz, Fmoc, trifluoroacetyl, triphenylmethyl, acetyl, or Ts). In certain embodiments, at least one instance of Y is O. In certain embodiments, at least one instance of Y is S. In certain embodiments, at least one instance of Y is NR^{E7} , wherein R^{E7} is hydrogen, substituted or unsubstituted C_{1-6} alkyl, or a nitrogen protecting group (*e.g.*, NMe). In certain embodiments, a is 1. In certain embodiments, a is 2. In certain embodiments, at least one

instance of z is 0. In certain embodiments, at least one instance of z is 1. In certain embodiments, at least one instance of z is 2. In certain embodiments, at least one instance of z is 3. In certain embodiments, at least one instance of z is 4. In certain embodiments, at least one instance of z is 5. In certain embodiments, at least one instance of z is 6.

[00138] In certain embodiments, the compound of Formula (I) is of the formula:





or a pharmaceutically acceptable salts, solvates, hydrates, polymorphs, co-crystals, tautomers, stereoisomers, isotopologue, and prodrugs thereof.

[00139] In certain embodiments, a compound described herein is a compound of Formula (I), or a pharmaceutically acceptable salt, solvate, hydrate, polymorph, co-derivative, crystal, tautomer, stereoisomer, isotopologue, or prodrug thereof. In certain embodiments, a compound described herein is a compound of Formula (I), or a pharmaceutically acceptable salt thereof.

Methods of Treatment and Uses

[00140] The present disclosure provides methods of modulating (*e.g.*, inhibiting or increasing) the activity (*e.g.*, aberrant activity, or undesired activity, such as increased or decreased activity) of a kinase (*e.g.*, JNK (*e.g.*, JNK2)). The present disclosure provides methods of modulating (*e.g.*, inhibiting or increasing) the activity (*e.g.*, aberrant activity, such as increased or decreased activity) of a JNK (*e.g.*, JNK2) in a subject, biological sample, tissue, or cell. The present disclosure also provides methods for the treatment of a wide range of diseases, such as diseases associated with the aberrant activity (*e.g.*, increased activity) of a kinase, *e.g.*, proliferative diseases (*e.g.*, cancer and benign neoplasms), inflammatory diseases (*e.g.*, rheumatoid arthritis), autoimmune diseases, and cardiovascular diseases (*e.g.*, atherosclerosis)) in a subject, biological sample, tissue, or cell. The present disclosure provides methods for the treatment and/or prevention of a proliferative diseases (*e.g.*, cancer and benign neoplasms), inflammatory diseases (*e.g.*, rheumatoid arthritis), autoimmune diseases, and cardiovascular diseases (*e.g.*, atherosclerosis)) in a subject, biological sample, tissue, or cell.

[00141] The present disclosure further provides methods of using the compounds described herein, *e.g.*, as biological probes to study the inhibition of the activity of a kinase (*e.g.*, JNK (*e.g.*, JNK2)), and as therapeutics, *e.g.*, in the treatment and/or prevention of diseases associated with the overexpression and/or aberrant activity of the kinase (*e.g.*, JNK (*e.g.*, JNK2)). In certain embodiments, the compounds covalently inhibit JNKs (*e.g.*, JNK2). In certain embodiments, the diseases treated and/or prevented include, but are not limited to, proliferative diseases (*e.g.*, cancer and benign neoplasms), inflammatory diseases (*e.g.*, rheumatoid arthritis), autoimmune diseases, and cardiovascular diseases (*e.g.*, atherosclerosis)) in a subject, biological sample, tissue, or cell. In certain embodiments, the cancer is associated with the overexpression and/or aberrant activity of a kinase (*e.g.*, JNK (*e.g.*, JNK2)). Also provided by the present disclosure are pharmaceutical compositions, kits, methods, and uses of a compound of Formula (I) as described herein.

[00142] Certain compounds described herein bind, covalently modify, and/or inhibit a kinase. In certain embodiments, the compounds described herein irreversibly inhibit a kinase. In certain embodiments, the kinase is a JNK. In certain embodiments, the kinase is JNK2. In certain embodiments, the compounds described herein covalently bind to the kinase (*e.g.*, JNK (*e.g.*, JNK2)). In certain embodiments, the compounds described herein non-reversibly bind to the kinase (*e.g.*, JNK (*e.g.*, JNK2)). In certain embodiments, the compounds described herein modulate the activity of a kinase (*e.g.*, JNK (*e.g.*, JNK1, JNK2, JNK3)). In certain embodiments, the compounds described herein inhibit the activity of a kinase (*e.g.*, a JNK (*e.g.*, JNK2)). In certain embodiments, the compounds described herein irreversibly inhibit the activity of a kinase (*e.g.*, JNK (*e.g.*, JNK2)).

[00143] The binding affinity of a compound described herein to a kinase (*e.g.*, JNK (*e.g.*, JNK2)) may be measured by the dissociation constant (K_d) value of an adduct of the compound and the kinase (*e.g.*, JNK (*e.g.*, JNK2)) using methods known in the art (*e.g.*, isothermal titration calorimetry (ITC)). In certain embodiments, the K_d value of the adduct is not more than about 100 μ M, not more than about 10 μ M, not more than about 1 μ M, not more than about 100 nM, not more than about 10 nM, or not more than about 1 nM.

[00144] In certain embodiments, the activity of a kinase (*e.g.*, JNK (*e.g.*, JNK2)) is inhibited by a compound described herein. The inhibition of the activity of a kinase (*e.g.*, JNK (*e.g.*, JNK2)) by a compound described herein may be measured by determining the half maximal inhibitory concentration (IC_{50}) of the compound when the compound, or a pharmaceutical composition thereof, is contacted with the kinase (*e.g.*, JNK (*e.g.*, JNK2)). The IC_{50} values may be obtained using methods known in the art (*e.g.*, by a competition binding assay). In certain embodiments, the IC_{50} value of a compound described herein is not more than about 1 mM, not more than about 100 μ M, not more than about 10 μ M, not more than about 1 μ M, not more than about 100 nM, not more than about 10 nM, or not more than about 1 nM.

[00145] In some embodiments, the activity of the kinase being inhibited is selectively inhibited by the compounds or pharmaceutical compositions described herein, compared to the activity of a different protein (*e.g.*, a different kinase). In certain embodiments, the activity of a JNK (*e.g.*, JNK2) is selectively inhibited by a compound or pharmaceutical composition described herein, compared to the activity of a different protein (*e.g.*, a different kinase). In certain embodiments, the activity of JNK2 is selectively inhibited by a compound or pharmaceutical composition described herein, compared to the activity of another JNK (*e.g.*, JNK1 or JNK3).

[00146] The selectivity of a compound or pharmaceutical composition described herein in inhibiting the activity of a kinase over a different protein (*e.g.*, a different kinase) may be measured by the quotient of the IC_{50} value of the compound or pharmaceutical composition in inhibiting the activity of the different protein over the IC_{50} value of the compound or pharmaceutical composition in inhibiting the activity of the kinase. The selectivity of a compound or pharmaceutical composition described herein for a kinase over a different protein may also be measured by the quotient of the K_d value of an adduct of the compound or pharmaceutical composition and the different protein over the K_d value of an adduct of the compound or pharmaceutical composition and the kinase. In certain embodiments, the selectivity is at least 2-fold, at least 3-fold, at least 5-fold, at least 10-fold, at least 30-fold, at least 100-fold, at least 300-fold, at least 1,000-fold, at least 3,000-fold, at least 10,000-fold, at least 30,000-fold, or at least 100,000-fold. In certain embodiments, the selectivity is not more than 100,000-fold, not more than 10,000-fold, not more than 1,000-fold, not more than 100-fold, not more than 10-fold, or not more than 2-fold. Combinations of the above-referenced ranges (*e.g.*, at least 2-fold and not more than 10,000-fold) are also within the scope of the disclosure.








[00147] The compounds described herein may selectively modulate the activity of a kinase (*e.g.*, JNK (*e.g.*, JNK2)). In certain embodiments, the compounds selectively increase the activity of a kinase (*e.g.*, JNK (*e.g.*, JNK2)). In certain embodiments, the compounds selectively inhibit the activity of a kinase (*e.g.*, JNK (*e.g.*, JNK2)). In certain embodiments, the compounds inhibit the activity of two or more kinases (*e.g.*, JNK (*e.g.*, JNK1, JNK2, JNK3)) to some extent.










[00148] In certain embodiments, the present disclosure provides selective inhibitors of a kinase (*e.g.*, JNK (*e.g.*, JNK2)). In certain embodiments, the inventive compounds selectively inhibit the activity of a JNK (*e.g.*, JNK2). The selectivity of a compound described herein for inhibiting the activity of a first kinase (*e.g.*, JNK (*e.g.*, JNK2)) over a second kinase (*e.g.*, JNK (*e.g.*, JNK1, JNK3)) may be measured by the quotient of the IC_{50} value of the compound in inhibiting the activity of the second kinase (*e.g.*, JNK (*e.g.*, JNK1, JNK3)) over the IC_{50} value of the compound in inhibiting the activity of the first kinase (*e.g.*, JNK (*e.g.*, JNK2)). The selectivity of a compound described herein in modulating the activity of a first kinase (*e.g.*, JNK (*e.g.*, JNK2)) over a second kinase (*e.g.*, JNK (*e.g.*, JNK1, JNK3)) may also be measured by the quotient of the K_d value of an adduct of the compound and the second JNK (*e.g.*, JNK1, JNK3) over the K_d value of an adduct of the compound and the first JNK (*e.g.*, JNK2). In certain embodiments, the selectivity is at least about 1-fold, at least about 3-fold, at








least about 10-fold, at least about 30-fold, at least about 100-fold, at least about 300-fold, at least about 1,000-fold, at least about 3,000-fold, at least about 10,000-fold, at least about 30,000-fold, or at least about 100,000-fold.









[00149] Table 1 shows the results of an IC₅₀ assay for JNK kinase inhibition for JNK1, JNK2, and JNK3 with exemplary compounds of the disclosure.


Table 1. IC₅₀ assay with exemplary compounds

Structure	ID	JNK1 (nM)	JNK2 (nM)	JNK3 (nM)
	I-1	44.7	3.65	2.36
	I-2	64	11	20
	I-3	26	5.67	16.2
	I-4	21.4	2.88	22.5
	I-5	569	24	15
	I-6	278	40	1090
	I-7	12.5	2.75	25

	I-8	73.4	5.59	21.4
	I-9	403	15.9	96.1
	I-10	243	7.88	48.1
	I-11	152	4.91	51.4
	I-12	320	17.6	110
	I-13	308	31	20
	I-14	314	29	252
	I-15	481	38.9	40.3
	I-16	37.6	6.94	10.9

	I-17	>10000	7890	>10000
	I-18	99.3	12.4	15.7
	I-19	2080	71	82.1
	I-20	168	10	12
	I-21	3360	585	359
	I-22	85	5.57	3.87
	I-23	1140	142	396

	I-24	18.4	0.952	5.53
	I-25	90.7	3.92	18.3
	I-26	8.90	67.6	10.3
	I-27	2600	99.5	790
	I-28	223	17.6	60.1
	I-29	261	35.6	132
	I-30	89.9	5.48	26.2
	I-31	2390	85.8	274

	I-32	1810	222	>3,330
---	-------------	------	-----	--------

[00150] It is expected that the compounds described herein may be useful in treating and/or preventing diseases associated with aberrant activity (*e.g.*, increased activity, undesired activity, abnormal activity) of a kinase (*e.g.*, a JNK (*e.g.*, JNK2)). It is known in the art that kinases are implicated in a wide range of diseases and conditions, such as proliferative diseases (*e.g.*, cancer and benign neoplasms), inflammatory diseases (*e.g.*, rheumatoid arthritis), autoimmune diseases, and cardiovascular diseases (*e.g.*, atherosclerosis)) in a subject, biological sample, tissue, or cell.. Therefore, the compounds described herein are expected to be useful in treating and/or preventing diseases (*e.g.*, proliferative diseases, inflammatory diseases, autoimmune diseases, cardiovascular diseases).

[00151] The present disclosure also provides a compound of Formula (I), or a pharmaceutically acceptable salt, co-crystal, tautomer, stereoisomer, solvate, hydrate, polymorph, isotopologue, or prodrug, or composition thereof, for use in the treatment of diseases, such as proliferative diseases (*e.g.*, cancer and benign neoplasms), inflammatory diseases (*e.g.*, rheumatoid arthritis), autoimmune diseases, and cardiovascular diseases (*e.g.*, atherosclerosis)) in a subject, biological sample, tissue, or cell.

[00152] The present disclosure also provides uses of a compound of Formula (I), or a pharmaceutically acceptable salt, co-crystal, tautomer, stereoisomer, solvate, hydrate, polymorph, isotopologue, or prodrug, or composition thereof, in the manufacture of a medicament for the treatment of diseases, such as proliferative diseases (*e.g.*, cancer and benign neoplasms), inflammatory diseases (*e.g.*, rheumatoid arthritis), autoimmune diseases, and cardiovascular diseases (*e.g.*, atherosclerosis)) in a subject, biological sample, tissue, or cell.

[00153] In another aspect, the present disclosure provides methods of modulating the activity of a kinase (*e.g.*, JNK (*e.g.*, JNK2)) in a subject, biological sample, tissue, or cell. In certain embodiments, provided are methods of inhibiting the activity of a kinase in a subject (*e.g.*, JNK (*e.g.*, JNK2)). In certain embodiments, provided are methods of inhibiting the activity of a kinase in a cell (*e.g.*, JNK (*e.g.*, JNK2)). In certain embodiments, provided are methods of increasing the activity of a kinase (*e.g.*, JNK (*e.g.*, JNK1, JNK2, or JNK3)) in a subject. The

compounds described herein may exhibit kinase inhibitory activity; the ability to inhibit a kinase; the ability to inhibit a JNK; the ability to inhibit JNK2, without inhibiting another JNK (*e.g.*, JNK1 or JNK3), a therapeutic effect and/or preventative effect in the treatment of cancers; a therapeutic effect and/or preventative effect in the treatment of proliferative diseases (*e.g.*, cancer and benign neoplasms), inflammatory diseases (*e.g.*, rheumatoid arthritis), autoimmune diseases, and cardiovascular diseases (*e.g.*, atherosclerosis)); and/or a therapeutic profile (*e.g.*, optimum safety and curative effect) that is superior to existing chemotherapeutic agents, or agents for treating proliferative diseases (*e.g.*, cancer and benign neoplasms), inflammatory diseases (*e.g.*, rheumatoid arthritis), autoimmune diseases, and cardiovascular diseases (*e.g.*, atherosclerosis)).

[00154] In certain embodiments, provided are methods of decreasing the activity of a kinase (*e.g.*, JNK (*e.g.*, JNK2)) in a subject or biological sample (*e.g.*, cell, tissue) by a method described herein by at least about 1%, at least about 3%, at least about 10%, at least about 20%, at least about 30%, at least about 40%, at least about 50%, at least about 60%, at least about 70%, at least about 80%, or at least about 90%. In certain embodiments, the activity of a kinase (*e.g.*, JNK (*e.g.*, JNK2, JNK3)) in a subject or cell is decreased by a method described herein by at least about 1%, at least about 3%, at least about 10%, at least about 20%, at least about 30%, at least about 40%, at least about 50%, at least about 60%, at least about 70%, at least about 80%, or at least about 90%. In some embodiments, the activity of a kinase (*e.g.*, JNK (*e.g.*, JNK2, JNK3)) in a subject, biological sample, tissue, or cell is selectively inhibited by the method. In some embodiments, the activity of a kinase (*e.g.*, JNK (*e.g.*, JNK1, JNK2, JNK3)) in a subject or cell is selectively decreased by the method.

[00155] Without wishing to be bound by any particular theory, the compounds described herein are able to bind (*e.g.*, covalently modify) the JNK being inhibited. In certain embodiments, a compound described herein is able to bind (*e.g.*, covalently modify) the JNK. In certain embodiments, the compound described herein is able to covalently bind a cysteine residue of the JNK. In certain embodiments, the compound is capable of covalently modifying Cys116 of a JNK. In certain embodiments, the compound is capable of covalently modifying Cys116 of a JNK. In certain embodiments, the compound is capable of covalently modifying Cys116 of JNK2. In certain embodiments, the compound is capable of covalently modifying JNK2.

[00156] In another aspect, the present disclosure provides methods of inhibiting the activity of a kinase in a subject, the methods comprising administering to the subject an effective amount (*e.g.*, therapeutically effective amount) of a compound, or pharmaceutical

composition thereof, as described herein. In another aspect, the present disclosure provides methods of inhibiting the activity of a kinase (*e.g.*, JNK (*e.g.*, JNK2)) in a biological sample, the methods comprising contacting the biological sample with an effective amount of a compound, or pharmaceutical composition thereof, as described herein. In another aspect, the present disclosure provides methods of inhibiting the activity of a kinase in a tissue or cell, the methods comprising contacting the tissue or cell with an effective amount of a compound, or pharmaceutical composition thereof, as described herein.

[00157] In another aspect, the present disclosure provides methods of inhibiting the activity of a kinase (*e.g.*, JNK (*e.g.*, JNK2)) in a cell, the methods comprising contacting the cell with an effective amount of a compound, or pharmaceutical composition thereof, as described herein.

[00158] In certain embodiments, the subject being treated is a mammal. In certain embodiments, the subject is a human. In certain embodiments, the subject is a non-human mammal. In certain embodiments, the subject is a domesticated animal, such as a dog, cat, cow, pig, horse, sheep, or goat. In certain embodiments, the subject is a companion animal, such as a dog or cat. In certain embodiments, the subject is a livestock animal, such as a cow, pig, horse, sheep, or goat. In certain embodiments, the subject is a zoo animal. In another embodiment, the subject is a research animal, such as a rodent, dog, or non-human primate. In certain embodiments, the subject is a non-human transgenic animal, such as a transgenic mouse or transgenic pig. In certain embodiments, the subject is a fish or reptile. In certain embodiments, the subject is an animal. The animal may be of either sex and may be at any stage of development. In certain embodiments, the subject described herein is a human. In certain embodiments, the subject is a non-human animal. In certain embodiments, the subject is a mammal.

[00159] In certain embodiments, the cell being contacted with a compound or composition described herein is *in vitro*. In certain embodiments, the cell being contacted with a compound or composition described herein is *in vivo*.

[00160] In certain embodiments, the biological sample being contacted with the compound or composition is breast tissue, bone marrow, lymph node, lymph tissue, spleen, or blood. In certain embodiments, the biological sample being contacted with the compound or composition is a tumor or cancerous tissue. In certain embodiments, the biological sample being contacted with the compound or composition is serum, cerebrospinal fluid, interstitial fluid, mucous, tears, sweat, pus, biopsied tissue (*e.g.*, obtained by a surgical biopsy or needle

biopsy), nipple aspirates, milk, vaginal fluid, saliva, swabs (such as buccal swabs), or any material containing biomolecules that is derived from a first biological sample.

[00161] In certain embodiments, the cell or tissue being contacted with the compound or composition is present *in vitro*. In certain embodiments, the cell or tissue being contacted with the compound or composition is present *in vivo*. In certain embodiments, the cell or tissue being contacted with the compound or composition is present *ex vivo*. In certain embodiments, the cell or tissue being contacted with the compound or composition is a malignant cell (*e.g.*, malignant blood cell). In certain embodiments, the cell being contacted with the compound or composition is a malignant hematopoietic stem cell (*e.g.*, malignant myeloid cell or malignant lymphoid cell). In certain embodiments, the cell being contacted with the compound or composition is a malignant lymphocyte (*e.g.*, malignant T-cell or malignant B-cell). In certain embodiments, the cell being contacted with the compound or composition is a malignant white blood cell. In certain embodiments, the cell being contacted with the compound or composition is a malignant neutrophil, malignant macrophage, or malignant plasma cell. In certain embodiments, the cell being contacted with the compound or composition is a carcinoma cell. In certain embodiments, the cell being contacted with the compound or composition is a breast carcinoma cell. In certain embodiments, the cell being contacted with the compound or composition is a sarcoma cell. In certain embodiments, the cell being contacted with the compound or composition is a sarcoma cell from breast tissue.

[00162] The disease (*e.g.*, proliferative disease, inflammatory disease, autoimmune disease, or cardiovascular disease) to be treated or prevented using the compounds described herein may be associated with increased activity of a kinase, such as a JNK (*e.g.*, JNK2). The disease (*e.g.*, proliferative disease, inflammatory disease, autoimmune disease, or cardiovascular disease) to be treated or prevented using the compounds described herein may be associated with the overexpression of a kinase, such as a JNK (*e.g.*, JNK2).

[00163] In certain embodiments, the disease (*e.g.*, proliferative disease, inflammatory disease, autoimmune disease, or cardiovascular disease) to be treated or prevented using the compounds described herein may be associated with the overexpression of a JNK (*e.g.*, JNK2). A disease (*e.g.*, proliferative disease, inflammatory disease, autoimmune disease, or cardiovascular disease) may be associated with aberrant activity of a JNK (*e.g.*, JNK2). Aberrant activity of a JNK (*e.g.*, JNK2) may be elevated and/or inappropriate and/or undesired activity of the JNK. The compounds described herein, and pharmaceutically acceptable salts, solvates, hydrates, polymorphs, co-crystals, tautomers, stereoisomers, isotopologue, prodrugs, and compositions thereof, may inhibit the activity of a JNK (*e.g.*,

JNK2) and be useful in treating and/or preventing diseases (*e.g.*, proliferative diseases, inflammatory diseases, autoimmune diseases, or cardiovascular diseases). The compounds described herein, and pharmaceutically acceptable salts, solvates, hydrates, polymorphs, co-crystals, tautomers, stereoisomers, isotopologues, prodrugs, and compositions thereof, may inhibit the activity of a JNK and be useful in treating and/or preventing diseases (*e.g.*, proliferative diseases, inflammatory disease, autoimmune disease, or cardiovascular disease). The compounds described herein, and pharmaceutically acceptable salts, solvates, hydrates, polymorphs, co-crystals, tautomers, stereoisomers, isotopologue, prodrugs, and compositions thereof, may inhibit the activity of a JNK and be useful in treating and/or preventing diseases (*e.g.*, proliferative diseases, inflammatory disease, autoimmune disease, or cardiovascular disease).

[00164] In certain embodiments, the disease (*e.g.*, proliferative disease, inflammatory disease, autoimmune disease, or cardiovascular disease) to be treated or prevented using the compounds described herein is cancer. All types of cancers disclosed herein or known in the art are contemplated as being within the scope of the invention. In certain embodiments, the proliferative disease is a hematological malignancy. In certain embodiments, the proliferative disease is a blood cancer. In certain embodiments, the proliferative disease is leukemia. In certain embodiments, the proliferative disease is chronic lymphocytic leukemia (CLL). In certain embodiments, the proliferative disease is acute lymphoblastic leukemia (ALL). In certain embodiments, the proliferative disease is T-cell acute lymphoblastic leukemia (T-ALL). In certain embodiments, the proliferative disease is chronic myelogenous leukemia (CML). In certain embodiments, the proliferative disease is acute myeloid leukemia (AML). In certain embodiments, the proliferative disease is acute monocytic leukemia (AMoL). In certain embodiments, the proliferative disease is myelodysplastic syndrome (MDS). In certain embodiments, the proliferative disease is a carcinoma. In certain embodiments, the proliferative disease is lymphoma. In certain embodiments, the proliferative disease is T-cell lymphoma. In some embodiments, the proliferative disease is Burkitt's lymphoma. In certain embodiments, the proliferative disease is a Hodgkin's lymphoma. In certain embodiments, the proliferative disease is a non-Hodgkin's lymphoma. In certain embodiments, the proliferative disease is multiple myeloma. In certain embodiments, the proliferative disease is melanoma. In certain embodiments, the proliferative disease is colorectal cancer. In certain embodiments, the proliferative disease is colon cancer. In certain embodiments, the proliferative disease is breast cancer. In certain embodiments, the proliferative disease is recurring breast cancer. In certain embodiments, the proliferative disease is mutant breast

cancer. In certain embodiments, the proliferative disease is HER2+ breast cancer. In certain embodiments, the proliferative disease is HER2- breast cancer. In certain embodiments, the proliferative disease is triple-negative breast cancer (TNBC). In certain embodiments, the proliferative disease is a bone cancer. In certain embodiments, the proliferative disease is sarcoma. In certain embodiments, the proliferative disease is osteosarcoma. In certain embodiments, the proliferative disease is Kaposi's sarcoma. In certain embodiments, the proliferative disease is Ewing's sarcoma. In some embodiments, the proliferative disease is a brain cancer. In some embodiments, the proliferative disease is neuroblastoma. In some embodiments, the proliferative disease is a lung cancer. In some embodiments, the proliferative disease is small cell lung cancer (SCLC). In some embodiments, the proliferative disease is non-small cell lung cancer. In some embodiments, the proliferative disease is liver cancer. In some embodiments, the proliferative disease is pancreatic cancer. In some embodiments, the proliferative disease is gastric cancer. In some embodiments, the proliferative disease is ovarian cancer. In some embodiments, the proliferative disease is ovarian cancer. In some embodiments, the proliferative disease is a benign neoplasm. All types of benign neoplasms disclosed herein or known in the art are contemplated as being within the scope of the invention. In some embodiments, the proliferative disease is associated with angiogenesis. All types of angiogenesis disclosed herein or known in the art are contemplated as being within the scope of the invention.

Pharmaceutical Compositions, Kits, and Administration

[00165] The present disclosure also provides pharmaceutical compositions comprising a compound described herein and optionally a pharmaceutically acceptable excipient. In certain embodiments, a compound described herein is a compound of Formula (I), or a pharmaceutically acceptable salt thereof, and a pharmaceutically acceptable excipient.

[00166] In certain embodiments, the compound described herein is provided in an effective amount in the pharmaceutical composition. In certain embodiments, the effective amount is a therapeutically effective amount. In certain embodiments, the effective amount is a prophylactically effective amount. In certain embodiments, a therapeutically effective amount is an amount effective for inhibiting the aberrant activity of a kinase (*e.g.*, JNK (*e.g.*, JNK1, JNK2, JNK3)). In certain embodiments, a therapeutically effective amount is an amount effective for treating a disease (*e.g.*, a disease associated with aberrant activity of a JNK (*e.g.*, proliferative diseases (*e.g.*, cancer and benign neoplasms), inflammatory diseases (*e.g.*, rheumatoid arthritis), autoimmune diseases, and cardiovascular diseases (*e.g.*,

atherosclerosis)) in a subject, biological sample, tissue, or cell.). In certain embodiments, a therapeutically effective amount is an amount effective for inducing apoptosis of a cell (*e.g.*, cell *in vivo* or *in vitro*). In certain embodiments, a prophylactically effective amount is an amount effective for inhibiting the aberrant activity of a protein (*e.g.*, JNK (*e.g.*, JNK1, JNK2, or JNK3)). In certain embodiments, a prophylactically effective amount is an amount effective for preventing or keeping a subject in need thereof in remission of a disease (*e.g.*, a disease associated with aberrant activity of a JNK (*e.g.*, proliferative disease). In certain embodiments, a prophylactically effective amount is an amount effective for inhibiting the aberrant activity of a JNK, and preventing or keeping a subject in need thereof in remission of a disease (*e.g.*, a disease associated with aberrant activity of a JNK (*e.g.*, a proliferative disease)).

[00167] In certain embodiments, the effective amount is an amount effective for inhibiting the activity of a kinase (*e.g.*, JNK (*e.g.*, JNK1, JNK2, or JNK3)) by at least 10%, at least 20%, at least 30%, at least 40%, at least 50%, at least 60%, at least 70%, at least 80%, at least 90%, at least 95%, or at least 98%. In certain embodiments, the effective amount is an amount effective for inhibiting the activity of a JNK (*e.g.*, JNK1, JNK2, or JNK3)) by not more than 10%, not more than 20%, not more than 30%, not more than 40%, not more than 50%, not more than 60%, not more than 70%, not more than 80%, not more than 90%, not more than 95%, or not more than 98%.

[00168] Another aspect of the disclosure relates to methods of inhibiting the activity of a kinase in a biological sample, tissue, cell, or subject. In certain embodiments, the JNK is JNK2. In certain embodiments, JNK2 is selectively inhibited over another kinase (*e.g.*, JNK (*e.g.*, JNK1, JNK3)). In certain embodiments, the activity of the kinase is aberrant activity of the kinase. In certain embodiments, the activity of the kinase is increased activity of the kinase. In certain embodiments, the inhibition of the activity of the kinase is irreversible. In certain embodiments, the methods of inhibiting the activity of the kinase include attaching a compound described herein to the kinase. In certain embodiments, the methods comprise covalently inhibiting a JNK (*e.g.*, JNK2). The present invention provides methods of inhibiting cell growth in a biological sample, tissue, cell, or subject.

[00169] In certain embodiments, the methods described herein include administering to a subject or contacting a biological sample with an effective amount of a compound described herein, or a pharmaceutically acceptable salt, solvate, hydrate, polymorph, co-crystal, tautomer, stereoisomer, isotopologue, or prodrug thereof, or a pharmaceutical composition thereof. All types of biological samples described herein or known in the art are contemplated

as being within the scope of the invention. In certain embodiments, the methods described herein include administering to a subject or contacting a biological sample with an effective amount of a compound described herein, or a pharmaceutically acceptable salt thereof, or a pharmaceutical composition thereof. In certain embodiments, the compound is contacted with a biological sample. In certain embodiments, the compound is administered to a subject. In certain embodiments, the compound is administered in combination with one or more additional pharmaceutical agents described herein. The additional pharmaceutical agent may be an anti-proliferative agent. In certain embodiments, the additional pharmaceutical agent is an anti-cancer agent. The additional pharmaceutical agent may also be a kinase inhibitor. In certain embodiments, the additional pharmaceutical agent is an inhibitor of a kinase. In certain embodiments, the additional pharmaceutical agent is an inhibitor of JNK. In certain embodiments, the additional pharmaceutical agent is an inhibitor of JNK1. In certain embodiments, the additional pharmaceutical agent is an inhibitor of JNK2. In certain embodiments, the additional pharmaceutical agent is an inhibitor of JNK3. In certain embodiments, the additional pharmaceutical agent is a selective inhibitor of a kinase. In certain embodiments, the additional pharmaceutical agent is a selective inhibitor of a JNK. In certain embodiments, the additional pharmaceutical agent is a selective inhibitor of JNK1. In certain embodiments, the additional pharmaceutical agent is a selective inhibitor of JNK2. In certain embodiments, the additional pharmaceutical agent is a selective inhibitor of JNK3. In certain embodiments, the additional pharmaceutical agent is a non-selective inhibitor of JNK1. In certain embodiments, the additional pharmaceutical agent is a non-selective inhibitor of JNK2. In certain embodiments, the additional pharmaceutical agent is a non-selective inhibitor of JNK3. In certain embodiments, the additional pharmaceutical agent is an anti-cancer agent (*e.g.*, chemotherapeutics), anti-inflammatory agent, steroid, immunosuppressant, radiation therapy, or other agent. In certain embodiments, the additional pharmaceutical agent is an anti-proliferative agent. In certain embodiments, the additional pharmaceutical agent is an inhibitor of a kinase. In certain embodiments, the additional pharmaceutical agent is a non-selective inhibitor of a kinase. In certain embodiments, the additional pharmaceutical agent is an immunotherapy agent (*e.g.*, PD1 inhibitor, PDL1 inhibitor). In certain embodiments, the additional pharmaceutical agent is an immune checkpoint inhibitor.

[00170] The additional pharmaceutical agents include, but are not limited to, anti-proliferative agents, anti-cancer agents, anti-angiogenesis agents, anti-inflammatory agents, immunosuppressants, anti-bacterial agents, anti-viral agents, cardiovascular agents,

cholesterol-lowering agents, anti-diabetic agents, anti-allergic agents, contraceptive agents, pain-relieving agents, and a combination thereof. In certain embodiments, the additional pharmaceutical agent is an anti-proliferative agent (*e.g.*, anti-cancer agent). In certain embodiments, the additional pharmaceutical agent is an anti-leukemia agent. In certain embodiments, the additional pharmaceutical agent is ABITREXATE (methotrexate), ADE, Adriamycin RDF (doxorubicin hydrochloride), Ambochlorin (chlorambucil), ARRANON (nelarabine), ARZERRA (ofatumumab), BOSULIF (bosutinib), BUSULFEX (busulfan), CAMPATH (alemtuzumab), CERUBIDINE (daunorubicin hydrochloride), CLAFEN (cyclophosphamide), CLOFAREX (clofarabine), CLOLAR (clofarabine), CVP, CYTOSAR-U (cytarabine), CYTOXAN (cyclophosphamide), ERWINAZE (Asparaginase *Erwinia Chrysanthemi*), FLUDARA (fludarabine phosphate), FOLEX (methotrexate), FOLEX PFS (methotrexate), GAZYVA (obinutuzumab), GLEEVEC (imatinib mesylate), Hyper-CVAD, ICLUSIG (ponatinib hydrochloride), IMBRUVICA (ibrutinib), LEUKERAN (chlorambucil), LINFOLIZIN (chlorambucil), MARQIBO (vincristine sulfate liposome), METHOTREXATE LPF (methotrexate), MEXATE (methotrexate), MEXATE-AQ (methotrexate), mitoxantrone hydrochloride, MUSTARGEN (mechlorethamine hydrochloride), MYLERAN (busulfan), NEOSAR (cyclophosphamide), ONCASPAR (Pegaspargase), PURINETHOL (mercaptopurine), PURIXAN (mercaptopurine), Rubidomycin (daunorubicin hydrochloride), SPRYCEL (dasatinib), SYNRIPO (omacetaxine mepesuccinate), TARABINE PFS (cytarabine), TASIGNA (nilotinib), TREANDA (bendamustine hydrochloride), TRISENOX (arsenic trioxide), VINCASAR PFS (vincristine sulfate), ZYDELIG (idelalisib), or a combination thereof. In certain embodiments, the additional pharmaceutical agent is an anti-lymphoma agent. In certain embodiments, the additional pharmaceutical agent is ABITREXATE (methotrexate), ABVD, ABVE, ABVE-PC, ADCETRIS (brentuximab vedotin), ADRIAMYCIN PFS (doxorubicin hydrochloride), ADRIAMYCIN RDF (doxorubicin hydrochloride), AMBOCHLORIN (chlorambucil), AMBOCLORIN (chlorambucil), ARRANON (nelarabine), BEACOPP, BECENUM (carmustine), BELEODAQ (belinostat), BEXXAR (tositumomab and iodine I 131 tositumomab), BICNU (carmustine), BLENOXANE (bleomycin), CARMUBRIS (carmustine), CHOP, CLAFEN (cyclophosphamide), COPP, COPP-ABV, CVP, CYTOXAN (cyclophosphamide), DEPOCYT (liposomal cytarabine), DTIC-DOME (dacarbazine), EPOCH, FOLEX (methotrexate), FOLEX PFS (methotrexate), FOLOTYN (pralatrexate), HYPER-CVAD, ICE, IMBRUVICA (ibrutinib), INTRON A (recombinant interferon alfa-2b), ISTODAX (romidepsin), LEUKERAN (chlorambucil), LINFOLIZIN (chlorambucil), Lomustine,

MATULANE (procarbazine hydrochloride), METHOTREXATE LPF (methotrexate), MEXATE (methotrexate), MEXATE-AQ (methotrexate), MOPP, MOZOBIL (plerixafor), MUSTARGEN (mechlorethamine hydrochloride), NEOSAR (cyclophosphamide), OEPA, ONTAK (denileukin diftitox), OPPA, R-CHOP, REVLIMID (lenalidomide), RITUXAN (rituximab), STANFORD V, TREANDA (bendamustine hydrochloride), VAMP, VELBAN (vinblastine sulfate), VELCADE (bortezomib), VELSAR (vinblastine sulfate), VINCASAR PFS (vincristine sulfate), ZEVALIN (ibritumomab tiuxetan), ZOLINZA (vorinostat), ZYDELIG (idelalisib), or a combination thereof. In certain embodiments, the additional pharmaceutical agent is REVLIMID (lenalidomide), DACOGEN (decitabine), VIDAZA (azacitidine), CYTOSAR-U (cytarabine), IDAMYCIN (idarubicin), CERUBIDINE (daunorubicin), LEUKERAN (chlorambucil), NEOSAR (cyclophosphamide), FLUDARA (fludarabine), LEUSTATIN (cladribine), or a combination thereof. In certain embodiments, the additional pharmaceutical agent is ABITREXATE (methotrexate), ABRAXANE (paclitaxel albumin-stabilized nanoparticle formulation), AC, AC-T, ADE, ADRIAMYCIN PFS (doxorubicin hydrochloride), ADRUCIL (fluorouracil), AFINITOR (everolimus), AFINITOR DISPERZ (everolimus), ALDARA (imiquimod), ALIMTA (pemetrexed disodium), AREDIA (pamidronate disodium), ARIMIDEX (anastrozole), AROMASIN (exemestane), AVASTIN (bevacizumab), BECENUM (carmustine), BEP, BICNU (carmustine), BLENOXANE (bleomycin), CAF, CAMPTOSAR (irinotecan hydrochloride), CAPOX, CAPRELSA (vandetanib), CARBOPLATIN-TAXOL, CARMUBRIS (carmustine), CASODEX (bicalutamide), CEENU (lomustine), CERUBIDINE (daunorubicin hydrochloride), CERVARIX (recombinant HPV bivalent vaccine), CLAFEN (cyclophosphamide), CMF, COMETRIQ (cabozantinib-s-malate), COSMEGEN (dactinomycin), CYFOS (ifosfamide), CYRAMZA (ramucirumab), CYTOSAR-U (cytarabine), CYTOXAN (cyclophosphamide), DACOGEN (decitabine), DEGARELIX, DOXIL (doxorubicin hydrochloride liposome), DOXORUBICIN HYDROCHLORIDE, DOX-SL (doxorubicin hydrochloride liposome), DTIC-DOME (dacarbazine), EFUDEX (fluorouracil), ELLENCE (epirubicin hydrochloride), ELOXATIN (oxaliplatin), ERBITUX (cetuximab), ERIVEDGE (vismodegib), ETOPOPHOS (etoposide phosphate), EVACET (doxorubicin hydrochloride liposome), FARESTON (toremifene), FASLODEX (fulvestrant), FEC, FEMARA (letrozole), FLUOROPLEX (fluorouracil), FOLEX (methotrexate), FOLEX PFS (methotrexate), FOLFIRI, FOLFIRI-BEVACIZUMAB, FOLFIRI-CETUXIMAB, FOLFIRINOX, FOLFOX, FU-LV, GARDASIL (recombinant human papillomavirus (HPV) quadrivalent vaccine), GEMCITABINE-CISPLATIN, GEMCITABINE-OXALIPLATIN,

GEMZAR (gemcitabine hydrochloride), GILOTRIF (afatinib dimaleate), GLEEVEC (imatinib mesylate), GLIADEL (carmustine implant), GLIADEL WAFER (carmustine implant), HERCEPTIN (trastuzumab), HYCAMTIN (topotecan hydrochloride), IFEX (ifosfamide), IFOSFAMIDUM (ifosfamide), INLYTA (axitinib), INTRON A (recombinant interferon alfa-2b), IRESSA (gefitinib), IXEMPRA (ixabepilone), JAKAFI (ruxolitinib phosphate), JEVTANA (cabazitaxel), KADCYLA (ado-trastuzumab emtansine), KEYTRUDA (pembrolizumab), KYPROLIS (carfilzomib), LIPODOX (doxorubicin hydrochloride liposome), LUPRON (leuprolide acetate), LUPRON DEPOT (leuprolide acetate), LUPRON DEPOT-3 MONTH (leuprolide acetate), LUPRON DEPOT-4 MONTH (leuprolide acetate), LUPRON DEPOT-PED (leuprolide acetate), MEGACE (megestrol acetate), MEKINIST (trametinib), METHAZOLASTONE (temozolomide), METHOTREXATE LPF (methotrexate), MEXATE (methotrexate), MEXATE-AQ (methotrexate), MITOXANTRONE HYDROCHLORIDE, MITOZYTREX (mitomycin c), MOZOBIL (plerixafor), MUSTARGEN (mechlorethamine hydrochloride), MUTAMYCIN (mitomycin c), MYLOSAR (azacitidine), NAVELBINE (vinorelbine tartrate), NEOSAR (cyclophosphamide), NEXAVAR (sorafenib tosylate), NOLVADEX (tamoxifen citrate), NOVALDEX (tamoxifen citrate), OFF, PAD, PARAPLAT (carboplatin), PARAPLATIN (carboplatin), PEG-INTRON (peginterferon alfa-2b), PEMETREXED DISODIUM, PERJETA (pertuzumab), PLATINOL (cisplatin), PLATINOL-AQ (cisplatin), POMALYST (pomalidomide), prednisone, PROLEUKIN (aldesleukin), PROLIA (denosumab), PROVENGE (sipuleucel-t), REVLIMID (lenalidomide), RUBIDOMYCIN (daunorubicin hydrochloride), SPRYCEL (dasatinib), STIVARGA (regorafenib), SUTENT (sunitinib malate), SYLATRON (peginterferon alfa-2b), SYLVANT (siltuximab), SYNOVIR (thalidomide), TAC, TAFINLAR (dabrafenib), TARABINE PFS (cytarabine), TARCEVA (erlotinib hydrochloride), TASIGNA (nilotinib), TAXOL (paclitaxel), TAXOTERE (docetaxel), TEMODAR (temozolomide), THALOMID (thalidomide), TOPOSAR (etoposide), TORISEL (temsirolimus), TPF, TRISENOX (arsenic trioxide), TYKERB (lapatinib ditosylate), VECTIBIX (panitumumab), VEIP, VELBAN (vinblastine sulfate), VELCADE (bortezomib), VELSAR (vinblastine sulfate), VEPESID (etoposide), VIADUR (leuprolide acetate), VIDAZA (azacitidine), VINCASAR PFS (vincristine sulfate), VOTRIENT (pazopanib hydrochloride), WELLCOVORIN (leucovorin calcium), XALKORI (crizotinib), XELODA (capecitabine), XELOX, XGEVA (denosumab), XOFIGO (radium 223 dichloride), XTANDI (enzalutamide), YERVOY (ipilimumab), ZALTRAP (ziv-aflibercept), ZELBORAF (vemurafenib), ZOLADEX (goserelin acetate), ZOMETA

(zoledronic acid), ZYKADIA (ceritinib), ZYTIGA (abiraterone acetate), ENMD-2076, PCI-32765, AC220, dovitinib lactate (TKI258, CHIR-258), BIBW 2992 (TOVOK™), SGX523, PF-04217903, PF-02341066, PF-299804, BMS-777607, ABT-869, MP470, BIBF 1120 (VARGATEF®), AP24534, JNJ-26483327, MGCD265, DCC-2036, BMS-690154, CEP-11981, tivozanib (AV-951), OSI-930, MM-121, XL-184, XL-647, and/or XL228), proteasome inhibitors (*e.g.*, bortezomib (Velcade)), mTOR inhibitors (*e.g.*, rapamycin, temsirolimus (CCI-779), everolimus (RAD-001), ridaforolimus, AP23573 (Ariad), AZD8055 (AstraZeneca), BEZ235 (Novartis), BGT226 (Novartis), XL765 (Sanofi Aventis), PF-4691502 (Pfizer), GDC0980 (Genetech), SF1126 (Semafoe) and OSI-027 (OSI)), oblimersen, gemcitabine, carminomycin, leucovorin, pemetrexed, cyclophosphamide, dacarbazine, procarbazine, prednisolone, dexamethasone, campathecin, plicamycin, asparaginase, aminopterin, methopterin, porfiromycin, melphalan, leurosidine, leurosine, chlorambucil, trabectedin, procarbazine, discodermolide, carminomycin, aminopterin, and hexamethyl melamine, or a combination thereof. In certain embodiments, the additional pharmaceutical agent is a BTK inhibitor. In certain embodiments, the additional pharmaceutical agent is ibrutinib.

[00171] In certain embodiments, the additional pharmaceutical agent is a kinase inhibitor (*e.g.*, a JNK family kinase inhibitor). In certain embodiments, the additional pharmaceutical agent is a binder or inhibitor of a JNK (*e.g.*, JNK1, JNK2, or JNK3)). In certain embodiments, the additional pharmaceutical agent is a binder or inhibitor of a JNK. In certain embodiments, the additional pharmaceutical agent is a binder or inhibitor of JNK1. In certain embodiments, the additional pharmaceutical agent is a binder or inhibitor of JNK2. In certain embodiments, the additional pharmaceutical agent is a binder or inhibitor of JNK3. In certain embodiments, the additional pharmaceutical agent is selected from the group consisting of epigenetic or transcriptional modulators (*e.g.*, DNA methyltransferase inhibitors, histone deacetylase inhibitors (HDAC inhibitors), lysine methyltransferase inhibitors), antimetabolic drugs (*e.g.*, taxanes and vinca alkaloids), hormone receptor modulators (*e.g.*, estrogen receptor modulators and androgen receptor modulators), cell signaling pathway inhibitors (*e.g.*, transcription factor inhibitors), modulators of protein stability (*e.g.*, proteasome inhibitors), Hsp90 inhibitors, glucocorticoids, all-*trans* retinoic acids, and other agents that promote differentiation. In certain embodiments, the compounds described herein or pharmaceutical compositions can be administered in combination with an anti-cancer therapy including, but not limited to, surgery, radiation therapy, transplantation (*e.g.*, stem cell transplantation, bone marrow transplantation), immunotherapy, and chemotherapy. In some

embodiments, the additional pharmaceutical agent is a BTK inhibitor (*e.g.*, Ibrutinib), a topoisomerase inhibitor, a MCL1 inhibitor, a BCL-2 inhibitor, a BCL-xL inhibitor, a BRD4 inhibitor, a BRCA1 inhibitor, BRCA2 inhibitor, HER1 inhibitor, HER2 inhibitor, a CDK9 inhibitor, a Jumonji histone demethylase inhibitor, or a DNA damage inducer. In some embodiments, the additional pharmaceutical agent is etoposide, obatoclox, navitoclax, JQ1, 4-(((5'-chloro-2'-(((1*R*,4*R*)-4-(((*R*)-1-methoxypropan-2-yl)amino)cyclohexyl)amino)-[2,4'-bipyridin]-6-yl)amino)methyl)tetrahydro-2H-pyran-4-carbonitrile, JIB04, or cisplatin. Exemplary chemotherapeutic agents include alkylating agents such as nitrogen mustards, ethylenimines, methylmelamines, alkyl sulfonates, nitrosoureas, and triazenes; antimetabolites such as folic acid analogs, pyrimidine analogs, in particular fluorouracil and cytosine arabinoside, and purine analogs; natural products such as vinca alkaloids epipodophyllotoxins, antibiotics, enzymes, and biological response modifiers; and miscellaneous products such as platinum coordination complexes, anthracenedione, substituted urea such as hydroxyurea, methyl hydrazine derivatives, and adrenocorticoid suppressant. Exemplary chemotherapeutic agents also include anthracycline antibiotics, actinomycin D, plicamycin, puromycin, gramicidin D, paclitaxel, colchicine, cytochalasin B, emetine, maytansine, amsacrine, cisplatin, carboplatin, mitomycin, altretamine, cyclophosphamide, lomustine, and carmustine. In certain embodiments, a pharmaceutical composition described herein further comprises a combination of the additional pharmaceutical agents described herein.

[00172] The inventive compounds or compositions may synergistically augment inhibition of JNK induced by the additional pharmaceutical agent(s) in the biological sample or subject. Thus, the combination of the inventive compounds or compositions and the additional pharmaceutical agent(s) may be useful in treating proliferative diseases resistant to a treatment using the additional pharmaceutical agent(s) without the inventive compounds or compositions.

[00173] In certain embodiments, a kit described herein includes a first container comprising a compound or pharmaceutical composition described herein. In certain embodiments, a kit described herein is useful in treating and/or preventing a disease, such as a proliferative diseases (*e.g.*, cancer and benign neoplasms), inflammatory diseases (*e.g.*, rheumatoid arthritis), autoimmune diseases, and cardiovascular diseases (*e.g.*, atherosclerosis)) in a subject. In certain embodiments, a kit described herein is useful in inhibiting the activity of a kinase (*e.g.*, a JNK (*e.g.*, JNK2)) in a subject, biological sample, tissue, or cell.

[00174] In certain embodiments, a kit described herein further includes instructions for using the compound or pharmaceutical composition included in the kit. A kit described herein may


also include information as required by a regulatory agency such as the U.S. Food and Drug Administration (FDA). In certain embodiments, the information included in the kits is prescribing information. In certain embodiments, the kits and instructions provide for treating a disease, (e.g., proliferative diseases (e.g., cancer and benign neoplasms), inflammatory diseases (e.g., rheumatoid arthritis), autoimmune diseases, and cardiovascular diseases (e.g., atherosclerosis)), preventing a disease (e.g., proliferative diseases (e.g., cancer and benign neoplasms), inflammatory diseases (e.g., rheumatoid arthritis), autoimmune diseases, and cardiovascular diseases (e.g., atherosclerosis)), inhibiting the activity of a kinase (e.g., JNK (e.g., JNK2)) in a subject, biological sample, tissue, or cell. A kit described herein may include one or more additional pharmaceutical agents described herein as a separate composition.

EXAMPLES

[00175] In order that the present disclosure may be more fully understood, the following examples are set forth. The synthetic and biological examples described in this application are offered to illustrate the compounds, pharmaceutical compositions, and methods provided herein and are not to be construed in any way as limiting their scope.

Example 1. Preparation of the compounds of the present disclosure.

Synthesis of I-1 and I-4



2-Chloro-4-(phenylethynyl)pyrimidine

[00176] To a solution of 2,4-dichloropyrimidine (600 mg, 4 mmol) and ethynylbenzene (500 mg, 4.8 mmol) in DMF (10 mL) were added Pd(dppf)Cl₂ (14 mg, 0.02 mmol), CuI (7.6 mg, 0.04 mmol) and Et₃N (5.5 mL, 40 mmol) under N₂ atmosphere. The reaction mixture was stirred at 30 °C overnight. After cooling to room temperature, the reaction mixture was diluted with water (50 mL), extracted with ethyl acetate, dried over Na₂SO₄ and concentrated *in vacuo*. The residue was purified by column chromatography on silica gel (EA/hexane = 1/4) to give the title compound (640 mg, 74%). LC/MS (ESI) *m/z* = 215 (M+H)⁺.

[00177] To a solution of 2-chloro-4-(phenylethynyl)pyrimidine (640 mg, 3 mmol) and 1-aminopyridinium iodide (800 mg, 3.6 mmol) in MeCN (10 mL) was added DBU (544 mg, 3.6 mmol) at 0 °C. The reaction mixture was stirred at 50 °C overnight. After cooling to room temperature, the reaction mixture was diluted with water (200 mL), the precipitated solid was filtered to give the title compound (700 mg, 76%). LC/MS (ESI) *m/z* = 307 (M+H)⁺.

tert-butyl (S)-3-((4-(2-phenylpyrazolo[1,5-a]pyridin-3-yl)pyrimidin-2-yl)amino)piperidine-1-carboxylate

[00178] To a solution of 3-(2-chloropyrimidin-4-yl)-2-phenylpyrazolo[1,5-a]pyridine (200 mg, 0.65 mmol) and tert-butyl (S)-3-aminopiperidine-1-carboxylate (195 mg, 1.5 mmol) in NMP (3 mL) was added DIEA (0.32 mL, 1.95 mmol). The reaction mixture was stirred at 140 °C overnight. The mixture was diluted with water (200 mL), extracted with ethyl acetate, washed with brine, dried over Na₂SO₄, and concentrated *in vacuo*. The residue was then used in the next step without any purification. LC/MS (ESI) *m/z* = 471 (M+H)⁺.

(S)-4-(2-phenylpyrazolo[1,5-a]pyridin-3-yl)-N-(piperidin-3-yl)pyrimidin-2-amine

[00179] To a solution of tert-butyl (S)-3-((4-(2-phenylpyrazolo[1,5-a]pyridin-3-yl)pyrimidin-2-yl)amino)piperidine-1-carboxylate (crude from last step) in dioxane (2 mL) was added 2 mL of HCl (4 N in dioxane). The reaction mixture was stirred at room temperature overnight, and then concentrated *in vacuo*. The residue was redissolved in MeOH, and then neutralized with 1 N NaHCO₃ aq to pH=9. The resulting mixture was extracted with isopropanol/chloroform (*v/v* = 1/3). The combined organic layer was washed with brine, dried over Na₂SO₄ and concentrated *in vacuo*. The residue was purified by column chromatography on silica gel (1.75 N NH₃ in methanol/DCM = 1/5) to give the title compound (93 mg, 38% for 2 steps). LC/MS (ESI) *m/z* = 371 (M+H)⁺.

(S)-(4-nitrophenyl)(3-((4-(2-phenylpyrazolo[1,5-a]pyridin-3-yl)pyrimidin-2-yl)amino)piperidin-1-yl)methanone

[00180] To a solution of (S)-4-(2-phenylpyrazolo[1,5-a]pyridin-3-yl)-N-(piperidin-3-yl)pyrimidin-2-amine (93 mg, 0.25 mmol) in pyridine (3 mL) was added 4-nitrobenzoyl chloride (70 mg, 0.38 mmol). The reaction mixture was stirred at room temperature overnight, and then concentrated in vacuo. The residue was redissolved in water (200 mL), and then extracted with isopropanol/chloroform (v/v = 1/3). The combined organic layer was concentrated in *vacuo* to give crude product, which was used to next step without any purification. LC/MS (ESI) m/z = 520 (M+H)⁺.


(S)-(4-aminophenyl)(3-((4-(2-phenylpyrazolo[1,5-a]pyridin-3-yl)pyrimidin-2-yl)amino)piperidin-1-yl)methanone (I-4)

[00181] To a solution of (S)-(4-nitrophenyl)(3-((4-(2-phenylpyrazolo[1,5-a]pyridin-3-yl)pyrimidin-2-yl)amino)piperidin-1-yl)methanone (crude from last step) in 5 mL of ethyl acetate/methanol (v/v = 1/1) was added SnCl₂ (380 mg, 8 mmol). The reaction mixture was stirred at 80 °C for 2 h. After cooling to room temperature, the reaction mixture was diluted with Na₂CO₃ (sat. aq.). The resulting mixture was extracted with isopropanol/chloroform (v/v = 1/3). The combined organic layer was concentrated in vacuo, and then purified by prep-HPLC (0.15% TFA in MeOH/H₂O, 0-100%) to give **I-4** (68 mg, 45% for 2 steps) as TFA salt. LC/MS (ESI) m/z = 490 (M+H)⁺.

(S,E)-4-(dimethylamino)-N-(4-(3-((4-(2-phenylpyrazolo[1,5-a]pyridin-3-yl)pyrimidin-2-yl)amino)piperidine-1-carbonyl)phenyl)but-2-enamide

[00182] To a solution of (S)-(4-aminophenyl)(3-((4-(2-phenylpyrazolo[1,5-a]pyridin-3-yl)pyrimidin-2-yl)amino)piperidin-1-yl)methanone (28 mg, 0.057 mmol) and DIEA (28 μL, 0.17 mmol) in anhydrous THF (1 mL) was added (*E*)-4-bromobut-2-enoyl chloride dropwise at 0 °C until the reaction finished. Then excess of dimethylamine (2 N in dioxane) was added. The mixture was stirred at room temperature for 1 h, and then concentrated in vacuo. The residue was purified by prep-HPLC (0.15% TFA in MeOH/H₂O, 0-100%) to give **I-1** (30 mg, 73%) as TFA salt. LC/MS (ESI) m/z = 601 (M+H)⁺.


Synthesis of I-5



(R,E)-4-(dimethylamino)-N-(4-(3-((4-(2-phenylpyrazolo[1,5-a]pyridin-3-yl)pyrimidin-2-yl)amino)piperidine-1-carbonyl)phenyl)but-2-enamide

[00183] I-5 (23 mg, 25%) is prepared by using the same procedure as for I-1. Tert-butyl (R)-3-aminopiperidine-1-carboxylate was used in the third step. LC/MS (ESI) $m/z = 601$ (M+H)⁺.


Synthesis of I-2



(S)-4-(dimethylamino)-N-(4-(3-((4-(2-phenylpyrazolo[1,5-a]pyridin-3-yl)pyrimidin-2-yl)amino)piperidine-1-carbonyl)phenyl)butanamide


[00184] I-2 (24.8 mg, 39%) is prepared by using the same procedure as for I-1. 4-Chlorobutanoyl chloride was used in the last step. LC/MS (ESI) $m/z = 603$ (M+H)⁺.

Synthesis of I-3




(S)-N-(4-(3-((4-(2-phenylpyrazolo[1,5-a]pyridin-3-yl)pyrimidin-2-yl)amino)piperidine-1-carbonyl)phenyl)acrylamide

[00185] I-3 (24.8 mg, 39%) is prepared by using the same procedure as for I-1. Acryloyl chloride was used in the last step. LC/MS (ESI) $m/z = 544$ (M+H)⁺.

Synthesis of I-6


(R)-4-(dimethylamino)-N-(4-(3-((4-(2-phenylpyrazolo[1,5-a]pyridin-3-yl)pyrimidin-2-yl)amino)piperidine-1-carbonyl)phenyl)butanamide

[00186] **I-6** (24.8 mg, 80%) is prepared by using the same procedure as for **I-5**. 4-Chlorobutanoyl chloride was used in the last step. LC/MS (ESI) $m/z = 603$ (M+H)⁺.

Synthesis of I-15


(E)-4-(4-(dimethylamino)but-2-enamido)-N-(3-((4-(2-phenylpyrazolo[1,5-a]pyridin-3-yl)pyrimidin-2-yl)amino)cyclohexyl)benzamide

[00187] **I-15** (34.4 mg, 95%) is prepared by using the same procedure as for **I-1**. Tert-butyl (3-aminocyclohexyl)carbamate was used in the third step. LC/MS (ESI) $m/z = 615$ (M+H)⁺.

Synthesis of I-7


(R,E)-4-(dimethylamino)-N-(4-(3-((4-(2-phenylpyrazolo[1,5-a]pyridin-3-yl)pyrimidin-2-yl)amino)pyrrolidine-1-carbonyl)phenyl)but-2-enamide

[00188] **I-7** (20.1 mg, 57%) is prepared by using the same procedure as for **I-1**. Tert-butyl (R)-3-aminopyrrolidine-1-carboxylate was used in the third step. LC/MS (ESI) $m/z = 587$ (M+H)⁺.

Synthesis of I-9


(R,E)-4-(dimethylamino)-N-(4-(3-((4-(2-phenylpyrazolo[1,5-a]pyridin-3-yl)pyrimidin-2-yl)amino)azepane-1-carbonyl)phenyl)but-2-enamide

[00189] I-9 (31.2 mg, 88%) is prepared by using the same procedure as for I-1. Tert-butyl (R)-3-aminoazepane-1-carboxylate was used in the third step. LC/MS (ESI) $m/z = 615$ (M+H)⁺.

Synthesis of I-10

(R)-4-(dimethylamino)-N-(4-(3-((4-(2-phenylpyrazolo[1,5-a]pyridin-3-yl)pyrimidin-2-yl)amino)azepane-1-carbonyl)phenyl)butanamide


[00190] I-10 (28.2 mg, 78%) is prepared by using the same procedure as for I-9. 4-Chlorobutanoyl chloride was used in the last step. LC/MS (ESI) $m/z = 617$ (M+H)⁺.

Synthesis of I-8

(R)-4-(dimethylamino)-N-(4-(3-((4-(2-phenylpyrazolo[1,5-a]pyridin-3-yl)pyrimidin-2-yl)amino)pyrrolidine-1-carbonyl)phenyl)butanamide

[00191] I-8 (6.8 mg, 30%) is prepared by using the same procedure as for I-7. 4-Chlorobutanoyl chloride was used in the last step. LC/MS (ESI) $m/z = 589$ (M+H)⁺.


Synthesis of I-11



(S,E)-4-(dimethylamino)-N-(4-(3-((4-(2-phenylpyrazolo[1,5-a]pyridin-3-yl)pyrimidin-2-yl)amino)pyrrolidine-1-carbonyl)phenyl)but-2-enamide

[00192] **I-11** (18 mg, 51%) is prepared by using the same procedure as for **I-1**. Tert-butyl (S)-3-aminopyrrolidine-1-carboxylate was used in the third step. LC/MS (ESI) $m/z = 587$ (M+H)⁺.


Synthesis of I-12



(S)-4-(dimethylamino)-N-(4-(3-((4-(2-phenylpyrazolo[1,5-a]pyridin-3-yl)pyrimidin-2-yl)amino)pyrrolidine-1-carbonyl)phenyl)butanamide

[00193] **I-12** (23.8 mg, 66%) is prepared by using the same procedure as for **I-11**. 4-Chlorobutanoyl chloride was used in the last step. LC/MS (ESI) $m/z = 589$ (M+H)⁺.


Synthesis of I-13



(S,E)-4-(dimethylamino)-N-(4-(3-((4-(2-phenylpyrazolo[1,5-a]pyridin-3-yl)pyrimidin-2-yl)amino)azepane-1-carbonyl)phenyl)but-2-enamide

[00194] **I-13** (26.6 mg, 75%) is prepared by using the same procedure as for **I-1**. Tert-butyl (S)-3-aminoazepane-1-carboxylate was used in the third step. LC/MS (ESI) $m/z = 615$ (M+H)⁺.


Synthesis of I-14



(S)-4-(dimethylamino)-N-(4-(3-((4-(2-phenylpyrazolo[1,5-a]pyridin-3-yl)pyrimidin-2-yl)amino)azepane-1-carbonyl)phenyl)butanamide

[00195] **I-14** (12.8 mg, 36%) is prepared by using the same procedure as for **I-13**. 4-Chlorobutanoyl chloride was used in the last step. LC/MS (ESI) $m/z = 617$ (M+H)⁺.


Synthesis of I-16



(S,E)-4-(dimethylamino)-N-(3-(3-((4-(2-phenylpyrazolo[1,5-a]pyridin-3-yl)pyrimidin-2-yl)amino)pyrrolidine-1-carbonyl)phenyl)but-2-enamide


[00196] **I-16** (2.6 mg, 62%) is prepared by using the same procedure as for **I-1**. 3-nitrobenzoyl chloride was used in the fifth step. LC/MS (ESI) $m/z = 587$ (M+H)⁺.

Synthesis of I-17




(E)-4-(dimethylamino)-N-(4-(6-((4-(2-phenylpyrazolo[1,5-a]pyridin-3-yl)pyrimidin-2-yl)amino)-2-azabicyclo[2.2.1]heptane-2-carbonyl)phenyl)but-2-enamide

[00197] **I-17** (7.6 mg, 44%) is prepared by using the same procedure as for **I-1**. Tert-butyl 6-amino-2-azabicyclo[2.2.1]heptane-2-carboxylate was used in the third step. LC/MS (ESI) $m/z = 613$ (M+H)⁺.

Synthesis of I-18


(S,E)-N-(4-(4-(dimethylamino)but-2-enamido)phenyl)-3-((4-(2-phenylpyrazolo[1,5-a]pyridin-3-yl)pyrimidin-2-yl)amino)pyrrolidine-1-carboxamide

[00198] I-18 (10 mg, 50%) is prepared by using the similar procedure as for **I-1**. 1-Isocyanato-4-nitrobenzene was used in the fifth step. LC/MS (ESI) $m/z = 602$ (M+H)⁺.

Synthesis of I-19


(E)-4-(dimethylamino)-N-(4-(((3S,4S)-3-methyl-4-((4-(2-phenylpyrazolo[1,5-a]pyridin-3-yl)pyrimidin-2-yl)amino)pyrrolidine-1-carbonyl)phenyl)but-2-enamide

[00199] I-19 (1.4 mg, 15%) is prepared by using the similar procedure as for **I-1**. Tert-butyl (3S,4S)-3-amino-4-methylpyrrolidine-1-carboxylate was used in the third step. LC/MS (ESI) $m/z = 601$ (M+H)⁺.

Synthesis of I-20


(S,E)-4-(dimethylamino)-N-(1-(3-((4-(2-phenylpyrazolo[1,5-a]pyridin-3-yl)pyrimidin-2-yl)amino)pyrrolidin-1-yl)isoquinolin-6-yl)but-2-enamide

[00200] I-20 (4.8 mg, 19 %) is prepared by using the similar procedure as for **I-1**. 1-chloro-6-nitroisoquinoline was used in the fifth step. LC/MS (ESI) $m/z = 610$ (M+H)⁺.

Synthesis of I-21


(S,E)-N-(4-(3-((5-chloro-4-(2-phenylpyrazolo[1,5-a]pyridin-3-yl)pyrimidin-2-yl)amino)pyrrolidine-1-carbonyl)phenyl)-4-(dimethylamino)but-2-enamide

[00201] I-21 (7.5 mg, 26 %) is prepared by using the similar procedure as for **I-1**. 2,4,5-Trichloropyrimidine was used in the first step. LC/MS (ESI) $m/z = 621$ (M+H)⁺.

Synthesis of I-22

(S,E)-4-(dimethylamino)-N-(4-(3-((4-(2-(4-fluorophenyl)pyrazolo[1,5-a]pyridin-3-yl)pyrimidin-2-yl)amino)pyrrolidine-1-carbonyl)phenyl)but-2-enamide


[00202] I-21 (5.1 mg, 21 %) is prepared by using the similar procedure as for **I-1**. 1-ethynyl-4-fluorobenzene was used in the first step. LC/MS (ESI) $m/z = 605$ (M+H)⁺.

Synthesis of I-23

(S,E)-4-(dimethylamino)-N-(4-(3-((4-(4-methyl-2-phenylpyrazolo[1,5-a]pyridin-3-yl)pyrimidin-2-yl)amino)pyrrolidine-1-carbonyl)phenyl)but-2-enamide

[00203] I-23 (27 mg, 53 %) is prepared by using the similar procedure as for **I-1**. 1-Amino-3-methylpyridinium iodide was used in the second step. LC/MS (ESI) $m/z = 601$ (M+H)⁺.


Synthesis of I-24



(S,E)-4-(dimethylamino)-N-(4-(3-((4-(6-methyl-2-phenylpyrazolo[1,5-a]pyridin-3-yl)pyrimidin-2-yl)amino)pyrrolidine-1-carbonyl)phenyl)but-2-enamide

[00204] I-24 (20 mg, 51 %) is prepared by using the similar procedure as for **I-23**. 3-(2-chloropyrimidin-4-yl)-6-methyl-2-phenylpyrazolo[1,5-a]pyridine was used in the third step. LC/MS (ESI) $m/z = 601$ (M+H)⁺.


Synthesis of I-25



(S,E)-N-(4-(3-((4-(2-(3-chlorophenyl)pyrazolo[1,5-a]pyridin-3-yl)pyrimidin-2-yl)amino)pyrrolidine-1-carbonyl)phenyl)-4-(dimethylamino)but-2-enamide


[00205] I-25 (12.3 mg, 39 %) is prepared by using the similar procedure as for **I-1**. 1-Chloro-3-ethynylbenzene was used in the first step. LC/MS (ESI) $m/z = 621$ (M+H)⁺.

Synthesis of I-26




(S,E)-N-(4-(3-((4-(2-(4-chlorophenyl)pyrazolo[1,5-a]pyridin-3-yl)pyrimidin-2-yl)amino)pyrrolidine-1-carbonyl)phenyl)-4-(dimethylamino)but-2-enamide

[00206] I-26 (21.1 mg, 29 %) is prepared by using the similar procedure as for **I-1**. 1-chloro-4-ethynylbenzene was used in the first step. LC/MS (ESI) $m/z = 621$ (M+H)⁺.

Synthesis of I-27


4-(dimethylamino)-N-(4-((3S,4S)-3-methyl-4-((4-(2-phenylpyrazolo[1,5-a]pyridin-3-yl)pyrimidin-2-yl)amino)pyrrolidine-1-carbonyl)phenyl)butanamide

[00207] **I-27** (4.8 mg, 40 %) is prepared by using the similar procedure as for **I-19**. 4-Chlorobutanoyl chloride was used in the last step. LC/MS (ESI) $m/z = 603$ (M+H)⁺.

Synthesis of I-28

(E)-4-(dimethylamino)-N-(4-((3R,4S)-3-methyl-4-((4-(2-phenylpyrazolo[1,5-a]pyridin-3-yl)pyrimidin-2-yl)amino)pyrrolidine-1-carbonyl)phenyl)but-2-enamide


[00208] **I-28** (10 mg, 50%) is prepared by using the similar procedure as for **I-1**. Tert-butyl (3S,4R)-3-amino-4-methylpyrrolidine-1-carboxylate was used in the third step. LC/MS (ESI) $m/z = 601$ (M+H)⁺.

Synthesis of I-29

(E)-4-(dimethylamino)-N-(4-((3R,4R)-3-methyl-4-((4-(2-phenylpyrazolo[1,5-a]pyridin-3-yl)pyrimidin-2-yl)amino)pyrrolidine-1-carbonyl)phenyl)but-2-enamide

[00209] **I-29** (10 mg, 57%) is prepared by using the similar procedure as for **I-1**. Tert-butyl (3R,4R)-3-amino-4-methylpyrrolidine-1-carboxylate was used in the third step. LC/MS (ESI) $m/z = 601$ (M+H)⁺.


Synthesis of I-30



(E)-4-(dimethylamino)-N-(4-((3S,4R)-3-methyl-4-((4-(2-phenylpyrazolo[1,5-a]pyridin-3-yl)pyrimidin-2-yl)amino)pyrrolidine-1-carbonyl)phenyl)but-2-enamide

[00210] I-30 is prepared by using the similar procedure as for I-1. Tert-butyl (3R,4S)-3-amino-4-methylpyrrolidine-1-carboxylate was used in the third step. LC/MS (ESI) $m/z = 601$ (M+H)⁺.


Synthesis of I-31



(E)-4-(dimethylamino)-N-(4-((3S,4S)-3-methyl-4-((4-(6-methyl-2-phenylpyrazolo[1,5-a]pyridin-3-yl)pyrimidin-2-yl)amino)pyrrolidine-1-carbonyl)phenyl)but-2-enamide

[00211] I-31 (3 mg, 26%) is prepared by using the similar procedure as for I-24. 3-(2-chloropyrimidin-4-yl)-6-methyl-2-phenylpyrazolo[1,5-a]pyridine was used in the third step. LC/MS (ESI) $m/z = 601$ (M+H)⁺.

Synthesis of I-32



(E)-4-(dimethylamino)-N-(4-((3S,4S)-3-((4-(4-methoxy-2-phenylpyrazolo[1,5-a]pyridin-3-yl)pyrimidin-2-yl)amino)-4-methylpyrrolidine-1-carbonyl)phenyl)but-2-enamide

[00212] I-32 (7.4 mg, 21%) is prepared by using the similar procedure as for I-1, except 1-amino-3-methoxypyridin-1-ium iodide was used in the second step. ¹H NMR (500 MHz, DMSO-*d*₆) δ 10.29 (s, 1H), 8.38 (dd, *J* = 9.4, 6.8 Hz, 1H), 8.25 (dd, *J* = 25.3, 5.0 Hz, 1H), 7.70 (d, *J* = 8.6 Hz, 2H), 7.47 (dd, *J* = 23.2, 8.3 Hz, 4H), 7.40 – 7.18 (m, 4H), 6.92 (q, *J* = 7.7 Hz, 1H), 6.74 (ddd, *J* = 21.8, 15.6, 6.7 Hz, 3H), 6.42 – 6.22 (m, 1H), 3.86 – 3.56 (m, 5H), 3.22 – 3.01 (m, 4H), 2.26 (s, 7H), 1.25 (s, 3H). LC/MS (ESI) $m/z = 631$ (M+H)⁺.

Example 2. Pulldown assay comparing JNK-IN-8 inhibition with I-11.

[00213] Multiple myeloma cells MM1.S (Figure 1) or triple negative breast cancer cells MDA-MB-231 (Figure 2) were treated with I-11 or other testing compounds at indicated doses for 6 h. Whole cell lysates were prepared and 0.5 mg lysate was subject to pulldown of JNK1/2 using Biotinylated JNK-IN-7 (Biotin-JNK-IN-7) at 1 μ M for 16 h at 4 °C. Proteins that were pulled down by the Biotin-JNK-IN-7 was enriched with streptavidin agarose beads by rotation for 2 h at 4 °C. Then 25 μ l 2 \times SDS-PAGE loading buffer was added to each sample, and enriched proteins were released from the beads by heating at 95 °C for 10 min. Western blotting was used subsequently to obtain semi-quantitative estimation of the binding of testing compounds

EQUIVALENTS AND SCOPE

[00214] In the claims articles such as “a,” “an,” and “the” may mean one or more than one unless indicated to the contrary or otherwise evident from the context. Claims or descriptions that include “or” between one or more members of a group are considered satisfied if one, more than one, or all of the group members are present in, employed in, or otherwise relevant to a given product or process unless indicated to the contrary or otherwise evident from the context. The disclosure includes embodiments in which exactly one member of the group is present in, employed in, or otherwise relevant to a given product or process. The disclosure includes embodiments in which more than one, or all of the group members are present in, employed in, or otherwise relevant to a given product or process.

[00215] Furthermore, the disclosure encompasses all variations, combinations, and permutations in which one or more limitations, elements, clauses, and descriptive terms from one or more of the listed claims is introduced into another claim. For example, any claim that is dependent on another claim can be modified to include one or more limitations found in any other claim that is dependent on the same base claim. Where elements are presented as lists, *e.g.*, in Markush group format, each subgroup of the elements is also disclosed, and any element(s) can be removed from the group. It should be understood that, in general, where the disclosure, or aspects described herein, is/are referred to as comprising particular elements and/or features, certain embodiments described herein or aspects described herein consist, or consist essentially of, such elements and/or features. For purposes of simplicity, those embodiments have not been specifically set forth *in haec verba* herein. It is also noted that the terms “comprising” and “containing” are intended to be open and permits the

inclusion of additional elements or steps. Where ranges are given, endpoints are included. Furthermore, unless otherwise indicated or otherwise evident from the context and understanding of one of ordinary skill in the art, values that are expressed as ranges can assume any specific value or sub-range within the stated ranges in different embodiments described herein, to the tenth of the unit of the lower limit of the range, unless the context clearly dictates otherwise.


[00216] This application refers to various issued patents, published patent applications, journal articles, and other publications, all of which are incorporated herein by reference. If there is a conflict between any of the incorporated references and the instant specification, the specification shall control. In addition, any particular embodiment of the present disclosure that falls within the prior art may be explicitly excluded from any one or more of the claims. Because such embodiments are deemed to be known to one of ordinary skill in the art, they may be excluded even if the exclusion is not set forth explicitly herein. Any particular embodiment described herein can be excluded from any claim, for any reason, whether or not related to the existence of prior art.

[00217] Those skilled in the art will recognize or be able to ascertain using no more than routine experimentation many equivalents to the specific embodiments described herein. The scope of the present embodiments described herein is not intended to be limited to the above Description, but rather is as set forth in the appended claims. Those of ordinary skill in the art will appreciate that various changes and modifications to this description may be made without departing from the spirit or scope of the present disclosure, as defined in the following claims.

CLAIMS

What is claimed is:

1. A compound of Formula (I):



(I),

or a pharmaceutically acceptable salt, solvate, hydrate, tautomer, or stereoisomer thereof,

wherein:

R¹ is optionally substituted aryl or optionally substituted heteroaryl;

R², R³, R⁴, and R⁵ are each independently hydrogen, halogen, optionally substituted acyl, optionally substituted alkyl, optionally substituted alkenyl, optionally substituted alkynyl, optionally substituted carbocyclyl, optionally substituted heterocyclyl, optionally substituted aryl, optionally substituted heteroaryl, -NO₂, -CN, -SCN, -OR^{D1}, -N(R^{D1})₂, or -SR^{D1}, wherein R^{D1} is independently hydrogen, optionally substituted acyl, optionally substituted alkyl, optionally substituted alkenyl, optionally substituted alkynyl, optionally substituted carbocyclyl, optionally substituted heterocyclyl, optionally substituted aryl, optionally substituted heteroaryl, an oxygen protecting group when attached to an oxygen atom, a nitrogen protecting group when attached to a nitrogen atom, or a sulfur protecting group when attached to a sulfur atom;

n is 1, 2, or 3;

m is 1, 2, 3, or 4;

L¹ is O, S, or -N(R^a)-, wherein R^a is hydrogen, optionally substituted acyl, optionally substituted C₁₋₆ alkyl, or a nitrogen protecting group;

L² is O, S, -N(R^{L2a})-, -C=O-, -N(R^{L2a})C(=O)-, or -C(=O)N(R^{L2a})-, wherein R^{L2a} is hydrogen, optionally substituted acyl, optionally substituted C₁₋₆ alkyl, or a nitrogen protecting group;

V¹ is C(R^{1a})H;

V² is C(R^{1b})H;


V³ is N or C(R^{1c});


R^{1a} and R^{1b} are independently hydrogen, halogen, optionally substituted acyl, optionally substituted alkyl, optionally substituted alkenyl, optionally substituted alkynyl, optionally substituted carbocyclyl, optionally substituted heterocyclyl, optionally substituted aryl, optionally substituted heteroaryl, $-\text{CN}$, $-\text{OR}^{\text{C}1}$, $-\text{N}(\text{R}^{\text{C}1})_2$, or $-\text{SR}^{\text{C}1}$, wherein $\text{R}^{\text{C}1}$ is independently hydrogen, optionally substituted acyl, optionally substituted alkyl, optionally substituted alkenyl, optionally substituted alkynyl, optionally substituted carbocyclyl, optionally substituted heterocyclyl, optionally substituted aryl, optionally substituted heteroaryl, a nitrogen protecting group when attached to a nitrogen atom, an oxygen protecting group when attached to an oxygen atom, or a sulfur protecting group when attached to a sulfur atom, or R^{1a} and R^{1b} are joined together to form an optionally substituted bridged ring;

R^{1c} is hydrogen, or substituted or unsubstituted C_{1-6} alkyl;


p is 1, 2, or 3;

D^1 is a warhead of any one of Formulae (i-1) to (i-42):







(i-16)




(i-17)




(i-18)




(i-19)




(i-20)




(i-21)




(i-22)




(i-23)




(i-24)




(i-25)




(i-26)




(i-27)




(i-28)




(i-29)




(i-30)




(i-31)




(i-32)




(i-33)








(i-34)




(i-35)



(i-36)



or



wherein:

L^3 is a bond or an optionally substituted C_{1-4} hydrocarbon chain, optionally wherein one or more carbon units of the hydrocarbon chain are independently replaced with $-O-$, $-S-$, $-NR^{L3a}-$, $-NR^{L3a}C(=O)-$, $-C(=O)NR^{L3a}-$, $-SC(=O)-$, $-C(=O)S-$, $-OC(=O)-$, $-C(=O)O-$, $-NR^{L3a}C(=S)-$, $-C(=S)NR^{L3a}-$, *trans*- $CR^{L3b}=CR^{L3b}-$, *cis*- $CR^{L3b}=CR^{L3b}-$, $-C\equiv C-$, $-S(=O)-$, $-S(=O)O-$, $-OS(=O)-$, $-S(=O)NR^{L3a}-$, $-NR^{L3a}S(=O)-$, $-S(=O)_2-$, $-S(=O)_2O-$, $-OS(=O)_2-$, $-S(=O)_2NR^{L3a}-$, or $-NR^{L3a}S(=O)_2-$, wherein R^{L3a} is hydrogen, substituted or unsubstituted C_{1-6} alkyl, or a nitrogen protecting group, and wherein each occurrence of R^{L3b} is independently selected from the group consisting of hydrogen, halogen, optionally substituted alkyl, optionally substituted alkenyl, optionally substituted alkynyl, optionally substituted carbocyclyl, optionally substituted heterocyclyl, optionally substituted aryl, and optionally substituted heteroaryl, or two R^{L3b} groups are joined to form an optionally substituted carbocyclic or optionally substituted heterocyclic ring;

L^4 is a bond or an optionally substituted C_{1-4} hydrocarbon chain;

R^{E1} is selected from the group consisting of hydrogen, halogen, optionally substituted alkyl, optionally substituted alkenyl, optionally substituted alkynyl, optionally substituted carbocyclyl, optionally substituted heterocyclyl, optionally substituted aryl, optionally substituted heteroaryl, $-CN$, $-CH_2OR^{E1a}$, $-CH_2N(R^{E1a})_2$, $-CH_2SR^{E1a}$, $-OR^{E1a}$, $-N(R^{E1a})_2$, $-Si(R^{E1a})_3$, and $-SR^{E1a}$, wherein each occurrence of R^{E1a} is independently selected from the group consisting of hydrogen, optionally substituted alkyl, optionally substituted alkenyl, optionally substituted alkynyl, optionally substituted carbocyclyl, optionally substituted heterocyclyl, optionally substituted aryl, and optionally substituted heteroaryl, or two R^{E1a} groups are joined to form an optionally substituted heterocyclic ring;

R^{E2} is selected from the group consisting of hydrogen, halogen, optionally substituted alkyl, optionally substituted alkenyl, optionally substituted alkynyl, optionally substituted

carbocyclyl, optionally substituted heterocyclyl, optionally substituted aryl, optionally substituted heteroaryl, $-\text{CN}$, $-\text{CH}_2\text{OR}^{\text{E}2\text{a}}$, $-\text{CH}_2\text{N}(\text{R}^{\text{E}2\text{a}})_2$, $-\text{CH}_2\text{SR}^{\text{E}2\text{a}}$, $-\text{OR}^{\text{E}2\text{a}}$, $-\text{N}(\text{R}^{\text{E}2\text{a}})_2$, and $-\text{SR}^{\text{E}2\text{a}}$, wherein each occurrence of $\text{R}^{\text{E}2\text{a}}$ is independently selected from the group consisting of hydrogen, optionally substituted alkyl, optionally substituted alkenyl, optionally substituted alkynyl, optionally substituted carbocyclyl, optionally substituted heterocyclyl, optionally substituted aryl, and optionally substituted heteroaryl, or two $\text{R}^{\text{E}2\text{a}}$ groups are joined to form an optionally substituted heterocyclic ring;

$\text{R}^{\text{E}3}$ is selected from the group consisting of hydrogen, halogen, optionally substituted alkyl, optionally substituted alkenyl, optionally substituted alkynyl, optionally substituted carbocyclyl, optionally substituted heterocyclyl, optionally substituted aryl, optionally substituted heteroaryl, $-\text{CN}$, $-\text{CH}_2\text{OR}^{\text{E}3\text{a}}$, $-\text{CH}_2\text{N}(\text{R}^{\text{E}3\text{a}})_2$, $-\text{CH}_2\text{SR}^{\text{E}3\text{a}}$, $-\text{OR}^{\text{E}3\text{a}}$, $-\text{N}(\text{R}^{\text{E}3\text{a}})_2$, and $-\text{SR}^{\text{E}3\text{a}}$, wherein each occurrence of $\text{R}^{\text{E}3\text{a}}$ is independently selected from the group consisting of hydrogen, optionally substituted alkyl, optionally substituted alkoxy, optionally substituted alkenyl, optionally substituted alkynyl, optionally substituted carbocyclyl, optionally substituted heterocyclyl, optionally substituted aryl, and optionally substituted heteroaryl, or two $\text{R}^{\text{E}3\text{a}}$ groups are joined to form an optionally substituted heterocyclic ring;

or $\text{R}^{\text{E}1}$ and $\text{R}^{\text{E}3}$, or $\text{R}^{\text{E}2}$ and $\text{R}^{\text{E}3}$, or $\text{R}^{\text{E}1}$ and $\text{R}^{\text{E}2}$ are joined to form an optionally substituted carbocyclic or optionally substituted heterocyclic ring;

$\text{R}^{\text{E}4}$ is a leaving group;

$\text{R}^{\text{E}5}$ is halogen;

Y is O, S, or $\text{NR}^{\text{E}6}$, wherein $\text{R}^{\text{E}6}$ is hydrogen, substituted or unsubstituted C_{1-6} alkyl, or a nitrogen protecting group;

a is 1 or 2; and



each instance of z is independently 0, 1, 2, 3, 4, 5, or 6.

2. The compound of claim 1, or a pharmaceutically acceptable salt, solvate, hydrate, tautomer, or stereoisomer thereof, wherein L^1 is $-\text{N}(\text{Ra})-$.

3. The compound of claim 1, or a pharmaceutically acceptable salt, solvate, hydrate, tautomer, or stereoisomer thereof, wherein L^1 is $-\text{NH}-$.

4. The compound of claim 1, 2, or 3, or a pharmaceutically acceptable salt, solvate, hydrate, tautomer, or stereoisomer thereof, wherein V^3 is $-\text{N}-$.

5. The compound of claim 4 of Formula (II):





or a pharmaceutically acceptable salt, solvate, hydrate, tautomer, or stereoisomer thereof, wherein p is 1, 2, or 3.

6. The compound of any one of claims 1-5, or a pharmaceutically acceptable salt, solvate, hydrate, tautomer, or stereoisomer thereof, wherein p = 1.

7. The compound of any one of claims 1-5, or a pharmaceutically acceptable salt, solvate, hydrate, tautomer, or stereoisomer thereof, wherein p = 2.

8. The compound of any one of claims 1-5, or a pharmaceutically acceptable salt, solvate, hydrate, tautomer, or stereoisomer thereof, wherein p = 3.



9. The compound of claim 4, of Formula (III):



or a pharmaceutically acceptable salt, solvate, hydrate, tautomer, or stereoisomer thereof.

10. The compound of any one of claims 1-9, or a pharmaceutically acceptable salt, solvate, hydrate, tautomer, or stereoisomer thereof, wherein L^2 is $-(C=O)-$.
11. The compound of any one of claims 1-9, or a pharmaceutically acceptable salt, solvate, hydrate, tautomer, or stereoisomer thereof, wherein L^2 is $-(C=O)N(R^{L2a})-$.
12. The compound of claim 3, or a pharmaceutically acceptable salt, solvate, hydrate, tautomer, or stereoisomer thereof, wherein V^3 is $C(R^{1c})$.
13. The compound of claim 12, or a pharmaceutically acceptable salt, solvate, hydrate, tautomer, or stereoisomer thereof, wherein R^{1c} is H.
14. The compound of claim 13, or a pharmaceutically acceptable salt, solvate, hydrate, tautomer, or stereoisomer thereof, wherein V^1 is $C(R^{1a})(H)$.
15. The compound of claim 14, or a pharmaceutically acceptable salt, solvate, hydrate, tautomer, or stereoisomer thereof, wherein R^{1a} is H.
16. The compound of claims 12-15, or a pharmaceutically acceptable salt, solvate, hydrate, tautomer, or stereoisomer thereof, wherein V^2 is $-C(R^{1b})(H)-$.
17. The compound of claim 16, or a pharmaceutically acceptable salt, solvate, hydrate, tautomer, or stereoisomer thereof, wherein R^{1b} is H.
18. The compound of any one of claims 12-17, or a pharmaceutically acceptable salt, solvate, hydrate, tautomer, or stereoisomer thereof, wherein L^2 is $N(R^{L2a})$.
19. The compound of claim 18, or a pharmaceutically acceptable salt, solvate, hydrate, tautomer, or stereoisomer thereof, wherein L^2 is $-NH-$.

20. The compound of claim 19 of Formula (IV):



or a pharmaceutically acceptable salt, solvate, hydrate, tautomer, or stereoisomer thereof.

21. The compound of any one of claims 1-20, or a pharmaceutically acceptable salt, solvate, hydrate, tautomer, or stereoisomer thereof, wherein R² is aryl.

22. The compound of claim 1-21, or a pharmaceutically acceptable salt, solvate, hydrate, tautomer, or stereoisomer thereof, wherein R² is phenyl.


23. The compound of claim 1-22, or a pharmaceutically acceptable salt, solvate, hydrate, tautomer, or stereoisomer thereof, wherein R² is unsubstituted phenyl.

24. The compound of any one of claims 1-23, or a pharmaceutically acceptable salt, solvate, hydrate, tautomer, or stereoisomer thereof, wherein R¹ is H.


25. The compound of any one of claims 1-24, or a pharmaceutically acceptable salt, solvate, hydrate, tautomer, or stereoisomer thereof, wherein R³ is H.


26. The compound of any one of claims 1-25, or a pharmaceutically acceptable salt, solvate, hydrate, tautomer, or stereoisomer thereof, wherein R⁴ is H.


27. The compound of any one of claims 1-26, wherein D¹ is selected from:



28. The compound of any one of claims 1-27, or a pharmaceutically acceptable salt, solvate, hydrate, tautomer, or stereoisomer thereof, wherein the compound is of the formula:







29. A pharmaceutical composition comprising a compound of any one of claims 1-28, or a pharmaceutically acceptable salt, solvate, hydrate, tautomer, or stereoisomer thereof, and optionally a pharmaceutically acceptable excipient.

30. A method of treating a disease in a subject in need thereof, the method comprising administering to the subject a therapeutically effective amount of a compound of any one of claims 1-28, or a pharmaceutically acceptable salt, solvate, hydrate, tautomer, or stereoisomer thereof, or a pharmaceutical composition of claim 29.

31. A method of treating a proliferative disease comprising administering to a subject in need thereof an effective amount of a compound of any one of claims 1-28, or a pharmaceutically acceptable salt thereof, or a pharmaceutical composition of claim 29.

32. A method of treating an inflammatory disease comprising administering to a subject in need thereof an effective amount of a compound of any one of claims 1-28, or a pharmaceutically acceptable salt thereof, or a pharmaceutical composition of claim 29.

33. A method of treating an autoimmune disease comprising administering to a subject in need thereof an effective amount of a compound of any one of claims 1-28, or a pharmaceutically acceptable salt thereof, or a pharmaceutical composition of claim 29.

34. A method of treating a cardiovascular disease comprising administering to a subject in need thereof an effective amount of a compound of any one of claims 1-28, or a pharmaceutically acceptable salt thereof, or a pharmaceutical composition of claim 29.
35. The method of any one of claims 30-34, wherein an effective amount is a therapeutically effective amount.
36. The method of any one of claims 30-34, wherein an effective amount is a prophylactically effective amount.
37. The method of any one of claims 30-34, wherein the compound is a JNK inhibitor.
38. The method of claim 37, wherein the compounds is a selective JNK inhibitor.
39. The method of claim 38, wherein the compound selectively inhibits JNK1, JNK2, and/or JNK3.
40. The method of claim 39, wherein the compound selectively inhibits JNK2.
41. The method of claim 40, wherein the compound selectively inhibits JNK2 over JNK1.
42. The method of claim 38, wherein the compound selectively inhibits JNK2 over JNK3.
43. The method of claim 31, wherein the proliferative disease is cancer.
44. The method of claim 43, wherein the cancer is lung cancer.
45. The method of claim 43, wherein the cancer is carcinoma.
46. The method of claim 43, wherein the cancer is glioblastoma.
47. The method of claim 43, wherein the cancer is skin cancer.
48. The method of claim 43, wherein the cancer is prostate cancer.

49. The method of claim 43, wherein the cancer is squamous cell carcinoma.
50. The method of claim 43, wherein the cancer is leukemia.
51. A method of treating a JNK-mediated condition, the method comprising administering to a subject in need thereof an effective amount of a compound of claim 1-28, or a pharmaceutically acceptable salt, solvate, hydrate, tautomer, or stereoisomer thereof, or a pharmaceutical composition of claim 29.
52. A method of inhibiting the activity of a c-Jun N-Terminal Kinase (JNK) in a biological sample, the method comprising administering to the subject or contacting the biological sample with a therapeutically effective amount of a compound of any one of claims 1-28, or a pharmaceutically acceptable salt, solvate, hydrate, tautomer, or stereoisomer thereof, or a pharmaceutical composition of claim 29.
53. A method of inhibiting the activity of a c-Jun N-Terminal Kinase (JNK) in a subject, the method comprising administering to the subject or contacting the biological sample with a therapeutically effective amount of a compound of any one of claims 1-28, or a pharmaceutically acceptable salt, solvate, hydrate, tautomer, or stereoisomer thereof, or a pharmaceutical composition of claim 29.
54. A compound of Formula (I), or a pharmaceutically acceptable salt, solvate, hydrate, tautomer, or stereoisomer thereof, for use in the treatment of a disease in a subject in need thereof.
55. A compound of Formula (I), or a pharmaceutically acceptable salt, solvate, hydrate, tautomer, or stereoisomer thereof, for use in the manufacture of a medicament for the treatment of a disease in a subject in need thereof.
56. The use of claim 54 or 55, wherein the disease is a proliferative disease, inflammatory disease, autoimmune disease, or cardiovascular disease.

57. A Compound of Formula (I), or a pharmaceutically acceptable salt, solvate, hydrate, tautomer, or stereoisomer thereof, for use in selectively inhibiting the activity of a kinase in a subject, biological sample, tissue, or cell.

58. The use of claim 57, wherein the kinase selectively inhibits JNK2.

59. A kit comprising: a compound of any one of claims 1-28, or a pharmaceutically acceptable salt, solvate, hydrate, tautomer, or stereoisomer thereof, or a pharmaceutical composition of claim 29; and

instructions for administering to a subject or contacting a biological sample with the compound, or the pharmaceutically acceptable salt, solvate, hydrate, tautomer, or stereoisomer thereof, or the pharmaceutical composition.




Figure 1

Competition pulldown — 6h live cell treatment followed by pulldown with Biotinylated JNK-IN-8




Figure 2

INTERNATIONAL SEARCH REPORT

International application No.

PCT/US19/66201

A. CLASSIFICATION OF SUBJECT MATTER

IPC - A61K 31/505, 31/506; C07D 403/02 (2020.01)

CPC - A61K 31/505, 31/506; C07D 403/02

According to International Patent Classification (IPC) or to both national classification and IPC

B. FIELDS SEARCHED

Minimum documentation searched (classification system followed by classification symbols)

See Search History document

Documentation searched other than minimum documentation to the extent that such documents are included in the fields searched

See Search History document

Electronic data base consulted during the international search (name of data base and, where practicable, search terms used)

See Search History document

C. DOCUMENTS CONSIDERED TO BE RELEVANT

Category*	Citation of document, with indication, where appropriate, of the relevant passages	Relevant to claim No.
Y	US 2016/0264551A1 (SYROS PHARMACEUTICALS, INC) 15 September 2016; abstract; paragraphs [0004], [0064], [0127], [0132], [0150], [0152], [0162], [0179]-[0180], [0215]	1-3, 4/1-3, 5/4/1-3, 9/4/1-3, 54-55, 56/54-55, 57-58
Y	US 2011/0039873 A1 (GAETA, FCA et al) 17 February 2011; abstract; figure 1D; paragraph [0174]	1-3, 4/1-3, 5/4/1-3, 9/4/1-3, 12-15, 16/12-15, 17/16/12-15, 54-55, 56/54-55, 57-58
Y	US 2016/0264554 A1 (DANA-FARBER CANCER INSTITUTE, INC) 15 September 2016; abstract; figure 1; paragraphs [0391]-[0392]	1, 3, 12-15, 16/12-15, 17/16/12-15
Y	US 2017/0204096 A1 (JANSSEN PHARMACEUTICA NV) 20 July 2017; paragraphs [0140], [0452]-[0453]; claim 45	9/4/1-3
A	WO 2012/066061 A1 (F. HOFFMANN-LA ROCHE AG) 24 May 2012; entire publication	1

Further documents are listed in the continuation of Box C.

See patent family annex.

* Special categories of cited documents:	"T" later document published after the international filing date or priority date and not in conflict with the application but cited to understand the principle or theory underlying the invention
"A" document defining the general state of the art which is not considered to be of particular relevance	"X" document of particular relevance; the claimed invention cannot be considered novel or cannot be considered to involve an inventive step when the document is taken alone
"D" document cited by the applicant in the international application	"Y" document of particular relevance; the claimed invention cannot be considered to involve an inventive step when the document is combined with one or more other such documents, such combination being obvious to a person skilled in the art
"E" earlier application or patent but published on or after the international filing date	"&" document member of the same patent family
"L" document which may throw doubts on priority claim(s) or which is cited to establish the publication date of another citation or other special reason (as specified)	
"O" document referring to an oral disclosure, use, exhibition or other means	
"P" document published prior to the international filing date but later than the priority date claimed	

Date of the actual completion of the international search

23 January 2020 (23.01.2020)

Date of mailing of the international search report

07 FEB 2020

Name and mailing address of the ISA/US

Mail Stop PCT, Attn: ISA/US, Commissioner for Patents
P.O. Box 1450, Alexandria, Virginia 22313-1450
Facsimile No. 571-273-8300

Authorized officer

Shane Thomas

Telephone No. PCT Helpdesk: 571-272-4300

INTERNATIONAL SEARCH REPORT

International application No.

PCT/US19/66201

Box No. II Observations where certain claims were found unsearchable (Continuation of item 2 of first sheet)

This international search report has not been established in respect of certain claims under Article 17(2)(a) for the following reasons:

- 1. Claims Nos.:
because they relate to subject matter not required to be searched by this Authority, namely:

- 2. Claims Nos.:
because they relate to parts of the international application that do not comply with the prescribed requirements to such an extent that no meaningful international search can be carried out, specifically:

- 3. Claims Nos.: 6-8, 10-11, 18-53, 59
because they are dependent claims and are not drafted in accordance with the second and third sentences of Rule 6.4(a).

Box No. III Observations where unity of invention is lacking (Continuation of item 3 of first sheet)

This International Searching Authority found multiple inventions in this international application, as follows:

- 1. As all required additional search fees were timely paid by the applicant, this international search report covers all searchable claims.
- 2. As all searchable claims could be searched without effort justifying additional fees, this Authority did not invite payment of additional fees.
- 3. As only some of the required additional search fees were timely paid by the applicant, this international search report covers only those claims for which fees were paid, specifically claims Nos.:

- 4. No required additional search fees were timely paid by the applicant. Consequently, this international search report is restricted to the invention first mentioned in the claims; it is covered by claims Nos.:

Remark on Protest

- The additional search fees were accompanied by the applicant's protest and, where applicable, the payment of a protest fee.
- The additional search fees were accompanied by the applicant's protest but the applicable protest fee was not paid within the time limit specified in the invitation.
- No protest accompanied the payment of additional search fees.